



(11) **EP 2 395 103 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.12.2011 Bulletin 2011/50

(51) Int Cl.:
C12Q 1/68 (2006.01) G01N 33/574 (2006.01)

(21) Application number: **11003912.0**

(22) Date of filing: **01.12.2005**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

- **Natesan, Sridaran Ashland MA 01721 (US)**
- **August, Paul Bridgewater New Jersey 08807 (US)**

(30) Priority: **08.12.2004 US 634298 P**

(74) Representative: **Körner, Kathrin et al Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Partnerschaft Geibelstraße 6 81679 München (DE)**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
05852717.7 / 1 831 398

(71) Applicant: **Aventis Pharmaceuticals Inc. Bridgewater, New Jersey 08807 (US)**

Remarks:

- Claims filed after the date of filing of the application (Rule 68(4) EPC).
- This application was filed on 12-05-2011 as a divisional application to the application mentioned under INID code 62.

(72) Inventors:

- **Grueneberg, Dorre Newtonville MA 02460 (US)**
- **Huang, Xi Arlington MA 02474 (US)**

(54) **Method for measuring resistance or sensitivity to docetaxel**

(57) The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers, in particular TTK kinase, as compared to controls. The present invention also provides kits that predict or monitor patient's response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.




Figure 1

EP 2 395 103 A1

DescriptionFIELD OF THE INVENTION

5 **[0001]** The present invention relates to novel, useful and heretofore unknown methods that may predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict or monitor patients' response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.

BACKGROUND OF THE INVENTION

10 **[0002]** Docetaxel is an anti-mitotic drug widely used for the treatment of breast, lung and ovarian cancer, and to a lesser extent used for treating head and neck, gastric and prostate carcinomas (Hong, *Oncology* 16:9, 2002). Docetaxel inhibits microtubule dynamics by binding to beta-tubulin and blocking disassembly of alpha- and beta-tubulin heterodimers thus abrogating tumor growth (Ringel and Horwitz, *J Natl Cancer Inst* 83:288, 1991). The anti-tumor activities of docetaxel and a related taxane, paclitaxel arise from targeting microtubules of the mitotic spindle to impede chromosome alignment and segregation, block cell cycle progression and activate apoptosis pathways (Wang et al., *Cancer* 88:2619, 2000). The proapoptotic activities of paclitaxel have been linked with the phosphorylation and inactivation of Bcl-2 through cell signaling events that involve p53/p21waf1/Cip1, raf/ras and mitogen-activated protein kinases (MAPKs) (Wang et al., *Cancer* 88:2619, 2000). Although docetaxel is a more potent anti-cancer agent than paclitaxel, the pathways involved in its cytotoxicity are less well defined (Katsumata, *Br J Cancer* 89:S9, 2003). Docetaxel-induced apoptosis has been observed in select cell lines through a mechanism involving Bcl-2 phosphorylation and caspase-3 activation (Kofschoten et al., *Biochem Pharmacol* 63:733, 2002). Other proteins that modulate taxane-induced cell killing in different cultured lines include Aurora-A in HeLa cells (Anand et al., *Cancer Cell* 3:51, 2003), HER-2 in breast cancer cells (Tanabe et al., *Int J Oncol* 22:875, 2003), p21waf1/Cip1 in glioblastoma cells (Li et al., *J Biol Chem* 277:11352, 2002) and JNK/MKK1 in ovarian cancer cells (Lee et al., *J Biol Chem* 273:28253, 1998).

20 **[0003]** There remains a need in the field to identify drugable proteins that mediate docetaxel resistance, which could lead to their utilization in drug discovery to identify reagents (small molecules, siRNA, etc.) that abrogate their in vivo function and potentially sensitize cells to anti-tumor drug chemotherapy. There also remains a need in the field for an assay which could confidently predict in advance of chemotherapy treatment which patients would and would not respond to anti-tumor docetaxel drug based chemotherapy. Applicants describe herein a novel assay that can predict resistance and or sensitivity to docetaxel and provide screening assays for the development of new therapies to abrogate drug resistance in cancer.

SUMMARY OF THE INVENTION

25 **[0004]** In accordance with the present invention, there is provided novel and useful methods to monitor and/or predict a patient's response to a molecule of the taxoid family by comparing the levels of activation and/or expression of specific genetic markers in patients and controls.

30 **[0005]** In one embodiment, the present invention provides a method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

- 35
- a) obtaining a test sample from a cancerous area of said patient;
 - 40 b) obtaining a control sample;
 - c) measuring the level of one or more genetic markers; and
 - d) comparing the measured levels of said one or more genetic markers in the test sample and the control sample; wherein a decrease in the level of said one or more genetic markers measured in the test sample as compared to the control sample indicates an increased resistance to a molecule of the taxoid family.

45 **[0006]** Particular genetic markers provided in this aspect of the present invention include:

BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);

50 Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);

Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);

55 GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);

EP 2 395 103 A1

Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB 1), mRNA (GenBank accession number: NM_004336);

hSeparase, Homo sapiens extra spindle poles like 1 (S. cerevisiae) (ESPL1), mRNA (GenBank accession number: NM_012291);

CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);

CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and

GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086).

[0007] In another embodiment, the present invention relates to a method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

a) obtaining a test sample from a cancerous area of said patient;

b) obtaining a control sample;

c) measuring the level of one or more genetic markers; and

d) comparing the measured levels of said one or more genetic markers in the test sample and the control sample; wherein a decrease in the level of said one or more genetic markers measured in the test sample as compared to the control sample indicates an increased sensitivity to a molecule of the taxoid family.

[0008] In this particular aspect of the invention one or more genetic markers may be selected from the group consisting of:

P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A(p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);

Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);

GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: NM_002053);

RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);

SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);

Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);

Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);

Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);

TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);

RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);

PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);

BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_006339);

HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);

STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and

MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719).

[0009] In yet a further embodiment, the present invention relates to a method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

a) obtaining a test sample from a cancerous area of said patient;

b) measuring the level of one or more genetic markers selected from the group consisting of:

BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);

Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);

Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);

GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (Gen-

EP 2 395 103 A1

Bank accession number: NM_133483);

Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336);

5 hSephase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);

CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);

10 CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and

GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086)

c) measuring the level of one or more reference genetic markers selected from the group consisting of:

15 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number: NM_002046); and

RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941);

20 d) comparing the measured levels of said one or more genetic markers and said one or more reference genetic markers in the test sample;

wherein a decrease in the level of said one or more genetic markers as compared to the level of said one or more reference genetic markers indicates an increased resistance to a molecule of the taxoid family.

25 **[0010]** Still yet a further embodiment of the present invention relates to a method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

a) obtaining a test sample from a cancerous area of said patient;

b) measuring the level of one or more genetic markers selected from the group consisting of:

30 P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);

Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);

35 GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: M_002053);

RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);

40 SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);

Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);

Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);

45 Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);

TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);

50 RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);

PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);

BRAF35, Homo sapiens high-mobility group 20B (HIV1G20B), mRNA (GenBank accession number: NM_006339);

55 HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);

STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and

MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719);

c) measuring the level of one or more reference genetic markers selected from the group consisting of:

EP 2 395 103 A1

GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941);

- 5 d) comparing the measured levels of said one or more genetic markers and said one or more reference genetic markers in the test sample;

wherein a decrease in the level of said one or more genetic markers as compared to the level of said one or more reference genetic markers indicates an increased susceptibility to a molecule of the taxoid family.

10 **[0011]** The present invention relates to methods for predicting or monitoring a cancer patient's response to a molecule of the taxoid family. This, a further embodiment of the present inventions includes the taxoid family molecules paclitaxel, docetaxel XRP9881 and XRP6258

[0012] The genetic markers described in the present inventions may be evaluated by measuring the levels of RNA, DNA or protein using a variety of techniques that are described in further detail below. Other embodiments of the present invention relate to kits for predicting or monitoring a patient's response to a molecule of the taxoid family.

15 **[0013]** The present invention, in particular, relates to the following:

1. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

- 20 a) obtaining a test sample from a cancerous area of said patient;
b) obtaining a control sample;
c) measuring the level of one or more genetic markers; and
d) comparing the measured levels of said one or more genetic markers in the test sample and the control sample;
25 wherein a decrease in the level of said one or more genetic markers measured in the test sample as compared to the control sample indicates an increased resistance to a molecule of the taxoid family.

2. The method of aspect 1, wherein said one or more genetic markers is selected from the group consisting of:

- 30 BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);
Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);
35 GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);
Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336);
hSepharase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);
40 CamKII δ , Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);
CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259);
and
45 GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086).

3. The method of aspect 1 wherein said molecule of the taxoid family is selected from the group consisting of paclitaxel, docetaxel XRP9881 and XRP6258.

50 4. The method of aspect 1 wherein said level of one or more genetic markers is measured by mRNA, DNA or protein.

5. The method of aspect 4 wherein said mRNA is measured by using a technique selected from the group consisting of in situ hybridization, reverse-transcriptase polymerase chain reaction, nucleic acid hybridization, electrophoresis, Northern blotting and mass spectrometry.

55 6. The method of aspect 4 wherein said DNA is measured by using a technique selected from the group consisting of quantitative polymerase chain reaction, genomic DNA-chips, in situ hybridization, electrophoresis, Southern blotting and mass spectrometry.

EP 2 395 103 A1

7. The method of aspect 4 wherein said protein is measured by using a technique selected from the group consisting of immunoassay, Western blots, ELISA, and mass spectrometry.

5 8. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

- a) obtaining a test sample from a cancerous area of said patient;
- b) obtaining a control sample;
- c) measuring the level of one or more genetic markers; and
- 10 d) comparing the measured levels of said one or more genetic markers in the test sample and the control sample;

15 wherein a decrease in the level of said one or more genetic markers measured in the test sample as compared to the control sample indicates an increased sensitivity to a molecule of the taxoid family.

9. The method of aspect 8, wherein said one or more genetic markers is selected from the group consisting of:

20 P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Clip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);

Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);

GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: NM_002053);

RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);

25 SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);

Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);

Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);

Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);

30 TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);

RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);

35 PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);

BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_006339);

HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);

40 STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and

MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719).

45 10. The method of aspect 8 wherein said molecule of the taxoid family is selected from the group consisting of paclitaxel, docetaxel XRP9881 and XRP6258.

11. The method of aspect 8 wherein said level of one or more genetic markers is measured by mRNA, DNA or protein.

50 12. The method of aspect 11 wherein said mRNA is measured by using a technique selected from the group consisting of in situ hybridization, reverse-transcriptase polymerase chain reaction, nucleic acid hybridization, electrophoresis, Northern blotting and mass spectrometry.

55 13. The method of aspect 11 wherein said DNA is measured by using a technique selected from the group consisting of quantitative polymerase chain reaction, genomic DNA-chips, in situ hybridization, electrophoresis, Southern blotting and mass spectrometry.

14. The method of aspect 11 wherein said protein is measured by using a technique selected from the group

EP 2 395 103 A1

consisting of immunoassay, Western blots, ELISA, and mass spectrometry.

5 15. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of aspect 1 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to said one or more genetic markers selected from the group consisting of

BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);

10 Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);

Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);

GEFT for Rac1/CDC42 Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);

15 Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336); hSepharase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);

CamKII δ , Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);

20 CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and

GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086).

25 16. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of aspect 8 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to said one or more genetic markers selected from the group consisting of:

30 P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: MM_000389);

Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);

GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: NM_002053);

35 RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);

SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: M_032905);

Hecl, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);

Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484); Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);

40 TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);

RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);

PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);

45 BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: M_006339);

HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);

STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and

50 MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719).

55 17. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of aspect 1 wherein the kit comprises the means of:

a) obtaining total RNA from a bodily sample;

b) reverse transcribing the total RNA to obtain cDNA; and

c) subjecting the cDNA to a polymerase chain reaction using a set of primers

EP 2 395 103 A1

wherein one or both primers are detectably-labeled and both primers are derived from a nucleotide sequence of one or more genetic markers selected from the group consisting of:

5 BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);
Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);
GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (Gen-
Bank accession number: NM_133483);
10 Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336);
hSeparase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);
CamKII δ , Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), tran-
script variant 3, mRNA (GenBank accession number: NM_001221);
15 CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259);
and
GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086).
20

18. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of aspect 8 wherein the kit comprises the means of:

- 25 a) obtaining total RNA from a bodily sample;
b) reverse transcribing the total RNA to obtain cDNA; and
c) subjecting the cDNA to a polymerase chain reaction using a set of primers

wherein one or both primers are detectably-labeled and both primers are derived from a nucleotide sequence of one or more genetic markers selected from the group consisting of:

30 P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);
Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);
GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank ac-
35 cession number: NM_002053);
RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);
SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);
Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);
40 Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);
Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551); TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (Gen-
Bank accession number: NM_006342);
RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypep-
45 tide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);
PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);
BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_006339);
50 HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);
STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and
55 MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719).

19. The detectable label of any one of aspects 15 - 18, wherein the detectable label is selected from the group consisting of an enzyme, a radioactive isotope, or a chemical which fluoresces, a chemiluminescent molecule,

EP 2 395 103 A1

radiopaque substances, liposomes, and haptenic molecules.

20. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

- 5
- a) obtaining a test sample from a cancerous area of said patient;
 - b) measuring the level of one or more genetic markers selected from the group consisting of:

10 BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);

Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);

Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);

GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);

15 Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: M_004336);

hSepharase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);

20 CamKII δ , Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);

CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and

GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086)

- 25
- c) measuring the level of one or more reference genetic markers selected from the group consisting of:

30 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number: NM_002046); and

RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941);

- d) comparing the measured levels of said one or more genetic markers and said one or more reference genetic markers in the test sample;

35 wherein a decrease in the level of said one or more genetic markers as compared to the level of said one or more reference genetic markers indicates an increased resistance to a molecule of the taxoid family.

21. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:

- 40
- a) obtaining a test sample from a cancerous area of said patient;
 - b) measuring the level of one or more genetic markers selected from the group consisting of:

45 P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);

Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);

GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: M_002053);

RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);

50 SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);

Hec1 Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);

Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);

55 Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);

TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);

RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light

EP 2 395 103 A1

polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);
PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession
number: NM_006254);
5 BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_
006339);
HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number:
NM_005345);
STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank
accession number: NM_000455); and
10 MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number:
L36719);

c) measuring the level of one or more reference genetic markers selected from the group consisting of:

15 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession
number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941);

d) comparing the measured levels of said one or more genetic markers and said one or more reference genetic
20 markers in the test sample;
wherein a decrease in the level of said one or more genetic markers as compared to the level of said one or
more reference genetic markers indicates an increased susceptibility to a molecule of the taxoid family.

22. The method of aspect 20 or 21 wherein said molecule of the taxoid family is selected from the group consisting
25 of paclitaxel, docetaxel XRP9881 and XRP6258.

23. The method of aspect 20 or 21 wherein said level of one or more genetic markers is measured by mRNA, DNA
or protein.

24. The method of aspect 23 wherein said mRNA is measured by using a technique selected from the group
30 consisting of in situ hybridization, reverse-transcriptase polymerase chain reaction, nucleic acid hybridization, elec-
trophoresis, Northern blotting and mass spectrometry.

25. The method of aspect 23 wherein said DNA is measured by using a technique selected from the group consisting
35 of quantitative polymerase chain reaction, genomic DNA-chips, in situ hybridization, electrophoresis, Southern blot-
ting and mass spectrometry.

26. The method of aspect 23 wherein said protein is measured by using a technique selected from the group
40 consisting of immunoassay, Western blots, ELISA, and mass spectrometry.

27. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the
method of aspect 20 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments
or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to
said one or more genetic markers and said one or more reference genetic markers selected from the group consisting
45 of:

BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number:
AF046079);
Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
50 Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);
GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (Gen-
Bank accession number: NM_133483);
Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank
accession number: NM_004336);
55 hSeparase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession
number: NM_012291);
CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), tran-
script variant 3, mRNA (GenBank accession number: NM_001221);

EP 2 395 103 A1

CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259);
GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank
accession number: NM_002086);
GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession
number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941).

28. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the
method of aspect 21 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments
or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to
said one or more genetic markers and said one or more genetic markers selected from the group consisting of:

P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1,
mRNA (GenBank accession number: NM_000389);
Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);
GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank ac-
cession number: NM_002053);
RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);
SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_
032905);
Hecl, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);
Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);
Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number:
AF008551);
TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank acces-
sion number: NM_006342);
RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypep-
tide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);
PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession
number: NM_006254);
BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_
006339);
HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_
005345);
STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank ac-
cession number: NM_000455); and
MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number:
L36719);
GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession
number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941).

29. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the
method of aspect 20 wherein the kit comprises the means of:

a) obtaining total RNA from a bodily sample;
b) reverse transcribing the total RNA to obtain cDNA; and
c) subjecting the cDNA to a polymerase chain reaction using a set of primers wherein one or both primers are
detectable-labeled and both primers are derived from a nucleotide sequence of one or more genetic markers
selected from the group consisting of:

BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession
number: AF046079);
Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);
GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA
(GenBank accession number: NM_133483);
Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA

EP 2 395 103 A1

(GenBank accession number: NM_004336);
hSephase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);
5 CamKII δ , Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);
CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and
GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086);
10 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941).

30. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the method of aspect 19 wherein the kit comprises the means of:

- a) obtaining total RNA from a bodily sample;
- b) reverse transcribing the total RNA to obtain cDNA; and
- c) subjecting the cDNA to a polymerase chain reaction using a set of primers wherein one or both primers are detectable-labeled and both primers are derived from a nucleotide sequence of one or more genetic markers selected from the group consisting of:

P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA (GenBank accession number: NM_000389);
25 Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);
GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession number: NM_002053);
RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);
30 SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);
Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);
Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);
35 Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number: AF008551);
TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession number: NM_006342);
RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);
40 PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number: NM_006254);
BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_006339);
45 HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_005345);
STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession number: NM_000455); and
MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719);
50 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number: NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941).

31. The detectable label of any one of aspects 24 - 27, wherein the detectable label comprises an enzyme, a radioactive isotope, or a chemical which fluoresces, a chemiluminescent molecule, radiopaque substances, liposomes, and haptenic molecules.

The above aspects and other aspects, features, and advantages of the present invention will be better understood from the following detailed description taken in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

5

[0014]

10

Figure 1 shows the characterization of genes whose downregulation confer docetaxel resistance. Docetaxel generated dose response curves shown for HCT116 cells transfected with RB1, BubR1, Mad2 and Mps1 siRNAs (solid squares) compared to control siRNA (open squares). RB 1 was an example of a siRNA that did not score in the screen. Cell viability was measured at an absorbance of 450 nM following WST-1 addition. The minimum ratio (MR) is the WST-1 value for a gene over the control at 40 nM docetaxel.

15

Figure 2 shows dose response curves of BubR1 and Mps1 shRNAs (solid squares) compared to control shRNA (open squares).

20

Figure 3 shows TaqMan real-time PCR analysis of BubR1 and Mps1 mRNA levels in cells containing BubR1 and Mps1 shRNA, respectively.

25

Figure 4 shows cell viability and morphology shown for HCT116 cells transfected with Mad2, BubR1 and Mps1 siRNAs with or without docetaxel treatment. Twenty-four hours after transfection, cells were left untreated (-Docetaxel) or treated with 200 nM docetaxel (+Docetaxel) and stained with Calcein-AM to visualize live cells 16 and 72 hours after treatment.

30

Figure 5 shows mitotic indices for HCT116 cells transfected with Mad2, BubR1, Mps1 and control siRNAs following docetaxel treatment. Twenty-four hours after transfection cells were treated with 200 nM docetaxel for 16 and 72 hours and processed. Mitotic cells were detected by a phosphorylated histone H3 antibody, shown here as red punctuate staining over the nucleus of cells (Mitotic Index Kit, Cellomics). Nuclei were stained blue with Hoechst dye.

35

Figure 6 shows TaqMan real-time PCR analysis of Mps1, BubR1 and Mad2 mRNA levels in HCT116 cells transfected with Mps1, BubR1 and Mad2 siRNA, respectively.

40

Figure 7 shows cell cycle analysis of HCT116 cells transfected with three mitotic checkpoint gene siRNAs. After transfection with Mps1, BubR1 and Mad2 siRNAs, cells were untreated (-Docetaxel) or treated with 200 nM docetaxel (+Docetaxel) for 24 hours. Seventy-two hours after the addition of docetaxel, cells were harvested and analyzed for cell cycle. Numbers above peaks indicate DNA content such as 2N, 4N, 8N, 16N or 32N.

45

Figure 8 shows clonogenic cell survival assay using stable knockdown cell lines. HCT116 cells containing BubR1 or vector control shRNAs were plated on 10 cm dishes and maintained in 5 nM docetaxel for 10 days. Colonies were washed with PBS and stained with crystal violet.

50

Figure 9 shows several dose response curves of genes whose down-regulation confer increased sensitivity to docetaxel. Docetaxel generated dose response curves shown for HCT116 cells transfected with RB1, Pim-1, p21, Aurora A and TACC3 siRNAs (solid squares) compared to control siRNA (open squares). The minimum ration (MR) is the ratio of WST-1 readout of a gene over that of the control at 40 nM docetaxel concentration. The IC50 (IR) ratio is the ratio of IC50 of a gene over that of the control.

55

Figure 10 shows a dose response curves of Aurora A shRNA (solid squares) compared to vector control (open squares).

Figure 11 shows TaqMan real-time PCR analysis of Aurora A mRNA levels in cells containing Aurora A shRNA.

Figure 12 shows differences in proliferation of HCT116 cells transfected with Pim-1 and TACC3 siRNAs (solid squares) compared to control siRNA (open squares). Number of cells remaining in 6-well plates at different time points after transfection with Pim-1, TACC3 and control siRNAs.

Figure 13 shows TaqMan analysis of Pim-1 and TACC3 mRNA levels after siRNA transfection.

Figure 14 shows active caspase-3 levels in HCT116 cells transfected with Pim-1 and BubR1 siRNAs. Active caspase-3 levels were shown as fluorescent intensity using the active caspase-3 beadmates kit (Upstate). Three docetaxel concentrations, 0, 5 and 40 nM, and three time points, 24, 48 and 72 hours after docetaxel addition were examined.

Figure 15 shows AKT phosphorylation levels in HCT116 cells transfected with Pim-1 and BubR1 siRNAs. The ratio of phosphorylated and total AKT levels was determined using a bead-based assay (Biosource). Twenty-four hours after transfection cells were left untreated or treated with 5 and 40 nM docetaxel. Forty-eight hours after docetaxel treatment cells lysates were analyzed. The phosphorylation level was calculated as the ratio of phosphorylated AKT (p-AKT) over total AKT (t-AKT).

Figure 16 shows Western blots showing the reduced levels of Pim-1 and BubR1 48 hours after transfection.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The present invention is broadly based upon applicants' identification of gene markers that can predict whether a test subject is resistant or sensitive to drugs in the taxoid family. Using a cell-based RNA interference (RNAi) screen, applicants observed that drug resistance or sensitivity to docetaxel was associated with particular gene markers.

[0016] It is noted that numerous terms and phrases are used throughout the instant specification and claims. Definitions of these terms and phrases are provided below:

As used herein, the term "prognosis" refers to the prediction or the likelihood of cancer-attributable death or progression, including drug resistance as well as recurrence, metastatic spread, and neoplastic disease.

As used herein, the term "prediction" refers to the likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs, and also the extent of those responses Such as whether the patient will survive, following surgical removal of the primary tumor and/or chemotherapy for a certain period of time without cancer recurrence. Predictive methods envisioned by the present invention can be used clinically to make treatment decisions by choosing the most appropriate treatment modalities, in particular a chemotherapeutic of the taxoid family, for any particular patient. The predictive methods of the present invention are valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such as chemotherapy with a given drug or drug combination, and/or radiation therapy, or whether long-term survival of the patient following termination of chemotherapy or other treatment modalities is likely.

As used herein, the term "tumor," refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

As used herein, the term "cancer" and "cancerous" refers to a physiological condition in mammals typically characterized by unregulated cell growth. Examples of cancer include but are not limited to the following: breast cancer; colon cancer; lung cancer; prostate cancer; hepatocellular cancer; gastric cancer; pancreatic cancer; cervical and ovarian cancer; liver cancer; bladder cancer; cancer of the urinary tract; carcinoma; melanoma; brain cancer including glioblastomas and medulloblastomas; biliary tract cancer; choriocarcinoma; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia; multiple myeloma; AIDS-associated leukemia and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma, sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and modullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor..

As used herein, the term "patient" refers preferably to a human but may also include a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. Preferably the subject is a human either suspected of having cancer, or having been diagnosed with cancer or in a high-risk category for developing cancer, for example, having a family history of cancer. In a preferred embodiment of the invention the cancer is breast cancer. Methods for identifying subjects suspected of having cancer may include manual examination, biopsy, subject's family medical history, subject's medical history, or a number of imaging technologies such as mammography, magnetic resonance imaging, magnetic resonance spectroscopy, or positron emission tomography. Diagnostic methods for cancer and the clinical characterizations of cancer diagnoses are well-known to those of skill in the medical arts.

As used herein, the term "sample" is tissue obtained using methods well-known to those of ordinary skill in the related medical arts. Methods such as biopsy include gross apportioning of a mass, microdissection, laser-based microdissection, or other art-known cell-separation methods. Because of the variability of the cell types in diseased-tissue biopsy material, and the variability in sensitivity of the diagnostic methods used, the sample size required for analysis may range from 1, 10, 50, 100, 200, 300, 500, 1000, 5000, 10,000, to 50,000 or more cells. The appropriate sample size may be determined based on the cellular composition and condition of the biopsy and the standard preparative steps for this determination and subsequent isolation of the nucleic acid for use in the invention are well known to one of ordinary skill in the art. For example, a sample from a biopsy may be sufficient for assessment of RNA expression without amplification. Conversely, the lack of a suitable number of cells in a small biopsy region may require use of RNA conversion and/or amplification methods or other methods to enhance resolution of the nucleic acid molecules. Such methods, which allow use of limited biopsy materials, are well known to those of ordinary skill in the art. Some examples include but are not limited to direct RNA amplification, reverse transcription of RNA to cDNA, amplification of cDNA, or the generation of radio-labeled nucleic acids.

As used herein, the term "test " with respect to a sample refers to a sample taken from a cancerous area of the body or from an area of the body exhibiting a stage of or characteristics of cancer.

As used herein, the term "control" with respect to a sample refers to samples which are used for comparative purposes. Preferably, these samples are "control" in the sense that the samples do not exhibit any indication of, or are believed to have, any disease or condition that would affect gene expression, particularly in respect of the disease for which they are to be used as the standard. Alternatively, it may be appreciated that different stages of a disease or condition can be compared and in such cases, the "control" sample corresponds to the earlier stage of the disease or condition. For example, a control sample can be a sample taken from a non-cancerous but comparable area of the body. Additionally, a control sample may be a comparable area of the body from the same subject or a non-cancerous area of the body from a second subject substantially similar to the first subject (same or similar species, age, weight, sex, etc.). Finally, a control sample could also be from a cancerous area of a second subject who respond well to treatment using a molecule of the taxoid family.

[0017] A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the non-transcribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

[0018] As used herein, the term "portion" of an isolated nucleic acid molecule that encodes for a particular protein, refers to a part or fragment of the isolated nucleic acid molecule that comprises a sufficient number of contiguous nucleotides that encode for a peptide or polypeptide. Naturally, a "portion" of an isolated nucleic acid molecule is greater than one nucleotide, and the peptide or polypeptide encoded by the portion contains numerous amino acid residues, as described in the definitions of peptide and polypeptide below.

[0019] As used herein, the term "peptide" refers to two or more amino acids covalently joined by peptide binds. In a particular embodiment, a peptide comprises at least 10, preferably at least 20, more preferably at least 30, even more preferably at least 40, and most preferably 50 or more amino acids.

[0020] As used herein, the term "polypeptide" refers to a linear polymer composed of multiple contiguous amino acids. In particular, a polypeptide may possess a molecular weight greater than 100 kD.

[0021] As used herein, the term "genetic marker" refers to a physiological composition whose measured RNA, DNA or protein level within a sample serves to predict whether a test subject is resistant or sensitive to drugs in the taxoid family. Moreover, a genetic marker may encode the particular protein or alternatively, may serve as a "surrogate" marker for a protein whose activity is related to the level of the genetic marker in a bodily sample. This relationship may be direct, wherein a decrease in the level of protein activity corresponds to a decrease in the level of the genetic marker, or alternatively, the relationship may be inverse, wherein a decrease in the level of protein activity corresponds to an increase in the level of the genetic marker. Such physiological compositions include, but certainly are not limited to, cells (e.g., progenitor stem cells) proteins, polypeptides, DNA, RNA, carbohydrates, or fatty acids, to name only a few. In a particular embodiment of the present invention, the measured levels of certain gene markers can predict whether a test

EP 2 395 103 A1

subject is resistant or sensitive to drugs in the taxoid family. Examples of such genetic markers include, but certainly are not limited to:

5 BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);
Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
Mps1, Homo sapiens TTK protein kinase (TTK), mRNA (GenBank accession number: NM_003318);
GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank
10 accession number: NM_133483);
Bub1, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank
accession number: NM_004336);
hSepharase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA. (GenBank accession number:
NM_012291);
15 CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript
variant 3, mRNA (GenBank accession number: NM_001221);
CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259); and
GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank acces-
sion number: NM_002086)
P21(Waf1), Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA
20 (GenBank accession number: NM_000389);
Pim-1, Homo sapiens pim-1 oncogene (PIM1), mRNA (GenBank accession number: NM_002648);
GBP-1, Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA (GenBank accession
number: NM_002053);
RXRA, Homo sapiens retinoid X receptor, alpha (RXRA), mRNA (GenBank accession number: NM_002957);
25 SPF45, Homo sapiens RNA binding motif protein 17 (RBM17), mRNA (GenBank accession number: NM_032905);
Hec1, Homo sapiens kinetochore associated 2 (KNTC2), mRNA (GenBank accession number: NM_006101);
Raf1, Human mRNA for raf oncogene (GenBank accession number: X03484);
Aurora A, Homo sapiens aurora-related kinase 1 (ARK1) mRNA, complete cds (GenBank accession number:
AF008551);
30 TACC3, Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA (GenBank accession
number: NM_006342);
RelB, Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide
gene enhancer in B-cells 3 (avian) (RELB), mRNA (GenBank accession number: NM_006509);
PRKCD, Homo sapiens protein kinase C, delta (PRKCD), transcript variant 1, mRNA (GenBank accession number:
35 NM_006254);
BRAF35, Homo sapiens high-mobility group 20B (HMG20B), mRNA (GenBank accession number: NM_006339);
HSPA1L, Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA (GenBank accession number: NM_
005345);
STK11, Homo sapiens serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA (GenBank accession
40 number: NM_000455); and
MKK3, Homo sapiens MAP kinase kinase 3 (MKK3) mRNA, complete cds (GenBank accession number: L36719)

[0022] As used herein, the term "reference genetic marker" refers to a physiological composition whose measured
RNA, DNA or protein levels remain unchanged before, during or after exposure to drugs in the taxoid family. "Reference
45 genetic markers" are referred to as housekeeping genes. These are genes that are selected based on the relatively
invariable levels of expression in the system which is being examined, for example, the in a particular disease such as
cancer. Housekeeping genes are used to normalize results of expression. Examples of such genetic markers include,
but certainly are not limited to:

50 GAPDH, Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA (GenBank accession number:
NM_002046); and
RPS9, Homo sapiens cDNA clone IMAGE:6647283, partial cds (GenBank accession number: BC071941).

[0023] As used herein, the term "a molecule of the taxoid family" refers to a class of chemotherapeutic compounds
55 to belonging to the taxane family. Specific members of the taxoid family include but are not limited to paclitaxel (taxol),
docetaxel (taxotere) and analogs thereof (i.e., XRP9881 and XRP6258; see Ojima and Geney, *Curr Opin Investig Drugs*
4:737, 2004). Since this class of molecules are beta-tubulin binders and stabilize the polymerized form of the microtubule
similar to docetaxel, it is anticipated that the clinical expression of the biomarker herein described will reflect similar

response states to these drugs.

[0024] As used herein, the terms "molecule", "compound" or "agent" refer to any composition presently known or subsequently discovered. Examples of compounds or agents having applications herein include organic compounds (e.g., man made, naturally occurring and optically active), peptides (man made, naturally occurring, and optically active, i.e., either D or L amino acids), carbohydrates, nucleic acid molecules, etc.

[0025] As used herein, "stringency of hybridization" or "hybridization under stringent conditions" refers to conditions readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., *Current Protocols in Molecular Biology*, Wiley Interscience Publishers, (1995).

[0026] As used herein, "stringent conditions" or "high stringency conditions", refers to those parameters that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) overnight hybridization in a solution that employs 50% formamide, 5x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 .mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42° C, with a 10 minute wash at 42° C in 0.2x SSC (sodium chloride/sodium citrate) followed by a 10 minute high-stringency wash consisting of 0.1x SSC containing EDTA at 55° C. Moderately stringent conditions may be identified as described by Sambrook et al., *Molecular Cloning: A Laboratory Manual*, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37° C in a solution comprising: 20% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1x SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. Preferably a minimum length for a hybridizable nucleic acid is at least about 12 nucleotides; preferably at least about 16 nucleotides; and more preferably the length is at least about 24 nucleotides; and most preferably at least 36 nucleotides.

[0027] As used herein, "label" or "detectable-label" refers to a detectable label compound or composition which is conjugated directly or indirectly to an antibody, oligopeptide or other organic molecule so as to generate a "labeled" antibody, oligopeptide or other organic molecule. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

[0028] As used herein, a "direct labels" refers an entity, which in its natural state, is readily visible, either to the naked eye, or with the aid of an optical filter and/or applied stimulation, e.g. ultraviolet light to promote fluorescence. Examples include, but are not limited to, colored labels, metallic sol particles, dye sol particles dyed latex or dyes encapsulated liposomes (described by U.S. Pat. No. 4,313,734, U.S. Pat. No. 4,373,932, WO 88/08534), EP-A 0 280 559, 0 281 327, U.S. Pat. No. 4,703,017). Other direct labels include a radionucleotide, radiopaque substances, a fluorescent moiety or a luminescent moiety.

[0029] As used herein, "indirect labels" refers to enzymes can also be used according to the present invention. Various types of enzyme linked immunoassays are well known in the art, for example, alkaline phosphatase and horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, urease, these and others have been discussed in detail by Eva Engvall in *Enzyme Immunoassay ELISA and EMIT in Methods in Enzymology*, 70: 419-439 (1980) and in U.S. Pat. No. 4,857,453.

[0030] As used herein, the term "kit" refers to an article of manufacture comprising one or more containers and a label or package insert on or associated with the containers. In a preferred embodiment, the containers may contain a detectable-labeled antibody, detectable-labeled antibody fragments or detectable-labeled oligonucleotides. In another embodiment, the containers provide the means to obtain total RNA from a bodily sample, reverse transcribe the total RNA to obtain cDNA and subject the cDNA to a polymerase chain reaction using a set of primers wherein one or both primers

are detectable-labeled. Additional containers of the kit may be included that contain, e.g., diluents and buffers, control antibodies, oligopeptides or small organic molecules. The label or package insert may provide a description of the composition as well as instructions for storage and for the intended in vitro or diagnostic use.

5 **[0031]** Furthermore, in accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook *et al.*, 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

10 **[0032]** In general, RNAi technology uses synthetic or vector-generated double stranded RNA to induce the degradation of mRNA containing homologous sequences (McManus and Sharp, *Nat Rev Genet* 3:737, 2002). RNAi screening has been used to elucidate gene function in many organisms such as *Caenorhabditis elegans* (Simmer *et al.*, *PLoS Biol* 1: E12, 2003), *Drosophila* (Lum *et al.*, *Science* 299:2039, 2003) and mammalian cells (Aza-Blanc *et al.*, *Mol Cell* 12:627, 2003).

15 **[0033]** In the present invention, HCT116 colon cancer cells were used to screen siRNAs directed against 101 cancer-related genes, mostly comprising the kinase family members, and the docetaxel killing effects were quantified by high-resolution dose-response curves. Using this approach, applicants have shown that under-expression of 9 genes, including BubR1, Bub1, Mad2, Mps1 and GEFT Rac/CDC, can inhibit killing by docetaxel, whereas under-expressing 15 others, including Pim1, p21, TACC3 and Aurora-A, can potentiate docetaxel-induced cell death.

20 **[0034]** Thus, broadly the present invention extends to diagnostic methods and kits that may be used to identify whether an individual who is either taking or considering taking docetaxel will be resistant or sensitive to the drug.

25 **[0035]** Applicants have observed drug resistance to docetaxel, whereby drug resistance is associated with the loss of an expanded set of checkpoint control genes including BubR1, Bub1, Mad2, Msp1 and GEFT Rac/CDC.

[0036] Increased docetaxel sensitivity corresponds with the loss of any one of several genes, including GBP-1, STK11, RXRA, Hec1, SPF45, Raf1, RELB, MKK3, PRKCD, HSPA1A, BRAF35, Aurora-A, Pim-1, TACC3 and p21waf1/Cip1, and inhibitors against these genes may serve as a valuable adjunct to docetaxel therapy.

30 **[0037]** The mitotic checkpoint genes serve as a failsafe mechanism to delay anaphase by the inhibition of Cdc20-APC (anaphase-promoting complex), until the kinetochores of sister chromatids are properly attached to the mitotic spindle and aligned at the equator (Zhou *et al.*, *J Cell Sci* 115:3547, 2002), thus allowing cells to reliably exit mitosis and enter additional cell cycles with a precise complement of DNA. In the presence of microtubule inhibitors, cells exiting from mitosis can no longer properly segregate their chromosomes and typically undergo apoptosis immediately or after several cell cycles (Taylor and McKeon, *Cell* 89:727, 1997). The combination of microtubule inhibitors with loss of mitotic checkpoint genes such as BubR1 allows cells to escape mitotic arrest without undergoing apoptosis and lead to chromosome instability (CIN) and aneuploidy (Shin *et al.*, *Cancer Cell* 4:483, 2003). Recently, drug resistance data were generated when microtubule inhibitor paclitaxel was used to treat BubR1 and Mad2 down regulated MCF-7 cells (Sudo *et al.*, *Cancer Res* 64:2502, 2004).

35 **[0038]** The Pim-1 gene encodes a serine/threonine kinase that belongs to a small family of related kinases. Pim-1 function has been linked to proliferation, differentiation, apoptosis, tumorigenesis, hypoxia, angiogenesis and mitosis (Wang *et al.*, *Biochim Biophys Acta* 1593:45, 2002). The microscopic imaging data, in conjunction with AKT hypophosphorylation data and elevated caspase-3 activity measurements, demonstrate that Pim-1 down regulation enhanced docetaxel-induced apoptosis by inactivating AKT signaling, which mediates cell survival. Pim-1 and p21 have very similar characteristics in sensitizing HCT116 cells to docetaxel; consistent with reports showing that p21 is a phosphorylation substrate of Pim-1 (Wang *et al.*, *Biochim Biophys Acta* 1593:45, 2002). Pim-1 down regulation induced some apoptosis in the absence of docetaxel but was more effective in the presence of drug, whereas down regulation of transforming acidic coiled-coil protein TACC3 did not induced cell death in the absence of docetaxel, indicating the RNAi alone had no effect on cell proliferation. These results suggest that depletion of different proteins can evoke different mechanisms for sensitizing cells to docetaxel.

40 **[0039]** Accordingly, in one aspect of the invention, activation of one or more of the genes described in Table I and II and protein levels of these genes may be utilized to select a therapeutic treatment strategy and to monitor effectiveness of the selected treatment strategy.

45 **[0040]** In a particular embodiment, a method is provided that monitors the activation levels of one or more genes shown in Table I and II during the course of chemotherapy to assess and predict effectiveness of chemotherapy for the patient. Biopsies from tumors (e.g., breast, colon, non-small cell lung, and gastric tumors) or short-term culture of tumor biopsies from undiagnosed cancer patients or patients currently undergoing treatment is processed in order to isolate DNA (Hafner *et al.*, *Arch Pathol Lab Med* 127:1221, 2003; Rodriguez *et al.*, *Clin Cancer Res* 10:5785, 2004), messenger

RNA (Chang et al., *Lancet*. 362:340, 2003) and/or proteins (Espina et al., *J Immunol Methods* 290:121, 2004) to assess the levels of gene activation or protein levels of the genes described in Table I and II or a subset thereof. Gene transcription and protein expression profiling has utility in diagnosis, prediction of therapeutic responses to potential treatment strategies and may be a useful tool to monitor a patient's response to therapy.

5 **[0041]** According to the present invention, RNA may be isolated from tumor samples using any of the available methods commonly used in the art (Ullmann et al., *JBiomol Screen* 9:95, 2004; Badiiee et al., *BMC Biotechnol* 3:23, 2003). One or more cells from test subjects are obtained and RNA is isolated from these cells. As examples, peripheral blood leukocytes (PBLs) cells may be obtained from the subject or it is also possible to obtain a cell sample and enrich the sample for a desired cell type. Cells may be isolated from a cell mixture using a variety of techniques, such as cell
10 isolation using antibodies that bind to an particular epitope on the desired cell type. Where the desired cells are in a solid tissue, particular cells may be dissected, for example, by microdissection or by laser capture microdissection (LCM) (Bonner et al., *Science* 278:1481, 1997; Fend et al., *Am J Path* 154:61, 1999). RNA may be extracted from tissue or cell samples by a variety of methods, for example, guanidium thiocyanate lysis followed by CsCl centrifugation (Chirgwin et al., *Biochemistry* 18:5294, 1979). RNA from single cells may be obtained as described in methods for preparing cDNA
15 libraries from single cells (Dulac, *Curr Top Dev Biol.* 36:245, 1998). The RNA sample can be further enriched for a particular species. In one embodiment, for example, poly(A)+RNA may be isolated from an RNA sample. In particular, poly-T oligonucleotides may be immobilized on a solid support to serve as affinity ligands for mRNA. Kits for this purpose are commercially available, for example, the MessageMaker kit (Life Technologies, Grand Island, N.Y.). Enrichment may be accomplished, for example, by primer-specific cDNA synthesis, or multiple rounds of linear amplification based
20 on cDNA synthesis and template-directed in vitro transcription (Wang et al., *Proc Natl Acad. Sci USA* 86:9717, 1989; Dulac *et al.*, supra).

[0042] A variety of amplification methods are suitable for use in the methods of the present invention, including, for example, PCR; ligase chain reaction (LCR) (Wu and Wallace, *Genomics* 4:560, 1989); self-sustained sequence replication (SSR) (Guatelli et al., *Proc Natl Acad Sci USA* 87:1874, 1990); nucleic acid based sequence amplification (NASBA)
25 and transcription amplification (Kwoh et al., *Proc Natl Acad Sci USA* 86:1173, 1989). Methods for PCR technology are well known in the art (see, e.g., *PCR Technology: Principles and Applications for DNA Amplification* (ed H. A. Erlich, Freeman Press, N.Y., N.Y., 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, Calif., 1990).

[0043] The RNA may be labeled for detection by using any of the methods known to those persons skilled in the art. For example, using microarrays, such as those manufactured by Affymetrix. RNA is labeled and detected by hybridization
30 using any of the methods commonly used, such as, direct RNA labeling with dyes such as Cyanine-3 or Cyanine-5 (Perkin Elmer MPS544001KT). Additional methods include direct cDNA labeling that is done by reverse transcription using nucleotides labeled with Cyanine-3 or Cyanine-5 (Badiiee A 2003), fluorescein or Alexa dyes (Molecular Probes), or other fluorophores. Furthermore, indirect cDNA labeling such as FairPlay™/aminoallyl labeling (Stratagene Catalog
35 number: 252002), 3DNA dendrimer labeling (Genisphere Inc) or enzymatic signal amplification (MICROMAX TSA, Perkin Elmer) may be utilized. Alternatively, RNA may be quantified by using RNA probes that are detected by enzymatic, fluorescence, radioactive or light emitting methods.

[0044] In one aspect of the present invention, RNA is obtained from the tumor sample and Taqman technology is employed in the detection of genetic markers. Primers are generated to detect the specific RNAs designated in Table I
40 and II or subset thereof and amplified using reverse transcriptase. Detection of the specific fragment amplified by reverse transcription is accomplished by gel electrophoresis, polymer electrophoresis, direct DNA sequencing, light detection, loss of a fluorescence signal, enzymatic reaction, or detection by hybridization to a complementary RNA.

[0045] In another aspect of the present invention, Real Time PCR is utilized to detect oligonucleotides. The mRNA obtained from a tumor sample is reverse translated into cDNA. Primers are generated to amplify the specific RNAs
45 designated in Table I and II or subset thereof using polymerase chain reaction technology. Detection of mRNA level is achieved by gel electrophoresis and ethidium bromide or CYBR green staining, or by measuring the fluorescence intensity from fluorophore-labeled sequence specific probes released by polymerase.

[0046] In a further aspect of the present invention, Northern blotting technology is utilized. RNA is obtained from the tumor sample and then separated by gel electrophoresis and transferred onto a membrane. RNA abundance is deter-
50 mined by hybridization using probes labeled with radioactive isotope such as P³² or by enzymatic based chromogenic or luminescent assays.

[0047] In yet another aspect of the present invention, gene dosage may be used as a surrogate indicator of transcript levels. The gene dosage of the transcripts in Table I and II or a subset thereof may be quantitatively determined and assessed for whether a tumor will be responsive or not to docetaxel therapy. (Rodriguez et al., *Clin Cancer Res* 10:
55 5785, 2004). Since this assessment may be drawn prior to neoadjuvant (treatment prior to surgery) therapy, the patient may be treated with docetaxel if they are classified as a responder or another chemotherapeutic agent may be administered if they are classified as a non-responder.

[0048] DNA is extracted from patient tumor biopsies and purified to remove contaminants using methods as performed

by those skilled in the art. Methods utilized to determine the gene dosage in the tumor DNA include, but are not limited to, quantitative PCR, genomic DNA-chips, in situ hybridization or Southern (Hafner et al., Arch Pathol Lab Med 127: 1221, 2003; Rodriguez et al., Clin Cancer Res 10:5785, 2004). Accordingly, these methods may be utilized to determine copy number of one or more genes in Table I and II and compared to a control sample or reference markers.

5 [0049] In yet another aspect of the present invention, protein levels are used as a surrogate measure of transcript levels. Protein levels have been shown to correlate with suppression or elevation of the transcript levels. Thus, the present invention encompasses techniques to measure levels of proteins that correspond to the polypeptide products encoded by the transcripts in Table I and II. Proteins are detected and used as markers of a predictive response to docetaxel. Methods of protein detection are well known in the art. For example, immunoassays are methodologies that
10 employ antibodies to detect the expression of a target protein.

[0050] In a particular embodiment, an immunoassay is used to detect the protein products of one or more genes listed in Table I and II. Additionally, antibodies against any one of the proteins listed in Table I and II may be used in a number of other detection methods. These detection methods include, but are not limited to, the following: Western blots, ELISA assays, sandwich ELISA. Alternatively, other assays not employing antibodies are contemplated and include approaches
15 that utilize DNA oligonucleotides or polypeptides that recognize proteins encoded by transcripts in Table I and II (e.g., aptamers). Mass spectrometric analysis of biological samples may also be used that determine the composition of polypeptides by determining the precise molecular weight of peptide fragments after proteolytic cleavage.

[0051] The present invention further encompasses suitable labels including enzymes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, chromo-
20 phores, radioisotopes, chelating agents, dyes, colloidal gold, latex particles, ligands (e.g., biotin), and chemiluminescent agents.

[0052] In an aspect of the present invention, the radioactive label used may be isotopes such as ³H, ¹⁴C, ³²P, ³⁵S, ³⁶Cl, ⁵¹Cr, ⁵⁷Co, ⁵⁸Co, ⁵⁹Fe, ⁹⁰Y, ¹²⁵I, ¹³¹I, and ¹⁸⁶Re. Quantification of radioactivity levels may be performed through currently known and available counting procedures. Conversely, the use of radiopaque substances may be
25 used. In the embodiment where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

[0053] A further aspect of the invention is the use of peptide binding agents such as antibodies or fragments of antibodies. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W. R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for
30 example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Thus, an embodiment of the present invention utilizes a detectable-labeled antibody fragment such as the F(ab')₂ fragment. Similarly, an antibody from which the Fc
35 region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

[0054] As is well-known in the art, within the antigen-binding portion of an antibody, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated
45 respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity. It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to
50 human FR and/or Fc/pFc' regions to produce a functional antibody (refer to U.S. Pat. Nos. 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205).

[0055] Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not
55 provoke human anti-mouse antibody (HAMA) responses when administered to humans.

[0056] Therefore, it is readily apparent to one of ordinary skill in the art, the present invention also encompasses F(ab')₂, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light

chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

[0057] The present invention may be better understood by reference to the following nonlimiting Examples, which are provided as exemplary of the invention. The following Examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLES

EXAMPLE 1: siRNA Screening

[0058] In order to identify genes that render cells more resistant or sensitive to docetaxel treatment, siRNAs against 101 genes were screened in HCT116 cells using a range of docetaxel concentrations for the generation of dose-response curves. Human colon cancer cell line HCT116 was obtained from ATCC and cultured in McCoy 5A supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 4 mM L-glutamine and 10% fetal bovine serum at 37°C with 95% CO₂ and 5% O₂. The siRNA list was comprised of cancer-related genes, including those that were over expressed in docetaxel-resistant breast tumors as detected by gene expression profiling experiments (Chang et al., Lancet 362:362, 2003). Additional criteria were that the targets be amenable to drug development. The overall scheme is summarized as follows. On the first day, HCT116 cells were plated at 5,000 cells per well in a 96-well format and on the following day transfected with a pool of 3-4 siRNAs per gene. A representative sample of the siRNAs used is shown in Table I and II. Lipofectamine 2000 (Invitrogen) was used to transfect siRNAs (Dharmacon) into HCT 116 cells in 96 well plates. On the third day siRNA was removed and docetaxel was added at concentrations ranging from 0 to 40nM. On the sixth day cell viability was quantified using WST-1 assay. This is an assay that monitors the activity of mitochondrial dehydrogenases present in viable cells that results in the cleavage of tetrazolium salt WST-1 to form formazan. On the day of assay, media were taken off from 96 well plates. WST-1 reagent (Roche) was diluted 10 times in McCoy 5A medium and 100ul was added to each well. Plates were then incubated for 40 - 80 minutes at 37°C before reading on SpectroMax (Molecular Devices) at 450nm. The WST-1 values were clustered hierarchically by calculating the ratio of the experimental to the control siRNA and a total of 15 genes were characterized as conferring sensitivity, and 9 genes conferring resistance shown in Table III below. The sensitive and resistant populations could be further divided into additional groups: 1) where the siRNA effect was observed at lower concentrations of docetaxel (1-6 nM) to shift the IC₅₀ or 2) where the major effect was observed at higher concentrations (> 6nM) with a smaller shift in IC₅₀.

[0059] As compared to Mad2, BubR1 and Mps1 siRNAs, the siRNAs targeting Grb2, CDK6, separase, and calcium/calmodulin-dependent protein kinase II delta (CamKIID) showed more pronounced effects at lower docetaxel concentrations (1-6 nM), with a characteristic shift in the IC₅₀. Overall, this subgroup showed weaker resistance than the mitotic checkpoint genes and the CamKIID siRNA generated the greatest level of protection, which was two-fold over control cells. These data demonstrate that loss of four mitotic checkpoint genes along with several other genes can increase docetaxel resistance to varying degrees.

[0060] The data in Figure 1 show several characteristic dose-response curves for cells transfected with siRNAs followed by exposure to various concentrations of docetaxel. The siRNAs against four mitotic checkpoint genes, including BubR1, Bub1, Mad2, and Mps1 (data not shown for Bub1) as well as guanine nucleotide exchange factor (GEFT) for Rac/Cdc42 demonstrated significant docetaxel resistance with the effect being more pronounced at higher docetaxel concentrations (>6 nM). The greatest level of resistance was shown for Mad2 where cell viability increased five-fold over the control siRNA transfected cells. The majority of the siRNAs did not score in the screen and here we show human retinoblastoma 1 (RB 1) as a representative example.

[0061] Taken together, these results show that siRNA screening can provide insights about how down-regulating gene expression sensitizes or protects cells from docetaxel treatment and, depending on the concentrations, evokes different mechanisms of action to modulate docetaxel-mediated cell death.

Table I: Sequences of siRNAs Conferring Increased Sensitivity to Docetaxel:				
Gene Name	siRNA sequence	SEQ ID NO	siRNA sequence	SEQ ID NO
P21(Waf1)	GCGAUGGAACUUCGACUUU	1	AGACCAUGUGGACCUGUCA	3
	UGGAACUUCGACUUUGUCA	2		

EP 2 395 103 A1

(continued)

Table I: Sequences of siRNAs Conferring Increased Sensitivity to Docetaxel:				
Gene Name	siRNA sequence	SEQ ID NO	siRNA sequence	SEQ ID NO
Pim-1	CCUUCGAAGAAAUCCAGAA*	4	UAUUCUUUCGAGCAUGAC	6
	UGGUGUGUGGAGAUUUC	5		
GBP-1	CGAAAGGCAUGUACCAUAA	7	GAACAGGAGCAACUACUAA	9
	GAUACAGGCUGAAGAGAUU	8		
RXRA	GCAAGGACCUGACCUACAC	10	GACCCUGUCACCAACAUUU	12
	GCAAGGACCGGAACGAGAA	11		
SPF45	CAAUCCGCUGACUGAAAU	13	GACCCUAUGUUUCCUAAUG	15
	GAACAAGACAGACCGAGAU	14		
Hec1	GUGUAUUCGACAACUCUGU	16	GUACUCAGUUGCAGACAUU	18
	GAUUGCAAGAUUGGAACAA	17	GUAUCACAAAUUGGCUAGA	19
Raf1	GCACGGAGAUGUUGCAGUA	20	GACAUGAAAUCCAACAAUA	22
	GCAAAGAACAUCAUCCAUA	21	GGAAUGAGCUUGCAGACU	23
Aurora A	GAGAACUGCUACUUAUAUA	24	GAAGGUCGGAUGCAUGAUG	26
	GAAUAUGCACCACUUGGAA	25	GUAAAAGGAAAGUUUGGUA	27
TACC3	GCACCUCGCUUCCCACAAG	28	GAACGAAGAGUCACUGAAG	30
	GAGCGGACCUGUAAAACUA	29		
RelB	GCAGAAAGAGGACAUUAUCA	31	GCCCGUCUAUGACAAGAAA	33
	GCAGCGAGCCAUUGCCUUU	32		
PRKCD	GGACGUGGAUUGCAAACAA	34	GAAAGAACGCUUCAACAUC	36
	GCAUGAAUGUGCACCAUAA	35		
BRAF35	GGGCGUACCAGCAGUCUGA	37	GUCUGAAGCCUUAUAGAUG	39
	GCUCUGGGCUCAUGAACAC	38		
HSPA1L	GAGAUCGACUCCCUGUUUG	40	GAUCAACGACGGAGACAAG	42
	UGGAGGAGWCAAGAGAAA	41		
STK11	GAGAAGGAAAWCAACUA	43	GAAACAUCUCCGGCUGAA	45
	GAGAAGCGUUUCCCAGUGU	44		
MKK3	GGUGGAGGCUGAUGACUUG	46	GGAGGGCCAUGUGAAGAUG	48
	GGAGAUUGCUGUGUCUAUC	47	GAUGUGAAGCCCUCCAUG	49
*Individual sequences having demonstrated good knockdown				

Table II: Sequence of siRNAs Conferring Decreased Sensitivity to Docetaxel:				
Gene Name	siRNA sequence	SEQ ID NO	siRNA sequence	SEQ ID NO
BubR1	GCAAUGAGCCUUGGAUUAU*	50	GGAAGAAGAUUCUAGAUGUA	52
	GGAACAACCUCAUUCUAAA	51		
Mad2	GAAAUUCGUGGCCGAGUUCU	53	GCCGAGUUCUUCUCAUUCG	55

(continued)

Table II: Sequence of siRNAs Conferring Decreased Sensitivity to Docetaxel:

Gene Name	siRNA sequence	SEQ ID NO	siRNA sequence	SEQ ID NO
	GUGGCAUUAUCCAUCUGA	54	GGAACAACUGAAAGAUUGG	56
Mps1	GUCGUUACAGUCAAGCAAU*	57	GAUGAACUAAGCUUGAAUA	59
	GCACGUGACUACUUUCAAA	58	GAGCAGUACCACUAGAAAU	60
GEFT	GAACACAGCCUGGAUAUGU	61	GGAUGAAGAUGAGCUGUAA	63
	GCACCGAGACUAAUUUCUUG	62	GCAUGUGGCUCAGAUUCUUG	64
Bub1	GUACAACAGUGACCUCCA	65	GCUUGUGAUAAAGAGUCA	67
	GAUGCUGGAUGUGUGAAUA	66	GAUCCACCAGAUGCUAUUG	68
hSeparase	GCUGUCAGAUAGUUGAUUU	69	GUGGACAGUUGUAAAUCUA	71
	GCCUACAGCUUCUAUAGUC	70	GAAGAUCGUWCCUAUACA	72
CamKIID	GCACGAAAGCAAGAGAUUA	73	GCUAGAAUCUGCCGUCUUU	75
	GAAGAAACCAGAUGGAGUA	74	GAUCAAGGCUGGAGCUUUA	76
CDK6	GAACAUGUCGAUCAAGACU	77	GAGUAGUGCAUCGCGAUCU	79
	GUUUGUAACAGAUUUCGAU	78	GUAACAGAUUUCGAUGAAC	80
GRB2	GAACGAAGAAUGUGAUCAG	81	GGUACAAGGCAGAGCUUAA	83
	GUGGAUUAUCACAGAUCUA	82	GUGCCACAGCAGCCGACAU	84
Control Sequences:				
	GUCGACCAUUAUGUACCGGAU	85	GGAUUCGUAACGUGAUUAGCG	86
Sequences of siRNAs Not Affecting Docetaxel Response:				
RB1	GAAACAGAAGAACCUGAUU	87	GUACAUCUCAGAAUCUUGA	89
	GAAAGGACAUGUGAACUUA	88		
* Individual sequences having demonstrated good knockdown				

**Table III: Genes Affecting Docetaxel Response
siRNAs Conferring Increased Sensitivity to Docetaxel:**

Gene Name	SEQ ID NO	Accession number	IC50 ratio	p(IC50 ratio)	Min ratio	p(Min ratio)
P21 (Waf1)	90	NM_000389	0.70	0.0004	0.25	0.0000
Pim-1	91	NM_002648	0.80	0.0011	0.30	0.0000
GBP-1	92	NM_002053	0.59	0.0000	0.25	0.0000
RXRA	93	NM_002957	0.64	0.0011	0.36	0.3098
SPF45	94	NM_032905	0.72	0.0000	0.47	0.0000
Hec1	95	NM_006101	0.64	0.0000	0.31	0.0121
Raf1	96	X03484	0.90	0.0059	0.30	0.0000

(continued)

**Table III: Genes Affecting Docetaxel Response
siRNAs Conferring Increased Sensitivity to Docetaxel:**

Gene Name	SEQ ID NO	Accession number	IC50 ratio	p(IC50 ratio)	Min ratio	p(Min ratio)
Aurora A	97	AF008551	0.73	0.0000	1.37	0.0018
TACC3	98	NM_006342	0.29	0.0000	0.85	0.0077
RelB	99	NM_006509	0.56	0.0000	0.77	0.0052
PRKCD	100	NM_006254	0.46	0.0683	0.59	1.0000
BRAF35	101	NM_006339	0.44	0.0000	1.29	0.1361
HSPA1L	102	NM_005345	0.60	0.0404	1.08	1.0000
STK11	103	NM_000455	0.94	0.4544	0.27	0.0000
MKK3	104	L36719	0.51	0.0000	0.82	0.0553
siRNAs Conferring Increased Resistance to Docetaxel:						
Gene Name	SEQ ID NO	Accession number	IC50 ratio	p(IC50 ratio)	Min ratio	p(Min ratio)
BubR1	105	AF046079	1.88	0.2207	3.01	0.5663 [^]
Mad2	106	AJ000186	3.22	0.0076	5.06	1.0000 [^]
Mps1	107	NM_003318	3.55	0.0008	2.92	1.0000 [^]
GEFT for Rac1/CDC4 2	108	NM_133483	3.50	1.0000	2.42	1.0000 [^]
Bub1	109	NM_004336	1.38	0.0007	2.45	0.0000
hSeparase	110	NM_012291	1.99	0.0000	0.88	1.0000
CamKIID	111	NM_001221	2.03	0.0016	1.29	1.0000
CDK6	112	NM_001259	1.99	0.0000	1.14	1.0000
GRB2	113	NM_002086	1.97	0.0000	1.16	1.0000
siRNAs Having No Effect on the Response to Docetaxel:						
Gene Name	SEQ ID NO	Accession number	IC50 ratio	p(IC50 ratio)	Min ratio	p(Min ratio)
RB1	114	NM_000321	0.87	0.0061	1.03	0.4863
GAPDH	115	NM_002046	nd	nd	nd	nd
RPS9	116	BC071941	nd	nd	nd	nd
Notes: Min ratio: The ratio of a siRNA over the control at the highest docetaxel dose The smaller the p value is, the more significant the difference between sample and control The p values marked with ^ are high because of poor curve fitting on the dose response curves, even though the differences are significant and reproducible Nd=not determined						

EXAMPLE 2: Cross Validation on a Subset of siRNAs that Confer Increased Docetaxel Resistance

[0062] A potential drawback to siRNA screening approaches rests on the observation that siRNAs can anneal to transcripts with partial identity or initiate micro-RNA (miRNA) translational blocks, making it difficult to distinguish between target-specific effects and nonspecific (off-site) effects (Jackson et al., Nat Biotechnol 21:635, 2003). To confirm resistance using an independent approach with a second sequence, stable knock-down cells lines were generated for BubR1 and Mps1 by infecting HCT116 cells with a retroviral vector carrying DNA oligonucleotides encoding a short hairpin (sh)

RNA. The shRNA contained a different sequence than the siRNA, targeting a distinct region of the open reading frame. The retroviral packaging cell line GP2-293 was obtained from Clontech. The cells were maintained in DMEM supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 4 mM L-glutamine and 10% fetal bovine serum. Virus was generated by transiently transfecting GP2-293 cells. A total of 3.6×10^6 cells were seeded in a 10 cm dish 24 hours prior to transfection. The medium was replaced 4 hours prior to transfection with DMEM containing 10% FBS minus antibiotics. The cells were transfected with 6 µg vector DNA, 6 µg of envelope plasmid VSV-G (Clontech) and 72 µl Lipfectamine-2000. The medium was replaced after 14-16 hours; the viral supernatant was harvested 24 hours later, filtered through a 0.45 µM filter and used to infect HCT116 cells at an M.O.I of 5 in the presence of 8 µg/ml polybrene. Forty-eight hours post-infection the cells were selected in 0.5 µg/ml puromycin for 7 days or until the background cells died off. The dose response curves generated with the BubR1 and Mps1 knock-down cell lines again showed enhanced resistance that was more pronounced at higher docetaxel concentrations (Figure 2), similar to the results obtained by siRNA transient transfections. To examine whether the shRNAs reduced mRNA levels we employed real-time PCR to detect endogenous transcripts and confirmed that the RNA levels were diminished in the BubR1 and Mps1 stable knock-down cell lines as compared to the vector control stable line (Figure 3).

[0063] Cells were lysed and RNA was extracted using RNAqueous -96 (Ambion). Taqman™ probes and forward and reverse primers were designed with Primer Express™ software (PE Applied Biosystems, UK). BLAST searches of the probe and primer sequences revealed no significant identity to other sequences other than the specific gene under test. For real time PCR, 20 µl of master TaqMan™ mix was made for each well: 4.825 µl Rnase-free water, 12.5 µl 2x Universal PCR master mix and 0.625 µl 40x Multiscribe™ and Rnase Inhibitor Mix (Applied BioSystems), 0.9 µl forward and reverse primers (100 µM), 0.25 µl probe (100 µM). To each well, 5 µl sample RNA (about 1ng/µl) was added. Plates were analyzed on a TaqMan™ ABI Prism 7700 Sequence Detector™ (Perkin-Elmer, UK). Cycling parameters were 48°C for 30 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. Test gene mRNA values were extrapolated from the standard curve and presented as percent remaining.

EXAMPLE 3: Downregulation of Mad2, BubR1 and Mps1 Protects Cells from Docetaxel-Induced Death by Escaping Mitotic Arrest, Coupled with the Generation of Aneuploidy

[0064] As determined by the WST-1 assay, loss of mitotic checkpoint genes in the presence of docetaxel correlated with increased cell viability to signify resistance (Figure 1). To further test the validity of WST-1 measurements, cytological experiments were performed to look at cell morphology and viability (Figure 4). The cells were tracked using confocal microscopy and Calcein-AM, a vital dye converted to green fluorescence by intracellular esterase serving as an indicator of metabolically active cells. Figure 4 demonstrates that 16 hours post docetaxel addition, the Mad2, BubR1 and, to a lesser extent, Mps1 siRNA transfected cells prematurely exited mitosis into an apparent interphase state coincident with a flattened cell morphology, whereas the majority of the control siRNA transfected cells were arrested in mitosis with a rounded up cell morphology. The flat cell phenotype has been previously described for other microtubule inhibitors and refers to the ability of cells to exit from mitotic arrest into an apparent interphase state without actually completing mitosis (Kung et al., Proc Natl Acad Sci 87:9553, 1990; Lanni and Jacks, Mol Cell Biol 18:1055, 1998). At 72 hours post treatment, the most striking observations for Mad2, BubR1 or Mps1 siRNA down-regulated cells were the presence of many more cells and their very large size, as compared to the siRNA control transfected cells that were virtually eliminated by docetaxel treatment. In the absence of docetaxel, mitotic checkpoint down-regulated cells looked similar to control cells at the two different time points and the increased number of cells at 72 hours suggested the cells were actively growing in the presence of the siRNA.

[0065] Mitotic checkpoint-impaired cells can bypass mitotic arrest and prematurely exit mitosis following treatment with microtubule inhibitors such as, colcemid, nocodazole and paclitaxel (Taylor and McKeon, Cell 89:727, 1997; Shin et al., Cancer Cell 4:483, 2003; Masuda et al., Am J Pathol 163:1109, 2003; Sudo et al., Cancer Res 64:2502, 2004). To determine if docetaxel treated HCT116 cells prematurely exit from mitosis following suppression of three specific checkpoint genes Mad2, BubR1 or Mps1, we measured mitotic indices of transfected cells. Accordingly, siRNA transfected Mad2, BubR1 or Mps1 cells were harvested without (0) treatment or at 8, 16, 24, 36, 48 and 72 hours after docetaxel treatment, then fixed and incubated with a polyclonal antibody that detects phosphorylation of histone H3 as an indication of mitosis (Mitotic Index Kit, Cellomics). A graphic representation for all time points are shown in Figure 5. The mitotic index peaked between 16 and 24 hours post treatment indicating that in all cases there was mitotic arrest. The mitotic index reached the highest value for cells transfected with the control siRNA, whereas cells transfected with Mad2 and BubR1 siRNA showed a significant decrease in mitotic index. The Mps1 siRNA effects were not as severe as Mad2 and BubR1. These results clearly show that mitotic checkpoint impaired cells can bypass mitotic arrest induced by docetaxel and that BubR1 siRNA was the most effective followed by Mad2 and Mps1.

[0066] To rule out the possibility that changes in mitotic index were coincident with large differences in knockdown efficiencies, we employed real-time PCR to measure mitotic checkpoint transcript levels. The experiment shown in Figure 6 demonstrates that mRNA levels were diminished to comparable levels in Mad2, BubR1 and Mps1 siRNA transfected

cells, suggesting that the mitotic index differences were more reflective of gene function.

[0067] From the microscopy data, it appeared that the very large cells may harbor abnormal DNA content. In order to further investigate whether these mitotic checkpoint impaired cells were capable of overriding docetaxel-induced cell cycle arrest, and re-enter S-phase to generate aneuploid cells, we performed FACS analysis to measure DNA content. The, Mps1, BubR1, Mad2 and control siRNA transfected cells were grown in the absence or presence of docetaxel, fixed and stained with propidium iodide and analyzed by FACS. The data were collected at several different time points post docetaxel addition (data not shown) and histograms for the 72 hour time point are shown in Figure 7. At 72 hours post docetaxel addition, transfections with Mps1, BubR1, Mad2 and siRNAs caused an accumulation of cells with 8N, 16N and in the case of BubR1 32N DNA content. By just using the control siRNA, an 8N population of cells was detected in the presence of docetaxel, but the 8N numbers was far greater for the mitotic checkpoint down-regulated cells. At an earlier time point following docetaxel addition (data not shown), the majority of control cells were arrested at 4N, whereas cells transfected with Mps1, BubR1 and Mad2 siRNAs were advancing from 4N to 8N. These results indicate that knockdown of mitotic checkpoint genes allow cells to more rapidly accumulate abnormal DNA levels and cross a greater threshold of ploidy as compared to wild-type cells. Our results demonstrate roles for Mad2, BubR1 and Mps1 in regulating mitotic index and cell cycle progression with a previously uncharacterized microtubule inhibitor docetaxel.

EXAMPLE 4: Formation of Docetaxel Resistant Colonies in BubR1 Downregulated Cells

[0068] The apoptotic function of BubR1 appears to be important for the regulation of chromosome fidelity given that underexpression of BubR1 in combination with anti-microtubule agents was associated with aneuploidy, and restoration of BubR1 associated with an activated checkpoint and apoptosis of aneuploid cells (Shin et al., Cancer Cell 4:483, 2003). To determine if permanently downregulating mitotic checkpoint genes enables cells to grow with a greater proliferative capacity, the BubR1 and Mps1 stable knockdown lines (Figure 4) were tested for their ability to proliferate and establish colonies in the continuous presence of docetaxel. The Mad2 stable knockdown cell line could not be generated since impairment of Mad2 was lethal to cells (Michel et al., Proc Natl Acad Sci 101:4459, 2004). The BubR1, Mps1 and control shRNA stable knockdown cells lines were subjected to 5 nM docetaxel for 10 days and after that stained with crystal violet. Figure 8 shows that the BubR1 knockdown cell line produced many more large colonies as compared to the control cell line. The Mps1 knockdown cell line was not able to grow out colonies in the presence of 5 nM docetaxel. When the plates were incubated for as long as 17 days, colonies were observed on the control plates but were still fewer in number as compared to the BubR1 knockdown line. These results link low levels of BubR1, but not Mps1, with advanced cell growth in the presence of the chemotherapeutic drug docetaxel.

EXAMPLE 5: Cross Validation of siRNA that Confers Increased Docetaxel Sensitivity

[0069] In addition to identifying siRNAs that protect cells from docetaxel-induced killing, the screen identified siRNAs that sensitize cells to killing. In Table III, Pim-1, p21^{waf1/Cip1} GBP-1, RXRA, Hec1 SPF45, Raf1 represent a group of siRNAs that show pronounced killing at higher docetaxel concentrations (>6 nM) with just a small shift in IC₅₀. The siRNA dose-response curves for oncogenic serine/threonine kinase Pim-1 and cell cycle inhibitor p21^{waf1/Cip1} were very similar (Figure 9), which may reflect overlapping or cooperative roles within a signaling pathway; and previous reports have shown that p21^{waf1/Cip1} is a substrate for Pim-1 (Wang et al., Biochim Biophys Acta 1593:45, 2002). Of further interest were data on Pim-1 overexpression in prostate epithelial cells, which lead to mitotic checkpoint interference and genetic instability (Roh et al., Cancer Res 63:8079, 2003). These results are in alignment with Mad2, BubR1 and Mps1 under-expression data showing a comparable phenotype with opposing expression levels (see Figure 1). Another siRNA that conferred sensitivity to docetaxel was Hec1.

[0070] In Table III, TACC3, RELB, Aurora-A, PRKCD (PKC), HSPA1A, and BRAF35 represent siRNAs that increase sensitivity at lower docetaxel concentrations (1- 6 nM) with a characteristic shift in IC₅₀. Aurora-A is a serine/threonine kinase that functions at the onset of mitosis and has been implicated in centrosome maturation and spindle assembly (reviewed in Meraldi et al., Curr Opin Genet Dev 14:29, 2004). Of great interest were published data showing that Aurora-A over expression in HeLa cells protected cells from paclitaxel, in alignment with our results where under expression of Aurora-A enhanced docetaxel killing (Anand et al., Cancer Cell 3:51, 2003). Admittedly this was a small decrease in IC₅₀ for Aurora-A representing a 25% decrease in survival; however, the results were precisely duplicated by using retroviral delivery of shRNA generating a stable knock-down of Aurora-A in HCT116 cells (compare Figures 9 to Figures 10 and 11).

EXAMPLE 6: Pim1 Inhibits Proliferation of HCT116 cells in the Absence of Docetaxel

[0071] To further evaluate the positives from the screen, it was important to distinguish between siRNAs that affect cell viability in the absence of docetaxel, and those that act cooperatively with docetaxel to enhance killing. To distinguish

between the possibilities we studied effects of siRNA transfection on proliferation using a trypan blue exclusion assay with cell counting to determine the number of viable cells in 6-well plates at 24, 48, 72 hours post-transfection. Our results show that Pim-1 siRNAs inhibit growth in HCT116 cells whereas TACC3 siRNAs have no effect on growth (Figure 12; knockdown quantitated in Figure 13), although both siRNAs enhance docetaxel-induced cell death (Figure 9).

EXAMPLE 7: Validation of Subsets of Resistant and Sensitive Genes Using Live/Dead Assays

[0072] To visually compare siRNAs that confer docetaxel sensitivity and resistance, microscopic imaging is used to determine the ratio of live to dead cells where Calcein-AM is used to stain live cells green, and propidium iodide (PI) to stain the nucleus of dead cells red. Post docetaxel (72 hours) addition, siRNA transfected BubR1 cells had the greatest number of viable cells, whereas siRNA transfected Pim-1 and TACC3 had the greatest number of dead cells and the control cells were in between (data not shown). Although the BubR1 siRNA alone showed increased cell death by 72 hours, the cells ultimately become more resistant to docetaxel. Pim-1 siRNA alone induced cell death by 24 hours whereas the TACC3 siRNA did not cause death. These results demonstrate that BubR1 down regulation was associated with increased cell viability and drug resistance, whereas Pim-1 and TACC3 down regulation was associated with increased cell death and drug sensitivity. Both Pim-1 and TACC3 showed more killing in the presence of docetaxel but this assay could not distinguish between an additive effect and cooperative killing.

EXAMPLE 8: Docetaxel-Induced Caspase-3 Activity was Diminished by BubR1 Down Regulation and Enhanced by Pim-1 Down Regulation

[0073] Docetaxel can cause cell death through induction of apoptosis (Kim et al., Int Mol Med 11:799,2003). To determine whether Pim-1 and BubR1 siRNAs could modulate a canonical apoptotic pathway in the absence and presence docetaxel, we studied activated caspase-3 levels in HCT116 cells (using a bioplex assay) (Figure 14). After 48 hours of 40 nM docetaxel, caspase-3 activity was induced in control cells and induction was further enhanced by down regulating Pim-1 and diminished by down regulating BubR1 (middle and lower panels). In the absence of docetaxel, down regulation of Pim-1 caused a slight increase in caspase-3 activity at 24 hours, but returned to control level by 48 and 72 hours (upper panel), indicating that other apoptotic machinery were activated to maintain the enhanced killing observed at 72 hours by WST-1 and LIVE/DEAD assays. Down regulation of BubR1 in the absence of docetaxel caused a very slight increase in caspase-3 activity, which is consistent with the observation that BubR1 knockdown initially caused cell death at 72 hours in the LIVE/DEAD assay. These results further implicate Pim-1 and BubR1 as effectors of docetaxel killing through the modulation of caspase-3 activity.

EXAMPLE 9: Signaling Pathways Involved in Docetaxel-Induced Pim-1-Associated Sensitivity and BubR1-Associated Resistance

[0074] The activities attributed to Pim-1 strongly suggest that it plays a central role in blocking signaling events that lead to cell death while promoting those that foster cell survival. In an attempt to define the molecular basis for enhanced cell death associated with a Pim-1 knockdown, we examined the activation state of a key cellular pathway involved in cell survival, AKT. HCT116 were seeded at 4×10^5 cells/well on 6-well plates and the next day transfected with siRNAs at 16 nM using Lipofectamine 2000 (Invitrogen). After 24 hours, cells were untreated or treated with 5 and 40 nM docetaxel. Cells were lysed 24, 48 and 72 hours after docetaxel addition with ice-cold lysis buffer (50 mM HEPES beffer (PH7.4), 1% NP40, 2.5 mM EDTA, 100 mM sodium fluoride, 10 mM sodium PP_i , protease inhibitor cocktail tablet (Roche), 2 mM sodium orthovanadate) and centrifuged at 12,000 g for 10 minutes. Lysates were then quantified for total protein levels using DC protein assay (BioRad). Active caspase-3 levels were determined using an active caspase-3 beadmates kit (Upstate) and the Luminex 100™ system with protocols suggested by the manufacture. Total and phosphorylated AKT levels were determined using a total AKT antibody bead kit and a phosphospecific AKT S473 antibody bead kit (Biosource) and the Luminex 100™ system with protocols suggested by manufacture.

[0075] The experiment shown in Figure 15 demonstrates that Pim-1 downregulation decreased the baseline phosphorylation of AKT, as compared to the control and the effect was significantly accentuated with increasing concentrations of docetaxel. By comparison, BubR1 downregulation increased the baseline phosphorylation of AKT and the effect was accentuated at the lower but not higher concentration of docetaxel, indicating alternative-signaling pathways may be activated at higher doses.

[0076] Applicants performed Western Blot analysis using antibodies against Pim-1 and BubR1 to measure protein levels at the 48 hour time point. Equal amounts of proteins were loaded into NuPAGE Novex Bis-Tris gels (Invitrogen). Antibodies against Pim-1 (Santa Cruz biotechnology), BubR1 (BD bioscience) and α -tubulin (Sigma) were used as suggested by the manufacture. Secondary antibodies were conjugated to HRP (BioRad) and detected by ECL Western Blot Detection System (Amhersham Biosciences) followed by exposure to Hyperfilm ECL (Amhersham Biosciences).

The experiment shown in Figure 16 demonstrated that Pim-1 and BubR1 protein levels were diminished as compared to the control, showing that reduced protein levels corresponded with a functional change (Figure 15). These data suggest that downregulating Pim-1 protein levels can block the phosphorylation and activation of AKT in order to compel the cells towards apoptosis. Pim-1 appears to mediate cell survival by activating pro-survival pathways.

[0077] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[0078] All references cited herein are incorporated by reference in their entireties.

Anand S, Penrhyn-Lowe S, Venkitaraman AR. (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. *Cancer Cell*. 3:51-62.

Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. (2003) Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. *Mol Cell*. 12:627-37.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. *Lancet*. 362:362-9.

Hong, WK (2002) The current status of docetaxel in solid tumors. *Oncology* 16:9-15.

Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. (2003) Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol*. 21:635-7.

Katsumata N. (2003) Docetaxel: an alternative taxane in ovarian cancer. *Br J Cancer*. 89 Suppl 3:S9-S15.

Kim R, Tanabe K, Uchida Y, Emi M, Toge T. (2003) Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. *Int J Mol Med*. 11:799-804.

Kolfschoten GM, Hulscher TM, Duyndam MC, Pinedo HM, Boven E. (2002) Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. *Biochem Pharmacol*. 63:733-43.

Kung AL, Sherwood SW, Schimke RT. (1990) Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. *Proc Natl Acad Sci USA*. 87:9553-7.

Lanni JS, Jacks T. (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. *Mol Cell Biol*. 18:1055-64.

Lee LF, Li G, Templeton DJ, Ting JP. (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). *J Biol Chem*. 273:28253-60.

Li Y, Dowbenko D, Lasky LA. (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip*/WAF1 and promotes cell survival. *J Biol Chem*. 277:11352-61.

Lum L, Yao S, Mozer B, Rovescalli A, Von Kessler D, Nirenberg M, Beachy PA. (2003) Identification of Hedgehog pathway components by RNAi in *Drosophila* cultured cells. *Science*. 299:2039-45.

Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. *Am J Pathol*. 163:1109-16.

McManus MT, Sharp PA. (2002) Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet*. 3:737-47.

Meraldi P, Honda R, Nigg EA. (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. *Curr Opin Genet Dev*. 14:29-36.

EP 2 395 103 A1

Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R. (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. *Proc Natl Acad Sci USA*. 101:4459-64.

5 Ojima, I. and Geney, R. 109881 Aventis (2004) *Curr Opin Investig Drugs* 4:737-40.

Ringel I, Horwitz SB. (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. *J Natl Cancer Inst*. 83:288-91.

10 Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum IE, Abdulkadir SA. (2003) Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. *Cancer Res*. 63:8079-84.

15 Shin HJ, Baek KH, Jeon AH, Park MT, Lee SJ, Kang CM, Lee HS, Yoo SH, Chung DH, Sung YC, McKeon F, Lee CW. (2003) Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. *Cancer Cell*. 4:483-97.

20 Simmer F, Moorman C, Van Der Linden AM, Kuijk E, Van Den Berghe PV, Kamath R, Fraser AG, Ahringer J, Plasterk RH. (2003) Genome-Wide RNAi of *C. elegans* Using the Hypersensitive rrf-3 Strain Reveals Novel Gene Functions. *PLoS Biol*. 1:E12.

Sudo T, Nitta M, Saya H, Ueno NT. (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint *Cancer Res*. 64:2502-8.

25 Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. (2003) Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. *Int J Oncol*. 22:875-81..

Taylor SS, McKeon F. (1997) Kinetochores localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. *Cell*. 89:727-35.

30 Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. *Cancer*. 88:2619-28.

35 Wang Z, Bhattacharya N, Mixer PF, Wei W, Sedivy J, Magnuson NS. (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. *Biochim Biophys Acta*. 1593:45-55.

Zhou J, Yao J, Joshi HC. (2002) Attachment and tension in the spindle assembly checkpoint *J Cell Sci*. 115:3547-55.

40

45

50

55

SEQUENCE LISTING

5 <110> GRUENBERG, Dorre
 HUANG, Xi
 NATESAN, Sridaran
 AUGUST, Paul

10 <120> METHOD FOR MEASURING RESISTANCE OR SENSITIVITY TO DOCETAXEL
 <130> USAV2004/0088 US PCT
 <160> 116
 <170> PatentIn version 3.3

15 <210> 1
 <211> 19
 <212> RNA
 <213> Artificial

20 <220>
 <223> siRNA

<400> 1
 gcgauggaac uucgacuuu 19

25 <210> 2
 <211> 19
 <212> RNA
 <213> Artificial

30 <220>
 <223> siRNA

<400> 2
 uggaacuucg acuuuguca 19

35 <210> 3
 <211> 19
 <212> RNA
 <213> Artificial

40 <220>
 <223> siRNA

<400> 3
 agaccaugug gaccuguca 19

45 <210> 4
 <211> 19
 <212> RNA
 <213> Artificial

50 <220>
 <223> siRNA

<400> 4
 ccuucgaaga aauccagaa 19

55 <210> 5
 <211> 19
 <212> RNA

<213> Artificial
 <220>
 <223> siRNA
 5 <400> 5
 uggugugugg agauauucc 19

<210> 6
 <211> 19
 10 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 15 <400> 6
 uauuccuuuc gagcaugac 19

<210> 7
 <211> 19
 20 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 25 <400> 7
 cgaaaggcau guaccuuaa 19

<210> 8
 <211> 19
 30 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 35 <400> 8
 gauacaggcu gaagagauu 19

<210> 9
 <211> 19
 40 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 45 <400> 9
 gaacaggagc aacuacuaa 19

<210> 10
 <211> 19
 50 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 55 <400> 10
 gcaaggaccu gaccuacac 19

5
 <210> 11
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 11
 gcaaggaccg gaacgagaa 19

10
 <210> 12
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 12
 gaccuguca ccaacauuu 19

15
 <210> 13
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 13
 caauccgcu gacugaaau 19

20
 <210> 14
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 14
 gaacaagaca gaccgagau 19

25
 <210> 15
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 15
 gaccuaugu uuccuaaug 19

30
 <210> 16
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

35
 <210> 16
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

40
 <210> 16
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

45
 <210> 16
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

50
 <210> 16
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

55

	<400> 16 guguauucga caacucugu	19
5	<210> 17 <211> 19 <212> RNA <213> Artificial	
	<220> <223> siRNA	
10	<400> 17 gauugcaaga uuggaaca	19
15	<210> 18 <211> 19 <212> RNA <213> Artificial	
	<220> <223> siRNA	
20	<400> 18 guacucaguu gcagacauu	19
25	<210> 19 <211> 19 <212> RNA <213> Artificial	
	<220> <223> siRNA	
30	<400> 19 guaucacaaa uuggcuaga	19
35	<210> 20 <211> 19 <212> RNA <213> Artificial	
	<220> <223> siRNA	
40	<400> 20 gcacggagau guugcagua	19
45	<210> 21 <211> 19 <212> RNA <213> Artificial	
	<220> <223> siRNA	
50	<400> 21 gcaaagaaca ucauccaa	19
55	<210> 22 <211> 19 <212> RNA	

<213> Artificial
 <220>
 <223> siRNA
 5
 <400> 22
 gacaugaaau ccaacaaua 19

<210> 23
 <211> 19
 <212> RNA
 <213> Artificial
 10
 <220>
 <223> siRNA
 15
 <400> 23
 ggaaugagcu ugcaugacu 19

<210> 24
 <211> 19
 <212> RNA
 <213> Artificial
 20
 <220>
 <223> siRNA
 25
 <400> 24
 gagaacugcu acuuauaaua 19

<210> 25
 <211> 19
 <212> RNA
 <213> Artificial
 30
 <220>
 <223> siRNA
 35
 <400> 25
 gaauaugcac cacuuggaa 19

<210> 26
 <211> 19
 <212> RNA
 <213> Artificial
 40
 <220>
 <223> siRNA
 45
 <400> 26
 gaaggucgga ugcaugaug 19

<210> 27
 <211> 19
 <212> RNA
 <213> Artificial
 50
 <220>
 <223> siRNA
 55
 <400> 27
 guaaaggaaa guuugguaa 19

<210> 28
 <211> 19
 <212> RNA
 <213> Artificial
 5
 <220>
 <223> siRNA
 <400> 28
 gcaccucgcu ucccacaag 19
 10
 <210> 29
 <211> 19
 <212> RNA
 <213> Artificial
 15
 <220>
 <223> siRNA
 <400> 29
 gagcggaccu guaaaacua 19
 20
 <210> 30
 <211> 19
 <212> RNA
 <213> Artificial
 25
 <220>
 <223> siRNA
 <400> 30
 gaacgaagag ucacugaag 19
 30
 <210> 31
 <211> 19
 <212> RNA
 <213> Artificial
 35
 <220>
 <223> siRNA
 <400> 31
 gcagaaagag gacauauca 19
 40
 <210> 32
 <211> 19
 <212> RNA
 <213> Artificial
 45
 <220>
 <223> siRNA
 <400> 32
 gcagcgagcc auugccuuu 19
 50
 <210> 33
 <211> 19
 <212> RNA
 <213> Artificial
 55
 <220>
 <223> siRNA

	<400> 33 gcccgucuau gacaagaaa	19
5	<210> 34 <211> 19 <212> RNA <213> Artificial	
10	<220> <223> siRNA	
	<400> 34 ggacguggau ugcaaaca	19
15	<210> 35 <211> 19 <212> RNA <213> Artificial	
20	<220> <223> siRNA	
	<400> 35 gcaugaaugu gcaccauaa	19
25	<210> 36 <211> 19 <212> RNA <213> Artificial	
30	<220> <223> siRNA	
	<400> 36 gaaagaacgc uucaacauc	19
35	<210> 37 <211> 19 <212> RNA <213> Artificial	
40	<220> <223> siRNA	
	<400> 37 gggcguacca gcagucuga	19
45	<210> 38 <211> 19 <212> RNA <213> Artificial	
50	<220> <223> siRNA	
	<400> 38 gcucugggcu caugaacac	19
55	<210> 39 <211> 19 <212> RNA	

<213> Artificial
 <220>
 <223> siRNA
 5 <400> 39
 gucugaagcc uauaagaug 19

<210> 40
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 15 <400> 40
 gagaucgacu cccuguuug 19

<210> 41
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 25 <400> 41
 uggaggaguu caagagaaa 19

<210> 42
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 35 <400> 42
 gaucaacgac ggagacaag 19

<210> 43
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 45 <400> 43
 gaagaaggaa auucaacua 19

<210> 44
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 55 <400> 44
 gagaagcguu ucccagugu 19

5
 <210> 45
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 45
 gaaacauccu ccggcugaa 19

10
 <210> 46
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 46
 gguggaggcu gaugacuug 19

15
 <210> 47
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 47
 ggagauugcu gugucuauc 19

20
 <210> 48
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 48
 ggagggccau gugaagaug 19

25
 <210> 49
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 49
 gaugugaagc ccuccaaug 19

30
 <210> 50
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

35
 <210> 50
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

40
 <210> 50
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

45
 <210> 50
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

50
 <210> 50
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

55

	<400> 50 gcaaugagcc uuuggauau	19
5	<210> 51 <211> 19 <212> RNA <213> Artificial	
10	<220> <223> siRNA	
	<400> 51 ggaacaaccu cauucuaaa	19
15	<210> 52 <211> 19 <212> RNA <213> Artificial	
20	<220> <223> siRNA	
	<400> 52 ggaagaagau cuagaugua	19
25	<210> 53 <211> 19 <212> RNA <213> Artificial	
30	<220> <223> siRNA	
	<400> 53 gaaaucgugg ccgaguucu	19
35	<210> 54 <211> 19 <212> RNA <213> Artificial	
40	<220> <223> siRNA	
	<400> 54 guggcauaua uccaucuga	19
45	<210> 55 <211> 19 <212> RNA <213> Artificial	
50	<220> <223> siRNA	
	<400> 55 gccgaguucu ucucauucg	19
55	<210> 56 <211> 19 <212> RNA	

<213> Artificial
 <220>
 <223> siRNA
 5 <400> 56
 ggaacaacug aaagauugg 19

<210> 57
 <211> 19
 10 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 15 <400> 57
 gucguuacag ucaagcaau 19

<210> 58
 <211> 19
 20 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 25 <400> 58
 gcacgugacu acuuucaa 19

<210> 59
 <211> 19
 30 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 35 <400> 59
 gaugaacuaa gcuugaau 19

<210> 60
 <211> 19
 40 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 45 <400> 60
 gagcaguacc acuagaaau 19

<210> 61
 <211> 19
 50 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 55 <400> 61
 gagcaguacc acuagaaau 19

5
 <210> 62
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 62
 gcaccgagac uauuucuug 19

10
 <210> 63
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 63
 ggaugaagau gagcuguua 19

15
 <210> 64
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 64
 gcauguggcu cagaucuug 19

20
 <210> 65
 <211> 18
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 65
 guacaacagu gaccucca 18

25
 <210> 66
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 66
 gaugcuggau gugugaaua 19

30
 <210> 67
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

35
 <210> 67
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

40
 <210> 67
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

45
 <210> 67
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

50
 <210> 67
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

55

	<400> 67 gcuugugaua aagagucaa	19
5	<210> 68 <211> 19 <212> RNA <213> Artificial	
10	<220> <223> siRNA	
	<400> 68 gauccaccag augcuauug	19
15	<210> 69 <211> 19 <212> RNA <213> Artificial	
20	<220> <223> siRNA	
	<400> 69 gcugucagau aguugauuu	19
25	<210> 70 <211> 19 <212> RNA <213> Artificial	
30	<220> <223> siRNA	
	<400> 70 gccuacagcu ucuauaguc	19
35	<210> 71 <211> 19 <212> RNA <213> Artificial	
40	<220> <223> siRNA	
	<400> 71 guggacaguu guaaaucua	19
45	<210> 72 <211> 19 <212> RNA <213> Artificial	
50	<220> <223> siRNA	
	<400> 72 gaagaucguu uccuauaca	19
55	<210> 73 <211> 19 <212> RNA	

<213> Artificial
 <220>
 <223> siRNA
 5 <400> 73
 gcacgaaagc aagagauua 19

<210> 74
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 15 <400> 74
 gaagaaacca gauggagua 19

<210> 75
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 25 <400> 75
 gcuagaaucu gccgucuuu 19

<210> 76
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 35 <400> 76
 gaucaaggcu ggagcuuau 19

<210> 77
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 45 <400> 77
 gaacaugucg aucaagacu 19

<210> 78
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 55 <400> 78
 guuuguaaca gauaucgau 19

5
 <210> 79
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 79
 gaguagugca ucgcgaucu 19

10
 <210> 80
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 80
 guaacagaua ucgaugaac 19

15
 <210> 81
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 81
 gaacgaagaa ugugaucag 19

20
 <210> 82
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 82
 guggauuauac acagaucua 19

25
 <210> 83
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA
 <400> 83
 gguacaaggc agagcuuaa 19

30
 <210> 84
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

35
 <210> 84
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

40
 <210> 84
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

45
 <210> 84
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

50
 <210> 84
 <211> 19
 <212> RNA
 <213> Artificial
 <220>
 <223> siRNA

55

<400> 84
 gugccacagc agccgacau 19

5 <210> 85
 <211> 21
 <212> RNA
 <213> Artificial

10 <220>
 <223> siRNA

<400> 85
 gucgaccuu auguaccgga u 21

15 <210> 86
 <211> 21
 <212> RNA
 <213> Artificial

20 <220>
 <223> siRNA

<400> 86
 ggauucguaa cgugauuagc g 21

25 <210> 87
 <211> 19
 <212> RNA
 <213> Artificial

30 <220>
 <223> siRNA

<400> 87
 gaaacagaag aaccugau 19

35 <210> 88
 <211> 19
 <212> RNA
 <213> Artificial

40 <220>
 <223> siRNA

<400> 88
 gaaaggacau gugaacuua 19

45 <210> 89
 <211> 19
 <212> RNA
 <213> Artificial

50 <220>
 <223> siRNA

<400> 89
 guacaucuca gaaucuuga 19
 <210> 90
 <211> 2140
 <212> DNA
 <213> human

55

EP 2 395 103 A1

<400> 90
 agctgaggtg tgagcagctg ccgaagtcag ttccttgtgg agccggagct gggcgcggat 60
 tcgccgaggc accgaggcac tcagaggagg cgccatgtca gaaccggctg gggatgtccg 120
 5 tcagaacca tgcggcagca aggctgccg ccgcctcttc ggcccagtgg acagcgagca 180
 gctgagccgc gactgtgatg cgctaatggc gggctgcac caggaggccc gtgagcgatg 240
 gaacttcgac tttgtcaccg agacaccact ggaggggtgac ttcgcctggg agcgtgtgcg 300
 10 gggccttggc ctgcccaagc tctaccttcc cacggggccc cggcgaggcc gggatgagtt 360
 gggaggaggc aggcggcctg gcacctcacc tgctctgctg caggggacag cagaggaaga 420
 ccatgtggac ctgtcactgt cttgtaccct tgtgcctcgc tcaggggagc aggctgaagg 480
 15 gtccccaggt ggacctggag actctcaggg tcgaaaacgg cggcagacca gcatgacaga 540
 tttctaccac tccaaacgcc ggctgatctt ctccaagagg aagccctaata cggcccacag 600
 gaagcctgca gtcctggaag cgcgagggcc tcaaaggccc gctctacatc ttctgcctta 660
 20 gtctcagttt gtgtgtctta attattattt gtgttttaata ttaaacacct cctcatgtac 720
 ataccttggc cgccccctgc cccccagcct ctggcattag aattatttaa acaaaaacta 780
 ggcggttgaa tgagaggttc ctaagagtgc tgggcatttt tattttatga aatactattt 840
 25 aaagcctcct catcccgtgt tctccttttc ctctctcccg gaggttgggt gggccggctt 900
 catgccagct acttctcct cccacttgt ccgctgggtg gtaccctctg gaggggtgtg 960
 gctccttccc atcgtgtca caggcggtta tgaaattcac ccccttctct ggacactcag 1020
 acctgaattc ttttcattht gagaagtaaa cagatggcac tttgaagggg cctcaccgag 1080
 30 tgggggcatc atcaaaaact ttggagtccc ctacactcct ctaaggttgg gcagggtgac 1140
 cctgaagtga gcacagccta gggctgagct ggggacctgg taccctcctg gctcttgata 1200
 cccccctctg tcttgtgaag gcagggggaa ggtgggggtac tggagcagac caccctgcct 1260
 35 gccctcatgg cccctctgac ctgcactggg gagcccgtct cagtgttgag ccttttccct 1320
 ctttggctcc cctgtacctt ttgaggagcc ccagcttacc cttcttctcc agctgggctc 1380
 tgcaattccc ctctgctgct gtccctcccc cttgtctttc ccttcagtac cctctcatgc 1440
 40 tccaggtggc tctgaggtgc ctgtcccacc cccaccccca gctcaatgga ctggaagggg 1500
 aagggacaca caagaagaag ggcaccctag ttctacctca ggcagctcaa gcagcgaccg 1560
 cccctcctc tagctgtggg ggtgaggggc ccatgtgggt gcacaggccc ccttgagtgg 1620
 45 ggttatctct gtgttagggg tatatgatgg gggagtagat ctttctagga gggagacact 1680
 ggcccccaa atcgtccagc gaccttctc atccaccca tcctcccca gttcattgca 1740
 ctttgattag cagcgaaca aggagtcaga cattttaaga tgggtggcagt agaggctatg 1800
 50 gacagggcat gccacgtggg ctcatatggg gctgggagta gttgtctttc ctggcactaa 1860
 cgttgagccc ctggaggcac tgaagtgctt agtgacttg gagtattggg gtctgacccc 1920
 aaacacctc cagctcctgt aacatactgg cctggactgt tttctctcgg ctccccatgt 1980
 55 gtcctgggtc ccgtttctcc acctagactg taaacctctc gagggcaggg accacaccct 2040

EP 2 395 103 A1

gtactgttct gtgtctttca cagctcctcc cacaatgctg aatatacagc aggtgctcaa 2100
 taaatgattc ttagtgactt taaaaaaaaa aaaaaaaaaa 2140

5

<210> 91
 <211> 5449
 <212> DNA
 <213> human

10

<400> 91
 gcgccggggg cgcgcgcgcc cgccgcccgc tgcttgcgcc gccggccggg catgagttag 60

tcgcagacat ggacaccaa ctttcctgc cgctcgattt ctccaccag gtgaactcct 120

ccctcacctc cccgacgggg cgaggctcca tggctgcccc ctgctgcac ccgtccctgg 180

15

ggcctggcat cggctccccg ggacagctgc attctcccat cagcacctg agtccccca 240

tcaacggcat gggcccgcct ttctcggc tcaagctcccc catgggcccc cactccatgt 300

cggtgcccac cacaccacc ctgggcttca gcaactggcag cccccagctc agctcaccta 360

20

tgaaccccgt cagcagcagc gaggacatca agccccctt gggcctcaat ggcgtcctca 420

aggtccccgc ccaccctca ggaacatgg cttccttca caagcacatc tgcgccatct 480

gcggggaccg ctctcaggc aagcactatg gagtgtacag ctgaggggg tgcaagggt 540

25

tcttcaagcg gacggtgcgc aaggacctga cctacacctg ccgagacaac aaggactgcc 600

tgattgacaa gcggcagcgg aaccgggtgcc agtactgccg ctaccagaag tgcctggcca 660

tgggcatgaa gcgggaagcc gtgcaggagg agcggcagcg tggcaaggac cggaacgaga 720

30

atgaggtgga gtcgaccagc agcggcaacg aggacatgcc ggtggagagg atcctggagg 780

ctgagctggc cgtggagccc aagaccgaga cctacgtgga ggcaaacatg gggctgaacc 840

ccagctcgcc gaacgacct gtcaccaaca tttgccagc agccgacaaa cagcttttca 900

35

ccctggtgga gtgggccaag cggatcccac acttctcaga gctgcccctg gacgaccagg 960

tcctctgct gcgggcaggc tggaatgagc tgctcatcgc ctcttctcc caccgctcca 1020

tcgccgtgaa ggacgggatc ctcttgcca ccgggctgca cgtccaccgg aacagcggcc 1080

40

acagcgcagg ggtgggcgcc atctttgaca ggggtgctgac ggagcttgtg tccaagatgc 1140

gggacatgca gatggacaag acggagctgg gctgcctgag cgccatcgtc ctctttaacc 1200

ctgactcaa gggctctcg aaccgggccg aggtggaggc gctgaggag aaggtctatg 1260

45

cgctcttga ggcctactgc aagcacaagt acccagagca gccgggaagg ttcgctaagc 1320

tcttgcctcg cctgccggct ctgcgctcca tcgggctcaa atgcctggaa catctcttct 1380

tcttcaagct catcggggac acaccattg acaccttct tatggagatg ctggaggcgc 1440

50

cgcaccaa at gacttaggcc tgcgggcca tcctttgtgc ccaccgttc tggccaccct 1500

gcctggacgc cagctgttct tctcagcctg agccctgtcc ctgccccttct ctgctggcc 1560

tgtttgact ttggggcaca gcctgtcact gctctgccta agagatgtgt tgtcaccctc 1620

55

cttatttctg ttactacttg tctgtggccc agggcagtg ctttctgag gcagcagcct 1680

EP 2 395 103 A1

	tcgtggcaag aactagcgtg agcccagcca ggcgcctccc caccgggctc tcaggacacc	1740
	ctgccacacc ccacggggct tgggcgacta cagggctctc gggccccagc cctggagctg	1800
5	caggagttag gaacggggct tttgtttccg ttgctgttta tcgatgctgg ttttcagaat	1860
	tcctgtgtgg ccctcctgtc tggagtgaca tcttcatctg ctctgaatac tggtgcccag	1920
	ccagcccgtg acagcttccc cctaatacagg aggggacagc tgggggcgca agctgggtgtg	1980
10	tcatacagcaa agacctcagc cgcctcgggg atgagagggg actcgtgggg caagcaagct	2040
	gccctgtgct ctgagtgagg gggaaagtag cccctttttc caaagataac tcacagtttt	2100
	gccctcgagc caatgagaac atgagctgcc ctctgtgcaa ggtttcgggg ccacctccag	2160
15	gctgcagggg cgggtcactc acccccctgt tttctctctg ccttggtgtt ctggtttcag	2220
	actcccgact ccccgttcag accagagtgc cccggcccct cccagcctg agtcttctcc	2280
	ttgctctgcg ggggtgggctg aggcttgctc ttgtttcctg cagggctggc cctggctcgg	2340
20	gcaggggtgg gcataccac ctcactggcc ttgctggagg cacagggctc tgcggacctg	2400
	cagccatctg tgaggcccg cgggatggga ggggaggagg gtggcctgtt ggtttccctc	2460
	agagggggca ggtggcctgg agagagaggg gctcaggaac tgggagcctc gtgggtgggg	2520
25	cagatgctcc gcggcctgga gtggctctgc cggggcattg gtgggacccc tgctcaggcc	2580
	ttctctctgg ctgccagttg tgtctaaaag actcttgga tctgagaacc cggagtcgca	2640
	gcgccctcgg gcctgggcca cacgcaggcc ctggtgggac caccagcct ggtattgtcc	2700
30	acggacagcg ttgttcaccc agagccttac ttgggagcct cactgaacgc ctgctctggt	2760
	tgaaggtggg gtgggggagg ggcctggggc ctccctggct cagcccagtg cggcctggcg	2820
	ctcctcccgc aggcctctgcc cccgggctcc ggtggtgagg ggcctctca ggttgaactc	2880
35	gcctcttttg cactggaagg ccctcccttt ggcctgagta cttttcccg tccagcctca	2940
	gtcccgtgga cccagccttt gtcagtggca ggtgcctgaa cagaggggtg atggggggga	3000
	taccggaggg ggtcttgtct tcccagccgc agtctaggaa tgatgcgggg ggggtggacgc	3060
40	cttctccata gtctttccc acctggagca ggggcttct cagtgggtgag gggagctgcc	3120
	tacaggttag accgggaggc agtggcctgg agaggcagct ttccagcctt ggtggggaag	3180
	aaagtgtcca ttctttgcct tcctggagct cccagccaga gctgagctta ggcacccgag	3240
45	tggagcctgc agctgagtct gtgcccgaga caggctgtca gagattccag aagcctctcc	3300
	tccccgccgc cctccacccc tgcctttcag cgttgtggat ccctagaggt ggccccctgc	3360
	ccgatccacc gtcctgaggc agagtgttga gcctcatacc tgtaccaggt ccccgccag	3420
	ctgggcccct cccaggcact gccaggaagc cccagctgcc cctggcgggt gtgggtgaaa	3480
50	tggcaggagg gtgcaggtac tcttggggcc ccagcggtag gagtgcaaaa gaccaacgc	3540
	caacacctgg tgctttttgc agccagcgc caccatccg tgccccgacc cttgggaatg	3600
	cccgcggctc cagaggaaaa agcccagga cggggcctcc gttgcgggg gtcggctgct	3660
55	tcttgggaac tttgtcgttt ccggcgtgg ctggctggct ggctgtaaag cactgaagcc	3720

EP 2 395 103 A1

ccccgccgc caaccctga aagcagaacc tggcctccct ggccacagca gccttaccca 3780
 ccgctctacg tgtcccgggc acttcccgca gccttcccgt cctttctca tcggccttgt 3840
 5 agttgtacag tgctgttggg ttgaaaaggt gatgtgtggg gagtgcggct catcactgag 3900
 tagagaggta gaatttctat ttaaccagac ctgtagtagt attaccaatc cagttcaatt 3960
 aaggtgattt tttgtaatta ttattatattt ggtgggacaa tctttaattt tctaaagata 4020
 10 gcactaacat cagctcatta gccacctgtg cctgtccccg ccttggcccg gctggatgaa 4080
 gcggcttccc cgcagggccc cacttccca gtggctgctt cctggggacc cagggcacc 4140
 cggcaccttc aggcacgctc ctcagctggt cacctcccgg ctttgccgtt cagatggggc 4200
 15 tcctgaggct caggagtgaa gatgccacag agccgggctc ccctaggctg cgtcgggcat 4260
 gcttgggaagc tggcctgcca ggaccttcca ccctggggcc tgtgtcagcc gccggccctc 4320
 cgcaccctgg aagcacacgg cctctgggaa ggacagccct gaccttcggt tttccgagca 4380
 cgggtgtttcc caagaattct gggctggcgg cctggtggca gtgctggaga tgaccccag 4440
 20 cccctccccg tggggcacc caggaggccc tgccggaatg tgcagcctgt gggtagtcgg 4500
 ctggtgtccc tgtcgtggag ctggggtgcg tgatctggtg ctcgtccacg caggtgtgtg 4560
 gtgtaaacad gtatgtgctg tacagagaga cgcgtgtgga gagagccgca caccagcgc 4620
 25 acccaggaaa ggcggagcgg ttaccagtgt tttgtgttta tttttaatca agacgtttcc 4680
 cctgttttcc tataaatttg cttcgtgtaa gcaagtacat aaggaccctc ctttggtgaa 4740
 atccgggttc gaatgaatat ctcaaggcag gagatgcatc tattttaaga tgctttggag 4800
 30 cagacagctt tagccgttcc caatccttag caatgcctta gctgggacgc atagctaata 4860
 ctttagagag gatgacagat ccataaagag agtaaagata agagaaaatg tctaaagcat 4920
 ctggaaggt aaaaaaaaaa aatctatttt tgtacaaatg taattttatc cctcatgtat 4980
 35 acttgatagat ggcgggggga gggctgggac tgtttcgttt ctgcttctag agattgaggt 5040
 gaaagcttcg tccgagaaac gccaggacag acgatggcag aggagagggc tcctgtgacg 5100
 gcggcgaggc ttgggaggaa accgccgcaa tgggggtgtc ttcctcggg gcaggagggg 5160
 40 gggcctgagg ctttcaaggg ttttctccc tttcgagtaa tttttaagc cttgctctgt 5220
 tgtgtcctgt tgccgctct ggccctcctg tgactgactg tgaagtggct tctccgtacg 5280
 attgtctctg aaacatcgtg gcctcaggtg ccagggtttg atggacagta gcattagaat 5340
 45 tgtggaaaag gaacacgcaa agggagaagt gtgagaggag aaacaaaata tgagcgttta 5400
 aaatacatcg ccattcagtt cgtaaaaaa aaaaaaaaaa aaaaaaaaaa 5449

 <210> 92
 <211> 2881
 <212> DNA
 <213> human

 <400> 92
 50 acagaagtgc tagaagccag tgctcgtgaa ctaaggagaa aaagaacaga caaggaaca 60
 55 gcctggacat ggcatcagag atccacatga caggcccaat gtgcctcatt gagaacacta 120

EP 2 395 103 A1

atgggcgact gatggcgaat ccagaagctc tgaagatcct ttctgccatt acacagccta 180
 tgggtgggtg ggcaattgtg ggcctctacc gcacaggcaa atcctacctg atgaacaagc 240
 5 tggctggaaa gaaaaagggc ttctctctgg gctccacggt gcagtctcac actaaaggaa 300
 tctggatgtg gtgtgtgccc cacccaaga agccaggcca catcctagtt ctgctggaca 360
 ccgagggctc gggagatgta gagaagggtg acaaccagaa tgactcctgg atcttcgccc 420
 10 tggccgtcct cctgagcagc accttcgtgt acaatagcat aggaaccatc aaccagcagg 480
 ctatggacca actgtactat gtgacagagc tgacacatag aatccgatca aaatcctcac 540
 ctgatgagaa tgagaatgag gttgaggatt cagctgactt tgtgagcttc ttcccagact 600
 15 ttgtgtggac actgagagat ttctccctgg acttggaagc agatggacaa cccctcacac 660
 cagatgagta cctgacatac tccctgaagc tgaagaaagg taccagtcaa aaagatgaaa 720
 cttttaacct gccagactc tgtatccgga aattcttccc aaagaaaaaa tgctttgtct 780
 20 ttgatcggcc cgttcaccgc aggaagcttg cccagctcga gaaactacaa gatgaagagc 840
 tggaccccga atttgtgcaa caagtagcag acttctgttc ctacatcttt agtaattcca 900
 aaactaaaac tctttcagga ggcattccagg tcaacgggccc tcgtctagag agcctggtgc 960
 25 tgacctacgt caatgccatc agcagtgggg atctgcccgtg catggagaac gcagtcctgg 1020
 ccttgGCCca gatagagaac tcagctgcag tgcaaaaggc tattgcccac tatgaacagc 1080
 agatgggcca gaaggtgcag ctgcccacag aaagcctcca ggagctgctg gacctgcaca 1140
 gggacagtga gagagaggcc attgaagtct tcatcaggag ttccttcaaa gatgtggacc 1200
 30 atctatttca aaaggagtta gcggcccagc tagaaaaaaa gcgggatgac ttttgtaaac 1260
 agaatcagga agcatcatca gatcgttgct cagggttact tcaggtcatt ttcagtcctc 1320
 tagaagaaga agtgaaggcg ggaatttatt cgaaccagc gggctatcgt ctctttgttc 1380
 35 agaagctaca agacctgaag aaaaagtact atgaggaacc gaggaagggg atacaggctg 1440
 aagagattct gcagacatac ttgaaatcca aggagtctat gactgatgca attctccaga 1500
 cagaccagac tctcacagaa aaagaaaagg agattgaagt ggaacgtgtg aaagctgagt 1560
 40 ctgcacaggc ttcagcaaaa atgttgacagc aaatgcaaag aaagaatgag cagatgatgg 1620
 aacagaagga gaggagtatt caggaacact tgaaacaact gactgagaag atggagaacg 1680
 acagggcca gttgctgaaa gagcaagaga ggaccctcgc tcttaactt caggaacagg 1740
 45 agcaactact aaaagagggg tttcaaaaag aaagcagaat aatgaaaaat gagatacagg 1800
 atctccagac gaaaatgaga cgacgaaagg catgtaccat aagctaaaga ccagagcctt 1860
 cctgtcacc ctaaccaagg cataattgaa acaattttag aatttggaac aagcgtcact 1920
 50 acatttgata ataattagat cttgcatcat aacaccaaaa gtttataaag gcatgtggta 1980
 caatgatcaa aatcatgttt tttcttaaaa aaaaaaaaaa gactgtaaat tgtgcaacaa 2040
 agatgcattt acctctgtat caactcagga aatctcataa gctggtacca ctcaggagaa 2100
 55 gtttattctt ccagatgacc agcagtagac aaatggatac tgagcagagt cttaggtaaa 2160

EP 2 395 103 A1

5 agtcttggga aatatttggg cattggtctg gccaagtcta caatgtccca atatcaagga 2220
 caaccaccct agcttcttag tgaagacaat gtacagttat ccattagatc aagactacac 2280
 ggtctatgag caataatgtg atttctggac attgcccatg tataatcctc actgatgatt 2340
 tcaagctaaa gcaaaccacc ttatacagag atctagaatc tctttatgtt ctccagagga 2400
 aggtggaaga aaccatgggc aggagtagga attgagtgat aaacaattgg gctaataag 2460
 10 aaaacttctc ttattgttca gttcatccag attataactt caatgggaca ctttagacca 2520
 ttagacaatt gacactggat taaacaaatt cacataatgc caaatacaca atgtatttat 2580
 agcaacgtat aatttgcaaa gatggacttt aaaagatgct gtgtaactaa actgaaataa 2640
 15 ttcaattact tattatttag aatgttaaag cttatgatag tcttttctaa ttcttaacac 2700
 tcatacttga aatctttccg agtttcccca gaagagaata tgggattttt tttgacattt 2760
 ttgaccatt taataatgct cttgtgttta cctagtatat gtagactttg tcttatgtgt 2820
 20 caaaagtccct aggaaagtgg ttgatgtttc ttatagcaat taaaaattat ttttgaactg 2880
 a 2881

25 <210> 93
 <211> 2684
 <212> DNA
 <213> human

<400> 93
 30 CCCgagagga gtcggtggca gcggcggcgg cgggaccggc agcagcagca gcagcagcag 60
 cagcaaccac tagcctcctg ccccgcgcg cgtccgcacg agccccacga gccgctcacc 120
 ccgccgttct cagcgtgcc cgaccccgct ggcgcgccct cccgcccca gtcccggcag 180
 cgccctcagt tgtcctccga ctcgccctcg gccttcgcg ccagccgcag ccacagccgc 240
 35 aacgccacc gcagccacag ccacagccac agccccaggc atagccttcg gcacagcccc 300
 ggctccggct cctgcggcag ctctctggtg caccgtccct gcgccgacat cctggagggt 360
 gggatgctct tgtccaaaat caactcgctt gccacctgc gcgccgcgcc ctgcaacgac 420
 40 ctgcacgcca ccaagctggc gcccggaag gagaaggagc ccctggagtc gcagtaccag 480
 gtgggcccgc tactgggcag cggcggcttc ggctcggctt actcaggcat ccgcgtctcc 540
 gacaacttgc cgggtggccat caaacacgtg gagaaggacc ggatttccga ctggggagag 600
 ctgcctaata gcaactcgagt gcccatggaa gtggtcctgc tgaagaagggt gagctcgggt 660
 45 ttctccggcg tcattaggct cctggactgg ttcgagaggc ccgacagttt cgtcctgac 720
 ctggagaggc ccgagccggt gcaagatctc ttcgacttca tcacggaaag gggagccctg 780
 caagaggagc tggcccgcag cttcttctgg caggtgctgg aggccgtgcg gcaactgccac 840
 50 aactgcgggg tgctccaccg cgacatcaag gacgaaaaca tccttatcga cctcaatcgc 900
 ggcgagctca agctcatcga cttcgggtcg gggcgctgc tcaaggacac cgtctacacg 960
 gacttcgatg ggacccgagt gtatagccct ccagagtgga tccgctacca tcgctaccat 1020
 55

EP 2 395 103 A1

5 ggcaggtcgg cggcagtctg gtccttgggg atcctgctgt atgatatggt gtgtggagat 1080
 attcctttcg agcatgacga agagatcatc aggggccagg ttttcttcag gcagagggtc 1140
 tcttcagaat gtcagcatct cattagatgg tgcttggccc tgagaccatc agataggcca 1200
 accttcgaag aaatccagaa ccatccatgg atgcaagatg ttctcctgcc ccaggaaact 1260
 gctgagatcc acctccacag cctgtcggcc gggcccagca aatagcagcc tttctggcag 1320
 10 gtcctcccct ctcttgtcag atgcccgagg gaggggaagc ttctgtctcc agcttcccga 1380
 gtaccagtga cacgtctcgc caagcaggac agtgcttgat acaggaacaa catttacaac 1440
 tcattccaga tcccaggccc ctggaggctg cctcccaaca gtggggaaga gtgactctcc 1500
 aggggtccta ggcctcaact cctcccatag atactctctt cttctcatag gtgtccagca 1560
 15 ttgctggact ctgaaatc cccgggggtgg ggggtggggg tgggtcagaa ccctgccatg 1620
 gaactgtttt cttcatcatg agttctgctg aatgccgcga tgggtcaggt aggggggaaa 1680
 caggttggga tgggatagga ctagcaccat ttttaagtccc tgtcacctct tccgactctt 1740
 20 tctgagtgcc ttctgtgggg actccggctg tgctgggaga aatacttgaa cttgcctctt 1800
 ttacctgctg cttctcaaaa aatctgcctg ggttttgttc cctatttttc tctctgtcc 1860
 tccctacccc cctccttcat atgaaagggtg ccatggaaga ggctacaggg ccaaacgctg 1920
 25 agccacctgc cttttttct gcctccttta gtaaaactcc gagtgaactg gtcttctttt 1980
 ttggttttta cttaactgtt tcaaagccaa gacctcacac acacaaaaaa tgcacaaaca 2040
 atgcaatcaa cagaaaagct gtaaatgtgt gtacagttgg catggtagta tacaaaaaga 2100
 30 ttgtagtgga tctaattttt aagaaatttt gcctttaagt tattttacct gtttttgttt 2160
 cttgttttga aagatgcgca ttctaacctg gaggtcaatg ttatgtattt atttatttat 2220
 ttatttggtt cccttctat tccaagcttc catagctgct gccctagttt tctttcctcc 2280
 35 tttcctctc tgacttgggg accttttggg ggagggtgac gacgcttgct ctgtttggtg 2340
 ggtgacggga ctcaggcggg acagtgtgc agctccctgg cttctgtggg gccctcacc 2400
 tacttaccga ggtgggtccc ggctctgtgg gtgatgggga ggggcattgc tgactgtgta 2460
 40 tataggataa ttatgaaaag cagttctgga tgggtgtgct tccagatcct ctctggggct 2520
 gtgttttgag cagcaggtag cctgctgggt ttatctgagt gaaatactgt acaggggaat 2580
 aaaagagatc ttattttttt tttatactt ggcgtttttt gaataaaaac cttttgtctt 2640
 45 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2684

<210> 94
 <211> 2709
 <212> DNA
 <213> human

50 <400> 94
 ccctgacccc gcgcccgcga gcgcccctgag gactcagcga aggggtgggag ccgccgaggc 60
 ctctgccgc tggcgggttt ccgaggagt cgcggggct ccgctctgcc gccggcgcgg 120
 55 ctcatgggca gagtcggccg ggcgggcccg cattaaactg aagaaaagat gtcctgtac 180

EP 2 395 103 A1

gatgacctag gagtggagac cagtgactca aaaacagaag gctggtccaa aaacttcaaa 240
cttctgcagt ctcagcttca ggtgaagaag gcagctctca ctcaggcaaa gagccaaagg 300
5 acgaaacaaa gtacagtcct cgccccagtc attgacctga agcgaggtgg ctctcagat 360
gaccggcaaa ttgtggacac tccaccgat gtagcagctg ggctgaagga tcctgttccc 420
agtgggtttt ctgcagggga agttctgatt cccttagctg acgaatatga ccctatgttt 480
10 cctaattgatt atgagaaagt agtgaagcgc caaagagagg aacgacagag acagcgggag 540
ctggaaagac aaaaggaaat agaagaaagg gaaaaaaggc gtaaagacag acatgaagca 600
agtgggtttg caaggagacc agatccagat tctgatgaag atgaagatta tgagcgagag 660
15 aggaggaaaa gaagtatggg cggagctgcc attgccccac ccacttctct ggtagagaaa 720
gacaaagagt taccgagaga ttttcttat gaagaggact caagacctcg atcacagtct 780
tccaaagcag ccattcctcc cccagtgtac gaggaacaag acagaccgag atctccaacc 840
20 ggacctagca actccttctt cgtaacatg gggggcacgg tggcgcaaa gatcatgcag 900
aagtacggct tccgggaggg ccagggtctg ggggaagcatg agcagggcct gagcactgcc 960
ttgtcagtgg agaagaccag caagcgtggc ggcaagatca tcgtgggcca cgccacagag 1020
aaagatgcat ccaagaagtc agattcaaat ccgctgactg aaatacttaa gtgtcctact 1080
25 aaagtggctt tactaaggaa catggttggg gcgggagagg tggatgaaga cttggaagtt 1140
gaaaccaagg aagaatgtga aaaatatggc aaagtggaa aatgtgtgat atttgaaatt 1200
cctggtgccc ctgatgatga agcagtacgg atatTTTTtag aatttgagag agttgaatca 1260
30 gcaattaaag cggttgttga cttgaatggg aggtattttg gtggacgggt ggtaaaagca 1320
tgtttctaca atttggacaa attcaggggtc ttggatttgg cagaacaagt ttgattttaa 1380
gaactagagc acgagtcatc tccggtgatc cttaaatgaa ctgcaggctg agaaaagaag 1440
35 gaaaaaggtc acagcctcca tggctgttgc ataccaagac tcttggagg acttctaaga 1500
tatatgttga ttgatccctt ttttattttg tggtttttta atatagtata aaaatccttt 1560
taaaaaaaca acaatctgtg tgcctctctg gttgtttctc tttttatta ttactcctga 1620
40 gttgatgaca ttttttgtta gatttcatgg taattctcaa gtgcttcaat gatgcagcat 1680
ttcttgcaact aaaaaaaaaa aaaaaaaaaa aactagaaag ttttgggaca tgggggtata 1740
ttaaattatt ctttgttttt ctttttcttt taataaagcc tgcaagttac taaattgtag 1800
45 tttcataaat tctgtagtaa agtatcatct tggcagtgtg ccaagggtga aaatgatgct 1860
ttctctaaca gagaaattct tagtgactcc agtcgtagaa aaacgtcttt acaacctgaa 1920
taagattgaa gaattgtgaa cataccatgg cctattggat gaatcatttg ccgtaggcta 1980
aatcagactg tagggtttgt gatggattta tggagtatgt gggatagaa atcatgaatc 2040
50 tagcatttgt tttcagagat tcaagcatag tcttaagggt agatcagaaa tgacaaatga 2100
attcaaaacc tagcaggtgc attgtaaagt tgtgccagct tatgttttgg aaatggcagct 2160
tccttggggg catgtttcta ctggcaaaat ttgcaatagt gttctattgt atgtaatttt 2220
55

EP 2 395 103 A1

	aaaatttata agattatcca cgttgccaa gtaaactgta ctgc'caatag aattctggaa	2280
	ttgtgagaaa ttgtatcatt gaagttcagt aggatgtgtg gcttaaaaat ttatcaggac	2340
5	cacaaaaaag aaaacaaaa tatttggtac tgaggttcat tgccaggga ggaggattt	2400
	ccagaaaata ctcatgcctg tgttctgttc cttgctttcc caaactctgc atgtgacttt	2460
	cctaagcggc agctgaaaga ctcgagcccg tgctgtctcc tttggttatt atgacatgaa	2520
10	agtgtatcaa gaactcagca tttctttgca tccatggact tggtttgag acataaggaa	2580
	tattctgacc ctttttaaaa aaggattttc tcatgttttt atttaacata aataaaagaa	2640
	taacatttta tcttttgtgg tattatttta ttgaataaaa ttgagtttta tgataaaaaa	2700
15	aaaaaaaaa	2709
	<210> 95	
	<211> 2150	
	<212> DNA	
20	<213> human	
	<400> 95	
	ctcgagccac gaaggccccg ctgtcctgtc tagcagatac ttgcacggtt tacagaaatt	60
	cggtccttgg gtcgtgtcag gaaactggaa aaaagggtcat aagcatgaag cgcagttcag	120
25	tttccagcgg tgggtgctggc cgcctctcca tgcaggagtt aagatcccag gatgtaata	180
	aacaaggcct ctatacccct caaaccaaag agaaaccaac ctttgaaag ttgagtataa	240
	acaaaccgac atctgaaaga aaagtctcgc tatttgcaa aagaactagt ggacatggat	300
30	cccggaatag tcaacttggc atattttcca gttctgagaa aatcaaggac ccgagaccac	360
	ttaatgacaa agcattcatt cagcagtgtc ttcgacaact ctgtgagttt cttacagaaa	420
	atggttatgc acataatgtg tccatgaaat ctctacaagc tccctctgtt aaagacttcc	480
35	tgaagatctt cacatttctt tatggcttcc tgtgcccctc atacgaactt cctgacacaa	540
	agtttgaaga agaggttcca agaactttta aagaccttgg gtatcctttt gcactatcca	600
	aaagctccat gtacacagtg ggggctcctc atacatggcc tcacattgtg gcagccttag	660
40	tttggtctaat agactgcatc aagatacata ctgccatgaa agaaagctca cttttatttg	720
	atgatgggca gccttgggga gaagaaactg aagatggaat tatgcataat aagttgtttt	780
	tggactacac cataaaatgc tatgagagtt ttatgagtgg tgccgacagc tttgatgaga	840
45	tgaatgcaga gctgcagtca aaactgaagg atttatttaa tgtggatgct ttaagctgg	900
	aatcattaga agcaaaaaac agagcattga atgaacagat tgcaagattg gaacaagaaa	960
	gagaaaaaga accgaatcgt ctagagtcgt tgagaaaact gaaggcttcc ttacaaggag	1020
	atgttcaaaa gtatcaggca tacatgagca atttggagtc tcattcagcc attcttgacc	1080
50	agaaattaaa tggcttcaat gaggaaattg ctagagtaga actagaatgt gaaacaataa	1140
	aacaggagaa cactcgacta cagaatatca ttgacaacca gaagtactca gttgcagaca	1200
55	ttgagcgaat aatcatgaa agaaatgaat tgcagcagac tattaataaa ttaaccaagg	1260

EP 2 395 103 A1

	acctggaagc tgaacaacag aagttgtgga atgaggagtt aaaatatgcc agaggcaaag	1320
	aagcgattga aacacaatta gcagagtatc acaaattggc tagaaaatta aaacttattc	1380
5	ctaaagggtgc tgagaattcc aaaggttatg actttgaaat taagtttaat cccgaggctg	1440
	gtgccaactg ctttgtcaaa tacagggctc aagtttatgt acctcttaag gaactcctga	1500
	atgaaactga agaagaaatt aataaagccc taataaaaa aatgggtttg gaggatactt	1560
10	tagaacaatt gaatgcaatg ataacagaaa gcaagagaag tgtgagaact ctgaaagaag	1620
	aagttcaaaa gctggatgat ctttaccac aaaaaattaa ggaagcagag gaagaggatg	1680
	aaaaatgtgc cagtgagctt gagtccttgg agaaacacaa gcacctgcta gaaagtactg	1740
15	ttaaccaggg gctcagtga gctatgaatg aattagatgc tgttcagcgg gaataccaac	1800
	tagttgtgca aaccacgact gaagaaagac gaaaagtggg aaataacttg caacgtctgt	1860
	tagagatggt tgctacacat gttgggtctg tagagaaaca tcttgaggag cagattgcta	1920
20	aagttgatag agaatatgaa gaatgcatgt cagaagatct ctcggaaaat attaaagaga	1980
	ttagagataa gtatgagaag aaagctactc taattaagtc ttctgaagaa tgaagataaa	2040
	atgttgatca tgtatatata tccatagtga ataaaattgt ctcagtataa aaaaaaaaaa	2100
25	aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2150
	<210> 96	
	<211> 2977	
	<212> DNA	
	<213> human	
30	<400> 96	
	ccgaatgtga ccgcctcccc ctccctcacc cgccgcgggg aggaggagcg ggcgagaagc	60
	tgccgccgaa cgacaggacg ttggggcggc ctggctccct caggtttaag aattgtttaa	120
35	gctgcatcaa tggagcacat acagggagct tggaaagacga tcagcaatgg ttttggattc	180
	aaagatgccg tgtttgatgg ctccagctgc atctctccta caatagttca gcagtttggc	240
	tatcagcgcc gggcatcaga tgatggcaaa ctcacagatc cttctaagac aagcaact	300
40	atccgtgttt tcttgccgaa caagcaaga acagtgggtca atgtgcaaaa tggaatgagc	360
	ttgcatgact gccttatgaa agcactcaag gtgaggggccc tgcaaccaga gtgctgtgca	420
	gtgttcagac ttctccacga acacaaaggt aaaaaagcac gcttagattg gaatactgat	480
45	gctgctctt tgattggaga agaacttcaa gtagatttcc tggatcatgt tcccctcaca	540
	acacacaact ttgctcgaa gacgttcctg aagcttgctt tctgtgacat ctgtcagaaa	600
	ttctgctca atggatttcg atgtcagact tgtggctaca aatttcatga gcactgtagc	660
50	accaaagtac ctactatgtg tgtggactgg agtaacatca gacaactctt attgtttcca	720
	aattccacta ttggtgatag tggagtcca gcaactactt ctttgactat gcgtcgtatg	780
	cgagagtctg tttccaggat gcctgttagt tctcagcaca gatattctac acctcagcc	840
	ttcaacttta acacctccag tccctcatct gaaggttccc tctcccagag gcagaggctg	900
55	acatccacac ctaatgtcca catggctcagc accacgctgc ctgtggacag caggatgatt	960

EP 2 395 103 A1

gaggatgcaa ttcgaagtca cagcgaatca gcctcacctt cagccctgtc cagtagcccc 1020
 aacaatctga gcccaacagg ctggtcacag ccgaaaaccc ccgtgccagc acaaagagag 1080
 5 cgggcaccag tatctgggac ccaggagaaa aacaaaatta ggcctcgtgg acagagagat 1140
 tcaagctatt attgggaaat agaagccagt gaagtgatgc tgtccactcg gattgggtca 1200
 ggctcttttg gaactgttta taagggtaaa tggcacggag atgttgacgt aaagatccta 1260
 10 aaggttgtcg acccaacccc agagcaattc caggccttca ggaatgaggt ggctgttctg 1320
 cgcaaaacac ggcattgtgaa cattctgctt ttcattgggg acatgacaaa ggacaacctg 1380
 gcaattgtga cccagtgggt cgagggcagc agcctctaca aacacctgca tgtccaggag 1440
 15 accaagtttc agatgttcca gctaattgac attgcccggc agacggctca gggaatggac 1500
 tatttgcatg caaagaacat catccataga gacatgaaat ccaacaatat atttctccat 1560
 gaaggcttaa cagtgaaaat tggagatttt ggtttgcaa cagtaaagtc acgctggagt 1620
 20 ggttctcagc aggttgaaca acctactggc tctgtcctct ggatggcccc agaggtgatc 1680
 cgaatgcagg ataacaaccc attcagtttc cagtcggatg tctactccta tggcatcgta 1740
 ttgtatgaac tgatgacggg ggagcttctt tattctcaca tcaacaaccg agatcagatc 1800
 25 atcttcatgg tgggccgagg atatgcctcc ccagatctta gtaagctata taagaactgc 1860
 cccaaagcaa tgaagaggct ggtagctgac tgtgtgaaga aagtaaagga agagaggcct 1920
 ctttttcccc agatcctgtc ttccattgag ctgctccaac actctctacc gaagatcaac 1980
 cggagcgtt ccgagccatc cttgcatcgg gcagcccaca ctgaggatat caatgcttgc 2040
 30 acgctgacca cgtccccgag gctgcctgtc ttctagttga ctttgcacct gtcttcaggc 2100
 tgccagggga ggaggagaag ccagcaggca ccacttttct gctcccttcc tccagaggca 2160
 gaacacatgt tttcagagaa gctctgctaa ggaccttcta gactgctcac agggccttaa 2220
 35 cttcatgttg cttcttttcc tatccctttg ggccctggga gaaggaagcc atttgcagtg 2280
 ctggtgtgtc ctgctccctc cccacattcc ccattgctcaa ggcccagcct tctgtagatg 2340
 cgcaagtgga tgttgatggt agtacaaaaa gcaggggccc agccccagct gttggctaca 2400
 40 tgagtattta gaggaagtaa ggtagcaggc agtccagccc tgatgtggag acacatggga 2460
 ttttgaaaat cagcttctgg aggaatgcat gtcacaggcg ggactttctt cagagagtgg 2520
 tgcagcgcca gacattttgc acataaggca ccaaacagcc caggactgcc gagactctgg 2580
 45 ccgcccgaag gagcctgctt tggactatg gaacttttct taggggacac gtcctccttt 2640
 cacagcttct aagggtgtcca gtgcattggg atggttttcc aggcaaggca ctcggccaat 2700
 ccgcatctca gccctctcag gagcagctt ccattcatgct gaattttgtc ttccaggagc 2760
 50 tgcccctatg gggcgggccc cagggccagc ctgtttctct aacaaacaaa caaacaacaa 2820
 gccttgtttc tctagtcaca tcatgtgtat acaaggaagc caggaatata ggttttcttg 2880
 atgatttggg ttttaatttt gtttttattg cacctgacaa aatacagtta tctgatggtc 2940
 55 cctcaattat gttattttta taaaataaat taaattt 2977

EP 2 395 103 A1

<210> 97
 <211> 1212
 <212> DNA
 <213> human

5
 <400> 97
 atggaccgat ctaaagaaaa ctgcatttca ggacctgtta aggctacagc tccagttgga 60
 ggtccaaaac gtgttctcgt gactcagcaa tttccttgtc agaatccatt acctgtaa at 120
 10 agtggccagg ctcagcgggt cttgtgtcct tcaaattctt cccagcgcac tcctttgcaa 180
 gcacaaaagc ttgtctccag tcacaagccg gttcagaatc agaagcagaa gcaattgcag 240
 gcaaccagtg tacctcatcc tgtctccagg cactgaata acacccaaaa gagcaagcag 300
 15 cccctgccat cggcacctga aaataatcct gaggaggaac tggcatcaaa acagaaaaat 360
 gaagaatcaa aaaagaggca gtgggctttg gaagactttg aaattggctg ccctctgggt 420
 aaaggaaagt ttggaatgt ttatttggca agagaaaagc aaagcaagtt tattctggct 480
 20 cttaaagtgt tatttaaagc tcagctggag aaagccggag tggagcatca gctcagaaga 540
 gaagtagaaa tacagtccca ccttcggcat cctaatttc ttagactgta tggttatttc 600
 catgatgcta ccagagtcta cctaattctg gaatatgcac cacttggaa agtttataga 660
 gaacttcaga aactttcaa gttgatgag cagagaactg ctacttatat aacagaattg 720
 25 gcaaatgcc tgtcttactg ccattcgaag agagttattc atagagacat taagccagag 780
 aacttacttc ttggatcagc tggagagctt aaaattgcag attttgggtg gtcagtacat 840
 gctccatctt ccaggaggac cactctctgt ggcaccctgg actacctgcc ccctgaaatg 900
 30 attgaaggtc ggatgcatga tgagaagggt gatctctgga gccttggagt tctttgctat 960
 gaatttttag ttggaagcc tccttttgag gcaaacacat accaagagac ctacaaaaga 1020
 atatcacggg ttgaattcac attccctgac tttgtaacag agggagccag ggacctcatt 1080
 35 tcaagactgt tgaagcataa tcccagccag aggccaatgc tcagagaagt acttgaacac 1140
 ccctggatca cagcaaattc atcaaaacca tcaaattgcc aaaacaaaga atcagctagc 1200
 aaacagtctt ag 1212

40
 <210> 98
 <211> 2788
 <212> DNA
 <213> human

45
 <400> 98
 ggcggcggta gcagccaggc ttggcccccg gcgtggagca gacgcggacc cctccttctt 60
 ggcggcggcg gcgcgggctc agagcccggc aacgggcggg cgggcagaat gagtctgcag 120
 gtcttaaacg acaaaaatgt cagcaatgaa aaaaatacag aaaattgcga cttcctgttt 180
 50 tcgccaccag aagttaccgg aagatcgtct gttcttcgtg tgtcacagaa agaaaatgtg 240
 ccaccaaga acctggccaa agctatgaag gtgacttttc agacacctct gcgggatcca 300
 cagacgcaca ggattctaag tcctagcatg gccagcaaac ttgaggctcc tttcactcag 360
 55

EP 2 395 103 A1

gatgacacc ttggactgga aaactcacac ccggtctgga cacagaaaga gaaccaacag 420
 ctcatcaagg aagtggatgc caaaactact catggaattc tacagaaacc agtggaggct 480
 5 gacaccgacc tcctggggga tgcaagccca gcctttggga gtggcagctc cagcgagtct 540
 ggcccagggtg ccctggctga cctggactgc tcaagctctt cccagagccc aggaagttct 600
 gagaaccaa tggtgtctcc aggaaaagtg tctggcagcc ctgagcaagc cgtggaggaa 660
 10 aaccttagtt cctattcctt agacagaaga gtgacaccg cctctgagac cctagaagac 720
 ccttgcaagg cagagtccca gcacaaagcg gagactccgc acggagccga ggaagaatgc 780
 aaagcggaga ctccgcacgg agccgaggag gaatgccggc acggtggggg ctgtgctccc 840
 15 gcagcagtgg ccacttcgcc tcctggtgca atccctaagg aagcctgcgg aggagcacc 900
 ctgcagggtc tgcttgccga agccctgggc tgccctgcgg gtgtgggcac ccccgtgcca 960
 gcagatggca ctcagaccct tacctgtgca cacacctctg ctctgagag cacagcccca 1020
 20 accaaccacc tggtggctgg cagggccatg accctgagtc ctcaggaaga agtggctgca 1080
 ggccaaatgg ccagctcctc gaggagcggg cctgtaaac tagaatttga tgatatctgat 1140
 ggccaccacca gcaaaagggc acccccacca aggagactgg gagagaggtc cggcctcaag 1200
 25 cctcccttga ggaaagcagc agtgaggcag caaaaggccc cgcaggaggt ggaggaggac 1260
 gacggtagga gcggagcagg agaggacccc ccatgccag cttctcgggg ctcttaccac 1320
 ctcgactggg acaaaatgga tgacccaaac ttcattcccgt tcggaggtga caccaagtct 1380
 ggttgcaagt aggcccagcc cccagaaagc cctgagacca ggctgggcca gccagcggct 1440
 30 gaacagttgc atgctgggccc tgccacggag gagccaggtc cctgtctgag ccagcagctg 1500
 cattcagcct cagcggagga cacgcctgtg gtgcagttgg cagccgagac cccaacagca 1560
 gagagcaagg agagagcctt gaactctgcc agcacctcgc tcccacaag ctgtccaggc 1620
 35 agtgagccag tgcccacca tcagcagggg cagcctgcct tggagctgaa agaggagagc 1680
 ttcagagacc ccgctgaggt tctaggcacg ggccggagg tggattacct ggagcagttt 1740
 ggaacttctc cgtttaagga gtcggccttg aggaagcagt cttatacct caagtctgac 1800
 40 cccctcctga gggacagtcc tggtagacca gtgcccgtgg ccaccgagac cagcagcatg 1860
 cacggtgcaa atgagactcc ctcaggacgt ccgcgggaag ccaagcttgt ggagttcgat 1920
 ttcttgggag cactggacat tcctgtgcca ggcccacccc caggtgttcc cgcgcctggg 1980
 45 ggcccacccc tgtccaccgg acctatagtg gacctgctcc agtacagcca gaaggacctg 2040
 gatgcagtgg taaaggcgac acaggaggag aaccgggagc tgaggagcag gtgtgaggag 2100
 ctccacggga agaacctgga actggggaag atcatggaca ggttcgaaga ggttgtgtac 2160
 50 caggccatgg aggaagtca gaagcagaag gaactttcca aagctgaaat ccagaaagtt 2220
 ctaaagaaa aagaccaact taccacagat ctgaactcca tggagaagtc cttctccgac 2280
 ctcttcaagc gttttgagaa acagaaagag gtgatcgagg gctaccgcaa gaacgaagag 2340
 55 tcaactgaaga agtgcgtgga ggattacctg gcaaggatca cccaggaggg ccagaggtac 2400

EP 2 395 103 A1

caagccctga aggccccacgc ggaggagaag ctgcagctgg caaacgagga gatcgcccag 2460
 gtccggagca aggccccaggc ggaagcgttg gccctccagg ccagcctgag gaaggagcag 2520
 5 atgcgcatcc agtcgctgga gaagacagtg gagcagaaga ctaaagagaa cgaggagctg 2580
 accaggatct gcgacgacct catctccaag atggagaaga tctgacctc acggagccgc 2640
 tgtccccgcc cccctgctcc cgtctgtctg tcctgtctga ttctcttagg tgtcatgttc 2700
 10 ttttttctgt cttgtcttca acttttttta aaactagatt gctttgaaaa catgactcaa 2760
 taaaagtttc ctttcaattt aaaaaaaaa 2788

<210> 99
 <211> 2287
 <212> DNA
 <213> human

<400> 99
 cgcgccccgc gcagccccgg gcgcccgcgc tcctgccccg cctgcggccc cagcccttgc 60
 20 gccgctcgtc cgacccgcga tcgtccacca gaccgtgcct cccggccgcc cggccggccc 120
 gcgtgcatgc ttcggtctgg gccagcctct gggccgtccg tccccactgg ccgggccatg 180
 ccgagtcgcc gcgtcgccag accgccggct gcgcccggagc tgggggcctt agggtcccc 240
 25 gacctctcct cactctcgtc cgccgtttcc aggagcacag atgaattgga gatcatcgac 300
 gagtacatca aggagaacgg cttcggcctg gacgggggac agccgggccc gggcgagggg 360
 ctgccacgcc tgggtgtctg cggggctgcg tccttgagca cggtcaccct gggccctgtg 420
 30 gcgccccag ccacgccgcc gccttggggc tgccccctgg gccgactagt gtccccagcg 480
 ccgggcccgg gcccgcagcc gcacctggtc atcacggagc agcccaagca gcgcgcatg 540
 cgcttccgct acgagtgcga gggccgctc gccggcagca tccttgggga gagcagcacc 600
 35 gaggccagca agacgctgcc cgccatcgag ctccgggatt gtggagggct gcgggaggtg 660
 gaggtgactg cctgcctggt gtggaaggac tggcctcacc gagtccacce ccacagcctc 720
 gtggggaaag actgcaccga cggcatctgc aggggtgcggc tccggcctca cgtcagcccc 780
 cggcacagtt ttaacaacct gggcatccag tgtgtgagga agaaggagat tgaggctgcc 840
 40 attgagcggg agattcaact gggcattgac ccctacaacg ctgggtccct gaagaacccat 900
 caggaagtag acatgaatgt ggtgaggatc tgcttcagg cctcatatcg ggaccagcag 960
 ggacagatgc gccggatgga tcctgtgctt tccgagccc tctatgacaa gaaatccaca 1020
 45 aacacatcag agctgcggat ttgccgaatt aacaaggaaa gcgggcccgtg caccggtggc 1080
 gaggagctct acttgctctg cgacaagggtg cagaaagagg acatatcagt ggtgttcagc 1140
 agggcctcct ggggaaggctg ggctgacttc tcccaggccg acgtgcaccg ccagattgcc 1200
 50 attgtgttca agacgccgcc ctacaggac ctggagattg tcgagcccgt gacagtcaac 1260
 gtcttctcgc agcggctcac cgatggggtc tgcagcgagc cattgccttt cacgtacctg 1320
 cctcgcgacc atgacagcta cggcgtggac aagaagcggg aacgggggat gcccgcgctc 1380

55

EP 2 395 103 A1

cttggggagc tgaacagctc tgacccccat ggcacgcaga g'caaacggcg gaagaaaaag 1440
 ccggccatcc tggaccactt cctgcccacac cacggctcag gcccgttcct cccgccgtca 1500
 5 gccctgctgc cagaccctga cttcttctct ggcaccgtgt ccctgcccgg cctggagccc 1560
 cctggcgggc ctgacctcct ggacgatggc tttgcctacg accctacggc cccacactc 1620
 ttcacatgc tggacctgct gccccggca ccgccacacg ctacgcctgt tgtgtgcagc 1680
 10 ggagtgccg gggccgtggt tggggagacc cccggccctg aacctactgac actggactcg 1740
 taccaggccc cgggccccgg ggatggaggc accgccagcc ttgtgggcag caacatgttc 1800
 cccaatcatt accgcgaggc ggcctttggg ggcggcctcc tatccccggg gcctgaagcc 1860
 15 acgtagcccc gcgatgccag aggaggggca ctgggtgggg agggaggtgg aggagccgtg 1920
 caatcccaac caggatgtct agcaccacca tcccctggc ccttctcat gcttctgaag 1980
 tggacatatt cagccttggc gagaagctcc gttgcacggg tttccccttg agccatttt 2040
 20 acagatgagg aaactgagtc cggagaggaa aaggacatg gctcccgtgc actagcttgt 2100
 tacagctgcc tctgtcccca catgtggggg caccttctcc agtaggattc ggaaaagatt 2160
 gtacatatgg gaggaggggg cagattcctg gccctccctc cccagacttg aaggtagggg 2220
 25 gtaggttggg tgttcagagt cttccaata aagatgagtt tttgagctc aaaaaaaaaa 2280
 aaaaaa 2287

 <210> 100
 <211> 2850
 <212> DNA
 <213> human

 <400> 100
 tcgcacttcc gtgtgccgcg gcgccggagc ccgaggcggc tgtagccac atctcccag 60
 35 cgacccccgg cggccgcccg ccgcgcggag gcccgggcca cacctactg gccgcttggc 120
 ccatcccagt cagcgcgccc ccgaaccccg tccgcgcgcg ccggggagcg gcgcccccg 180
 cgctgccgcc gcgaccttg gcgcctgcc ctgcaacggg aggtctgcag ggaactggcc 240
 aggcaagggg gcaggcccgt ttctcttggg ggttgggtgc ttgtagcagc agcgggagcc 300
 40 aggactaagg acaagcagga gctgggagcc ccagccccac tgcaggcccc accatggcgc 360
 cgttcttgcg catcgcttc aactcctatg agctgggctc cctgcaggcc gaggacgagg 420
 cgaaccagcc cttctgtgcc gtgaagatga aggaggcgt cagcacagag cgtgggaaaa 480
 45 cactggtgca gaagaagccg accatgtatc ctgagtggaa gtcgacgttc gatgccaca 540
 tctatgaggg gcgcgtcatc cagattgtgc taatgcgggc agcagaggag ccagtgtctg 600
 aggtgaccgt ggggtgtgctg gtgctggccg agcgtgcaa gaagaacaat ggcaaggctg 660
 50 agttctggct ggacctgcag cctcaggcca aggtgttgat gtctgttcag tatttcttgg 720
 aggacgtgga ttgcaaacag tctatgcgca gtgaggacga ggccaagttc ccaacgatga 780
 accgccgagg agccatcaaa caggccaaa tccactacat caagaacct gagtttatcg 840
 55 ccaccttctt tgggcaacct accttctggt ctgtgtgcaa agactttgtc tggggcctca 900

EP 2 395 103 A1

acaagcaagg ctacaaatgc aggcaatgta acgctgccat ccacaagaaa tgcacgcaca 960
 agatcatcgg cagatgcact ggcaccgagg ccaacagccg ggacactata ttccagaaag 1020
 5 aacgcttcaa catcgacatg ccgcaccgct tcaagggtca caactacatg agccccacct 1080
 tctgtgacca ctgcggcagc ctgctctggg gactggtgaa gcagggatta aagtgtgaag 1140
 actgcggcat gaatgtgcac cataaatgcc gggagaaggt ggccaacctc tgcggcatca 1200
 10 accagaagct tttggctgag gccttgaacc aagtcacca gagagcctcc cggagatcag 1260
 actcagcctc ctgagagcct gttgggatat atcagggttt cgagaagaag accggagttg 1320
 ctggggagga catgcaagac aacagtggga cctacggcaa gatctgggag ggcagcagca 1380
 15 agtgcaacat caacaacttc atcttcaca aggtcctggg caaaggcagc ttcgggaagg 1440
 tgctgcttgg agagctgaag ggcagaggag agtactttgc catcaaggcc ctcaagaagg 1500
 atgtggtcct gatcgacgac gacgtggagt gcacatggt tgagaagcgg gtgctgacac 1560
 20 ttgccgcaga gaatcccttt ctccccacc tcatctgcac cttccagacc aaggaccacc 1620
 tgttctttgt gatggagttc ctcaacgggg gggacctgat gtaccacatc caggacaaag 1680
 gccgctttga actctaccgt gccacgtttt atgccgctga gataatgtgt ggactgcagt 1740
 25 ttctacacag caagggcatc atttacaggg acctcaaact ggacaatgtg ctgctggacc 1800
 gggatggcca catcaagatt gccgactttg ggatgtgcaa agagaacata ttcggggaga 1860
 gccgggccag caccttctgc ggcaccctg actatatcgc ccctgagatc ctacagggcc 1920
 tgaagtacac attctctgtg gactggtggt ctttcggggg ctttctgtac gagatgctca 1980
 30 ttggccagtc ccccttccat ggtgatgatg aggatgaact cttcgagtcc atccgtgtgg 2040
 acacgccaca ttatccccgc tggatcacca aggagtcaa ggacatcctg gagaagctct 2100
 ttgaaagggg accaaccaag aggctgggag tgaccggaaa catcaaaatc cacccttct 2160
 35 tcaagacatc aaactggact ctgctggaaa agcggagggt ggagccacct ttcaggccca 2220
 aagtgaagtc acccagagac tacagtaact ttgaccagga gttcctgaac gagaaggcgc 2280
 gcctctccta cagcgacaag aacctcatcg actccatgga ccagtctgca ttcgctggct 2340
 40 tctcctttgt gaaccccaaa ttcgagcacc tcctggaaga ttgaggttcc tggacagatc 2400
 aggctagccc tgcctccac ccacacctgc ccgctccca cgataagcac cagtgggact 2460
 gtggtgactt ctgctgctgg ccccgccctt gccccagag cgtccttggc tgccgtctgg 2520
 45 ccgggctctc atggtacttc ctctgtgaac tgtgtgtgaa tctgcttttc ctctgccttc 2580
 ggagggaaat tgtaaatcct gtgtttcatt acttgaatgt agttatctat tgaaaatata 2640
 tattatatac atagacatat atatatatat aataggctgt atatattgct cagtagagaa 2700
 50 aaacatggg ggactggtga tatgttgatc tttttcaaaa aaatatatat atgacaaaaa 2760
 aaaaaaaaaa ggagcacaag ctgtttgaac caccaggttt atttgtgtgt ctaaataaac 2820
 accaaatagt accaaaaaaaaa aaaaaaaaaa 2850

55

EP 2 395 103 A1

<210> 101
 <211> 1584
 <212> DNA
 <213> human

5 <400> 101
 gttggttgga gcgctcgcga gtcgggaggt ccgggaaagt ttctttggag gtccggcccc 60
 gagcggccat gtcccacggc cccaagcagc ccggcgcggc cgccgcgccg gcgggcggca 120
 10 aggctccggg ccagcatggg ggcttcgtgg tgactgtcaa gcaagagcgc ggcgagggtc 180
 cacgcgcggg cgagaagggg tcccacgagg aggagccggt gaagaaacgc ggctggccca 240
 agggcaagaa gcggaagaag attctgccga atgggcccaa ggcaccggtc acgggctacg 300
 15 tgcgcttcct gaacgagcgg cgcgagcaga tccgcacgcg ccacccggat ctgccctttc 360
 ccgagatcac caagatgctg ggcgccgagt ggagcaagct gcagccaacg gaaaagcagc 420
 ggtacctgga tgaggccgag agagagaagc agcagtacat gaaggagctg cgggcgtacc 480
 agcagtctga agcctataag atgtgcacgg agaagatcca ggagaagaag atcaagaaag 540
 20 aagactcgag ctctgggctc atgaacactc tcctgaatgg acacaagggt ggggactgcg 600
 atggcttctc caccttcgat gttcccatct tactgaaga gttcttgac caaaacaaag 660
 cgcgtgaggc ggagcttcgg cgcttgcgga agatgaatgt ggcttcgag gacgagaacg 720
 25 cggactgca gaggcacacg cagagcatga gcagcgcgcg cgagcgtctg gacgaggagc 780
 tggcgtgga ggagcggagg acgctggcgc tgcagcagca gctccaggcc gtgcgccagg 840
 cgctcaccgc cagcttcgcc tactgcccg tgccgggcac gggcgaaacg cccacgctgg 900
 30 gcaactctgga cttctacatg gcccggcttc acggagccat cgagcgcgac cccgcccagc 960
 acgagaagct catcgtccgc atcaaggaaa tcctggccca ggtcgccagc gagcacctgt 1020
 gaggagtggg cgggcccacg atgcagagga gaagctgtgg gcgcggccct gccacacccc 1080
 35 acccctgga cgagaggctg ggggtccacc ctttggggcc tggctccatc ctgcacctg 1140
 ggggctccag cccccctaaa attaaatttc tgcagcatcc ctttagcttt caatctcccc 1200
 agccccctga acccggaaaa agcactcgtc gcgcgataca cccagaagaa cctcacagcc 1260
 40 gaggggtgccc ctctcggag gacagccacg cgctacactg gctctccggg ccacccccag 1320
 gacacagggc agacgaaacc cacccccagc acacggcagg acccccaaaa ttactcacta 1380
 cggggggctg tgccataggc cacacaggaa gctgccttgt ggggacttac ctgggggtgtc 1440
 45 ccccgcacgc ctgtaccca gatgggtggg ggccggcttt gccatcctg ctctcctcca 1500
 gccgaggac cctggtgggg gtggctcctt ctcactgctg gatccggact ttttaataa 1560
 aaacaagtaa aatttgtgtt ttaa 1584

50 <210> 102
 <211> 2383
 <212> DNA
 <213> human

55 <400> 102
 gctgctgcga cagtccacta cctttttcga gactgactcc cgttgtcca aggcttcca 60

EP 2 395 103 A1

gagcgaacct gtgcggctgc aggcaccggc gcgtcgagtt tccggcgtcc ggaaggaccg 120
 agctcttctc gcggatccag tgttccgttt ccagcccca atctcagagc cgagccgaca 180
 5 gagagcaggg aaccggcatg gccaaagccg cggcgatcgg catcgacctg ggcaccacct 240
 actcctgcgt gggggtgttc caacacggca aggtggagat catcgccaac gaccagggca 300
 accgcaccac ccccagctac gtggccttca cggacaccga gcggctcatc ggggatgagg 360
 10 ccaagaacca ggtggcgctg aaccgcaga acaccgtgtt tgacgcgaag cggctgatcg 420
 gccgcaagtt cggcgacccg gtggtgcagt cggacatgaa gactggcctt ttccaggtga 480
 tcaacgacgg agacaagccc aaggtgcagg tgagctacaa gggggacacc aaggcattct 540
 15 accccgagga gatctcgtcc atggtgctga ccaagatgaa ggagatcgcc gaggcgtacc 600
 tgggctacct ggtgaccaac gcggtgatca ccggtccggc ctacttcaac gactcgcagc 660
 gccaggccac caaggatgag ggtgtgatcg cggggctcaa cgtgctgagg atcatcaacg 720
 20 agcccacggc cgccgccatc gcctacggcc tggacagaac gggcaagggg gagcgcaacg 780
 tgctcatctt tgacctgggc gggggcacct tcgacgtgtc catcctgacg atcgacgacg 840
 gcatcttca ggtgaaggcc acggccgggg acaccacct ggggtggggag gactttgaca 900
 25 acaggctggt gaaccacttc gtggaggagt tcaagagaaa acacaagaag gacatcagcc 960
 agaacaagcg agccgtgagg cggctgcgca ccgcctgcga gaggccaag aggaccctgt 1020
 cgtccagcac ccaggccagc ctggagatcg actccctgtt tgagggcatc gacttctaca 1080
 cgccatcac cagggcgagg ttcgaggagc tgtgctccga cctgttccga agcaccctgg 1140
 30 agcccgtgga gaaggctctg cgcgacgcca agctggacaa ggcccagatt cagcactgg 1200
 tcctggtcgg gggctccacc cgcacccca aggtgcagaa gctgctgag gacttcttca 1260
 acgggagcga cctgaacaag agcatcaacc ccgacgaggc tgtggcctac ggggagcggg 1320
 35 tgagggcggc catcctgatg ggggacaagt ccgagaacgt gcaggacctg ctgctgctgg 1380
 acgtggctcc cctgtcgtg gggctggaga cggccggagg cgtgatgact gccctgatca 1440
 agcgcaactc caccatcccc accaagcaga cgcagatctt caccacctac tccgacaacc 1500
 40 aaccgggggt gctgatccag gtgtacgagg gcgagagggc catgacgaaa gacaacaatc 1560
 tgttggggcg cttcagctg agcggcatcc ctccggccc caggggctg ccccagatcg 1620
 aggtgaccti cgacatgat gccaacggca tcctgaacgt cacggccacg gacaagagca 1680
 45 ccggcaaggc caacaagatc accatcacca acgacaaggg ccgcctgagc aaggaggaga 1740
 tcgagcgcat ggtgcaggag gcggagaagt acaaagcggg ggacgaggtg cagcgcgaga 1800
 ggggtgcagc caagaacgcc ctggagtctt acgccttcaa catgaagagc gccgtggagg 1860
 50 atgaggggct caagggcaag atcagcgagg ccgacaagaa gaaggtgctg gacaagtgtc 1920
 aagaggtcat ctcgtggctg gacgccaaca ccttggccga gaaggacgag tttgagcaca 1980
 agaggaagga gctggagcag gtgtgtaacc ccatcatcag cggactgtac cagggtgccg 2040
 55 gtggtcccgg gcctgggggc ttcggggctc aggggtccca gggaggggtct gggtcaggcc 2100

EP 2 395 103 A1

ccaccattga ggaggtagat taggggcctt tccaagattg ctgtttttgt tttggagctt 2160
 caagactttg ctttcctag tttttctggt tgctagttct caatttcctg tgtttgcaat 2220
 5 gttgaaattt tttggtgaag tactgaactt gctttttttc cggtttctac atgcagagat 2280
 gaatttatac tgccatctta cgactatttc ttctttttaa tacacttaac tcaggccatt 2340
 10 ttttaagttg gttacttcaa agtaaataaa ctttaaaatt caa 2383

 <210> 103
 <211> 3283
 <212> DNA
 <213> human

 15 <400> 103
 gcgtgtcggg cgcggaaggg ggaggcggcc cggggcggcc gcgagtgagg cgcggggagg 60
 cgaaggagc gcgggtggcg gcaacttgctg ccgcggcctt ggatgggctg ggccccctc 120
 20 gccgctccgc ctctccaca cgcgcgggcg ccgcggcgag ggggacgcgc cgcccggggc 180
 ccggcacctt cgggaacccc ccggcccggg gcctgcggcc tgcgcccctt cggccgcccg 240
 gagccccgtg gagccccgc cgccgcggc ccccgcgagc cggacgctga gggcactcgg 300
 25 ggcggggcgc gcgctcgggc agacgtttgc ggggaggggg gcgcctgccg ggccccggcg 360
 accaccttgg gggtcgagg ccggctcggg gggcgcccag tgcgggccct cgcgggcgcc 420
 gggcagcgac cagccctgag cggagctgtt ggccgcggcg ggaggcctcc cggacgcccc 480
 cagccccccg aacgctcgc cgggccggcg ggagtcggcg cccccggga ggtccgctcg 540
 30 gtcgtccgcg gcggagcgtt tgctcctggg acaggcgggt ggaccggggc gtcgccggag 600
 acgccccag cgaagtggg ctctccaggt gtgggggtcc cggggggtag cgacgtcgcg 660
 gaccggcct gtgggatggg cggcccggag aagactgcgc tcggccgtgt tcatacttgt 720
 35 ccgtgggcct gaggtccccg gaggatgacc tagcactgaa aagccccggc cggcctcccc 780
 aggggtccccg aggacgaagt tgaccctgac cgggcccgtt cccagttctg aggccgggt 840
 cccactggaa ctgcgtctg agccgccgtc ccggaccccc ggtgcccgc ggtccgcaga 900
 40 ccctgcaccg ggttgact cgagccggg actgacgtgt agaacaatcg tttctgttg 960
 aagaagggtt tttcccttcc ttttgggggt tttgttcct ttttttttc tttttcttt 1020
 gtaaaatttt ggagaagggg agtcggaaca caaggaagga ccgctcacc gcggactcag 1080
 45 ggctggcggc gggactccag gaccctgggt ccagcatgga ggtggtggac ccgagcagc 1140
 tgggcatgtt cacggagggc gagctgatgt cgggtgggtat ggacacgttc atccaccgca 1200
 tcgactccac cgaggtcatc taccagccgc gccgcaagcg ggccaagctc atcggcaagt 1260
 50 acctgatggg ggacctgctg ggggaaggct cttacggcaa ggtgaaggag gtgctggact 1320
 cggagacgct gtgcaggagg gccgtcaaga tcctcaagaa gaagaagttg cgaaggatcc 1380
 ccaacgggga ggccaacgtg aagaaggaaa ttcaactact gaggaggta cggcacaaaa 1440
 55 atgtcatcca gctgggtgat gtgttataca acgaagagaa gcagaaaatg tatatggtga 1500

EP 2 395 103 A1

tggagtactg cgtgtgtggc atgcaggaaa tgctggacag cgtgccggag aagcgtttcc 1560
 cagtgtgcca ggccacaggg tacttctgtc agctgattga cggcctggag tacctgcata 1620
 5 gccagggcat tgtgcacaag gacatcaagc cggggaacct gctgctcacc accggtggca 1680
 ccctcaaaat ctccgacctg ggcgtggccg aggactgca cccgttcgcg gcggacgaca 1740
 cctgccggac cagccagggc tccccggctt tccagccgcc cgagattgcc aacggcctgg 1800
 10 acaccttctc cggcttcaag gtggacatct ggtcggctgg ggtcacctc tacaacatca 1860
 ccacgggtct gtacccttc gaaggggaca acatctacaa gttgtttgag aacatcggga 1920
 aggggagcta cgccatcccg ggcgactgtg gcccccgct ctctgacctg ctgaaagggg 1980
 15 tgcttgagta cgaaccggcc aagaggttct ccatccggca gatccggcag cacagctggt 2040
 tccggaagaa acatcctccg gctgaagcac cagtgcccat cccaccgagc ccagacacca 2100
 aggaccggtg gcgcagcatg actgtggtgc cgtacttggg ggacctgcac ggcgcggacg 2160
 aggacgagga cctcttcgac atcgaggatg acatcatcta cactcaggac ttcacggtgc 2220
 20 ccggacaggt cccagaagag gaggccagtc acaatggaca gcgccggggc ctccccaaagg 2280
 ccgtgtgtat gaacggcaca gaggcggcgc agctgagcac caaatccagg gcggagggcc 2340
 gggcccccaa ccctgcccgc aaggcctgct ccgccagcag caagatccgc cggctgtcgg 2400
 25 cctgcaagca gcagtgaggc tggccgcctg cagcccgtgt ccaggagccc cgccaggtgc 2460
 ccgcgccagg ccctcagtct tctgcccgtt tccgccgcc ctccccgaga ggtggccgcc 2520
 atgcttctgt gccgaccacg ccccaggacc tccggagcgc cctgcagggc cgggcagggg 2580
 30 gacagcaggg accgggcgca gccctcccc ctcggccgcc cggcagtgca cgcggcttgt 2640
 tgacttcgca gccccggcg gagccttccc gggcgggctt gggaggaggg aggcggcctc 2700
 catgcacttt atgtggagac tactggcccc gcccggtggc tcgtgctccg cagggcgccc 2760
 35 agcgcctcc ggcggccccg ccgcagacca gctggcgggt gtggagacca ggctcctgac 2820
 cccgccatgc atgcagcgc acctggaagc gcgcggccg ctttggtttt ttgtttggtt 2880
 ggttccattt tctttttttc ttttttttt taagaaaaa taaaagggtg atttgagctg 2940
 40 tggctgtgag ggggtgtttg gagctgctgg gtggcagggg ggctgtgggg tcgggctcac 3000
 gtcgcggccg cctttgcgct ctcgggtcac cctgctttgg cggcccggcc ggagggcagg 3060
 accctcacct ctcccccaag gccactgcmc tcttgggacc ccagagaaaa cccggagcaa 3120
 45 gcaggagtgt gcggtcaata tttatatcat ccagaaaaga aaaacacgag aaacgccatc 3180
 gcgggatggt gcagacgcg cggggactcg gaggggtccg tgcgggcgag gccgccccaa 3240
 tttggcaata aataaagctt ggaagcttg gacctgaaaa aaa 3283
 50
 <210> 104
 <211> 2030
 <212> DNA
 <213> human
 <400> 104
 55 tggctggcaa tggccttgct gacctcagc cgggcccacg tggggacctt tggagcacag 60

EP 2 395 103 A1

cctacgatcc tggtgcaagg ccggtggatg cagaggccag tccatatacc acccaggcct 120
 5 gcgaggagcg tgggtccccac ccatccagcc catatgtgca agtggcccttg acagagagggc 180
 tggtcatatc catggtgacc atttatgggc cacaacaggt ccccatctgc gcagtgaacc 240
 ctgtgctgag caccttgag acgtgatctt gcttcgtcct gcagcactgt gcggggcagg 300
 10 aaaatccaag aggaagaagg atctacggat atcctgcatg tccaagccac ccgcacccaa 360
 cccacacccc ccccggaacc tggactcccg gaccttcac accattggag acagaaactt 420
 tgagggtggag gctgatgact tggtgacat ctcagaactg ggccgtggag cctatgggggt 480
 ggtagagaag gtgcggcacg cccagagcgg caccatcatg gccgtgaagc ggatccgggc 540
 15 caccgtgaac tcacaggagc agaagcggct gctcatggac ctggacatca acatgcgcac 600
 ggtcgactgt ttctacactg tcaccttcta cggggcacta ttcagagagg gagacgtgtg 660
 gatctgcatg gagctcatgg acacatcctt ggacaagtgc taccggaagg tgctggataa 720
 20 aaacatgaca attccagagg acatccttgg ggagattgct gtgtctatcg tgcgggccct 780
 ggagcatctg cacagcaagc tgtcggatg ccacagagat gtgaagccct ccaatgtcct 840
 tatcaacaag gagggccatg tgaagatgtg tgactttggc atcagtggct acttgggtgga 900
 25 ctctgtggcc aagacgatgg atgccggctg caagccctac atggcccctg agaggatcaa 960
 cccagagctg aaccagaagg gctacaatgt caagtccgac gtctggagcc tgggcatcac 1020
 catgattgag atggccatcc tgcggttccc ttacgagtcc tgggggacct cgttccagca 1080
 30 gctgaagcag gtggtggagg agccgtccc ccagctccc gccgaccgtt tctccccga 1140
 gtttgtggac ttcactgctc agtgcctgag gaagaacccc gcagagcgta tgagctacct 1200
 ggagctgatg gagcaccctt tcttcacctt gcacaaaacc aagaagacgg acattgctgc 1260
 35 cttcgtgaag aagatcctgg gagaagactc ataggggctg ggcctcggac cccactccgg 1320
 ccctccagag cccacagcc ccatctgcgg gggcagtgct caccacacc ataagctact 1380
 gccatcctgg cccagggcat ctgggaggaa ccgagggggc tgctcccacc tggctctgtg 1440
 40 gcgagccatt tgtcccaagt gccaaagaag cagaccattg gggctcccag ccaggccctt 1500
 gtcggcccca ccagtgcctc tccctgctgc tcctaggacc cgtctccagc tgctgagatc 1560
 ctggactgag ggggcctgga tgccccctgt ggatgctgct gcccctgcac agcaggctgc 1620
 45 cagtgcctgg gtggatgggc caccgccttg cccagcctgg atgccatcca agttgtatat 1680
 ttttttaatc tctcgactga atggactttg cacactttgg cccaggggtg ccacacctt 1740
 atcccgctt tgggtcgggg tacacaagag gggatgagtt gtgtgaatac ccaagactc 1800
 50 ccatgagggg gatgcatga gccgcccag gccttcccct ggcactggca aacagggcct 1860
 ctgaggagca cactggctca cccagtcctg cccgccaccg ttatcgggtg cattcacctt 1920
 tcgtgtttt ttaatttat cctctgttga tttttctt tgctttatgg gtttggcttg 1980
 55 ttttcttgc atggtttgga gctgatcgt tctccccac ccctagggg 2030

EP 2 395 103 A1

<210> 105
 <211> 3583
 <212> DNA
 <213> human

5
 <400> 105
 aaaggcctgc agcaggacga ggacctgagc caggaatgca ggatggcggc ggtgaagaag 60
 gaagggggtg ctctgagtga agccatgtcc ctggaggag atgaatggga actgagtaaa 120
 10 gaaaatgtac aacctttaag gcaagggcgg atcatgtcca cgcttcaggg agcactggca 180
 caagaatctg cctgtaacaa tactcttcag cagcagaaac gggcatttga atatgaaatt 240
 cgattttaca ctggaaatga ccctctggat gtttgggata ggtatatcag ctggacagag 300
 15 cagaactatc ctcaaggtgg gaaagagagt aatatgtcaa cgttattaga aagagctgta 360
 gaagcactac aaggagaaaa acgatattat agtgatcctc gatttctcaa tctctggcct 420
 aaattagggc gtttatgcaa tgagcctttg gatatgtaca gttacttgca caaccaaggg 480
 attggtgttt cacttgctca gttctatata tcatgggcag aagaatatga agctagagaa 540
 20 aacttttaga aagcagatgc gatatttcag gaagggattc aacagaaggc tgaaccacta 600
 gaaagactac agtcccagca ccgacaattc caagctcgag tgtctcggca aactctgttg 660
 gcacttgaga aagaagaaga ggaggaagtt ttgagtctt ctgtaccaca acgaagcaca 720
 25 ctagctgaac taaagagcaa agggaaaaag acagcaagag ctccaatcat ccgtgtagga 780
 ggtgctctca aggctccaag ccagaacaga ggactccaaa atccatttcc tcaacagatg 840
 caaataata gtagaattac tgtttttgat gaaaatgctg atgaggcttc tacagcagag 900
 30 ttgtctaagc ctacagtcca gccatggata gcacccccca tgcccagggc caaagagaat 960
 gagctgcaag caggcccttg gaacacaggc aggtccttgg aacacaggcc tcgtggcaat 1020
 acagcttcac tgatagctgt acccgctgtg cttcccagtt tcaactcata tgtggaagag 1080
 35 actgcacaac agccagttat gacaccatgt aaaattgaac ctagtataaa ccacatccta 1140
 agcaccagaa agcctggaaa ggaagaagga gatcctctac aaagggttca gagccatcag 1200
 caagcgtctg aggagaagaa agagaagatg atgtattgta aggagaagat ttatgcagga 1260
 40 gtaggggaat tctcctttga agaaattcgg gctgaagttt tccggaagaa attaaaagag 1320
 caaagggag ccgagctatt gaccagtgc gagaagagag cagaaatgca gaaacagatt 1380
 gaagagatgg agaagaagct aaaagaaatc caaactactc agcaagaaag aacaggtgat 1440
 45 cagcaagaag agacgatgcc tacaaggag acaactaac tgcaaattgc ttccgagtct 1500
 cagaaaatac caggaatgac tctatccagt tctgtttgtc aagtaaactg ttgtgccaga 1560
 gaaacttcac ttgcggagaa catttggcag gaacaacctc attctaaagg tcccagtgta 1620
 50 ctttctcca tttttgatga gtttcttctt tcagaaaaga agaataaaag tctcctgca 1680
 gatccccac gagtttttagc tcaacgaaga ccccttgag ttctcaaac ctcaagaaagc 1740
 atcacctcaa atgaagatgt gtctccagat gtttgtgatg aatttacagg aattgaaccc 1800
 55 ttgagcgagg atgccattat cacaggcttc agaaatgtaa caatttgtcc taaccagaa 1860

EP 2 395 103 A1

5 gacacttggtg actttgccag agcagctcgt tttgtatcca ctctttttca tgagataatg 1920
 tccttgaagg atctcccttc tgatcctgag agactgttac cggaagaaga tctagatgta 1980
 aagacctctg aggaccagca gacagcttgt ggcactatct acagtcagac tctcagcatc 2040
 aagaagctga gcccaattat tgaagacagt cgtgaagcca cacactcctc tggcttctct 2100
 10 ggttcttctg cctcggttgc aagcacctcc tccatcaaat gtcttcaaat tcctgagaaa 2160
 ctagaactta ctaatgagac ttcagaaaac cctactcagt caccatgggtg ttcacagtat 2220
 cgcagacagc tactgaagtc cctaccagag ttaagtgcct ctgcagagtt gtgtatagaa 2280
 gacagaccaa tgcctaagtt ggaaattgag aaggaaattg aattaggtaa tgaggattac 2340
 15 tgcattaaac gagaatacct aatatgtgaa gattacaagt tattctgggt ggcgccaaga 2400
 aactctgcag aattaacagt aataaaggta tcttctcaac ctgtcccatg ggaactttat 2460
 atcaacctca agttaaagga acgtttaaat gaagattttg atcatttttg cagctgttat 2520
 caatatcaag atggctgtat tgtttggcac caatatataa actgcttcac ccttcaggat 2580
 20 cttctccaac acagtgaata tattacccat gaaataacag tgttgattat ttataacctt 2640
 ttgacaatag tggagatgct acacaaagca gaaatagtc atggtgactt gagtccaagg 2700
 tgtctgattc tcagaaacag aatccacgat ccctatgatt gtaacaagaa caatcaagct 2760
 25 ttgaagatag tggacttttc ctacagtgtt gaccttaggg tgcagctgga tgtttttacc 2820
 ctcagcggct ttcggactgt acagatcctg gaaggacaaa agatcctggc taactgttct 2880
 tctccctacc aggtagacct gtttggata gcagatntag cacatttact attgttcaag 2940
 30 gaacacctac aggtcttctg ggatgggtcc ttctggaaac ttagccaaaa tatttctgag 3000
 ctaaagatg gtgaattgtg gaataaattc tttgtgcgga ttctgaatgc caatgatgag 3060
 gccacagtgt ctgttcttgg ggagcttgca gcagaaatga atggggtttt tgacactaca 3120
 35 ttcaaagtc acctgaacaa agccttatgg aaggtaggga agttaactag tcctggggct 3180
 ttgctcttcc agtgagctag gcaatcaagt ctcacagatt gctgcctcag agcaatgggt 3240
 gtattgtgga aactgaaac tgtatgtgct gtaatttaaat ttaggacaca ttagatgca 3300
 40 ctaccattgc tgttctactt tttggtacag gtatattttg acgtcactga tattttttat 3360
 acagtgatat acttactcat ggccttgtct aacttttgtg aagaactatt ttattctaaa 3420
 cagactcatt acaaatgggt accttgttat ttaaccatt tgtcttact tttccctgta 3480
 45 cttttcccat ttgtaatttg taaaatgttc tcttatgatc accatgtatt ttgtaaataa 3540
 taaaatagta tctgttaaaa aaaaaaaaaa aaaaaaaaaa aaa 3583

50 <210> 106
 <211> 1379
 <212> DNA
 <213> human

55 <400> 106
 ctggtggagc cgctgtgggt gctgtccgcg gactggaagc gcgtgctttt gtttgtgtcc 60
 ctggccatgg cgctgcagct ctcccgggag cagggaatca ccctgcgcgg gagcgcgaa 120

EP 2 395 103 A1

atcgtggccg agttcttctc attcggcatc aacagcattt tatatcagcg tggcatatat 180
 ccatctgaaa cctttactcg agtgcagaaa tacggactca ccttgcttgt aactactgat 240
 5 cttgagctca taaaatacct aaataatgtg gtggaacaac tgaaagattg gttatacaag 300
 tgttcagttc agaaactggt tgtagttatc tcaaatattg aaagtggta ggtcctggaa 360
 agatggcagt ttgatattga gtgtgacaag actgcaaaag atgacagtgc acccagagaa 420
 10 aagtctcaga aagctatcca ggatgaaatc cgttcagtga tcagacagat cacagctacg 480
 gtgacatttc tgccactggt ggaagtttct tgttcatttg atctgctgat ttatacagac 540
 aaagatttgg ttgtacctga aaaatgggaa gagtcgggac cacagtttat taccaattct 600
 15 gaggaagtcc gccttcgttc atttactact acaatccaca aagtaaataag catggtggcc 660
 tacaaaattc ctgtcaatga ctgaggatga catgaggaaa ataatgtaat tgtaattttg 720
 aaatgtgggt ttcctgaaat caagtcatct atagttagata tgttttattt cattgggttaa 780
 20 tttttacatg gagaaaacca aatgatact tactgaactg tgtgtaattg ttcctttatt 840
 tttttggtac ctatttgact taccatggag ttaacatcat gaatttattg cacattgttc 900
 aaaaggaacc aggaggtttt tttgtcaaca ttgtgatgta tattcctttg aagatagtaa 960
 25 ctgtagatgg aaaaacttgt gctataaagc tagatgcttt cctaaatcag atgttttgggt 1020
 caagtagttt gactcagtat aggtagggag atatttaagt ataaaataca acaaaggaag 1080
 tctaaatatt cagaatcttt gttaaggtcc tgaaagtaac tcataatcta taaacaatga 1140
 30 aatattgctg tatagctcct tttgacctc atttcatgta tagttttccc tattgaatca 1200
 gtttccaatt atttgacttt aatttatgta acttgaacct atgaagcaat ggatatttgt 1260
 actgtttaat gttctgtgat acagaactct taaaatgtt ttttcatgtg ttttataaaa 1320
 35 tcaagtttta agtgaaagtg aggaaataaa gttaagtttg ttttaattt gtcttaaaa 1379

 <210> 107
 <211> 2984
 <212> DNA
 <213> human
 40
 <400> 107
 ggaaattcaa acgtgtttgc ggaaaggagt ttgggttcca tcttttcatt tccccagcgc 60
 agctttctgt agaaatggaa tccgaggatt taagtggcag agaattgaca attgattcca 120
 45 taatgaacaa agtgagagac attaaaaata agtttaaaaa tgaagacctt actgatgaac 180
 taagcttgaa taaaatttct gctgatacta cagataactc gggaaactgtt aaccaaatta 240
 tgatgatggc aaacaacca gaggactggt tgagtttgtt gctcaacta gagaaaaaca 300
 50 gtgttccgct aagtgatgct cttttaaata aattgattgg tcgttacagt caagcaattg 360
 aagcgcttcc cccagataaa tatggccaaa atgagagttt tgctagaatt caagtgagat 420
 ttgctgaatt aaaagctatt caagagccag atgatgcacg tgactacttt caaatggcca 480
 55 gagcaactg caagaaattt gcttttgttc atatatcttt tgcacaattt gaactgtcac 540

EP 2 395 103 A1

aaghtaattgt caaaaaaagt aaacaacttc ttcaaaaagc tgtagaacgt ggagcagtac 600
 cactagaaat gctggaaatt gccctgcgga atttaaaccct ccaaaaaaag cagctgcttt 660
 5 cagaggagga aaagaagaat ttatcagcat ctacggtatt aactgcccaa gaatcatttt 720
 ccggttccact tgggcattta cagaatagga acaacagttg tgattccaga ggacagacta 780
 ctaaagccag gtttttatat ggagagaaca tgccaccaca agatgcagaa ataggttacc 840
 10 ggaattcatt gagacaaact aacaaaacta aacagtcatg cccatttgga agagtcccag 900
 ttaaccttct aaatagccca gattgtgatg tgaagacaga tgattcagtt gtacctgtt 960
 ttatgaaaag acaaacctct agatcagaat gccgagattt ggttgtgcct ggatctaaac 1020
 caagtggaaa tgattcctgt gaattaagaa atttaaagtc tgttcaaaat agtcatttca 1080
 15 aggaacctct ggtgtcagat gaaaagagtt ctgaacttat tattactgat tcaataacc 1140
 tgaagaataa aacggaatca agtcttctag ctaaattaga agaaactaaa gagtatcaag 1200
 aaccagaggt tccagagagt aaccagaaac agtggcaatc taagagaaag tcagagtgt 1260
 20 ttaaccagaa tctgtctgca tcttcaaatc actggcagat tccggagtta gcccgaaaag 1320
 ttaatacaga gcagaaacat accacttttg agcaacctgt cttttcagtt tcaaacagtt 1380
 caccaccaat atcaacatct aaatggtttg acccaaatc tttttgtaag acaccaagca 1440
 25 gcaatacctt ggatgattac atgagctggt ttagaactcc agttgtaaag aatgactttc 1500
 cacctgcttg tcagttgtca acaccttatg gccaacctgc ctgtttcag cagcaacagc 1560
 atcaaaact tgccactcca cttcaaaatt tacaggtttt agcatcttct tcagcaaatg 1620
 30 aatgcatttc ggttaaagga agaatttatt ccattttaaa gcagatagga agtggagggt 1680
 caagcaaggt atttcaggtg ttaaagaaa agaaacagat atatgctata aaatatgtga 1740
 acttagaaga agcagataac caaactcttg atagttaccg gaacgaaata gcttatttga 1800
 35 ataaactaca acaacacagt gataagatca tccgacttta tgattatgaa atcacggacc 1860
 agtacatcta catggtaatg gagtgtggaa atattgatct taatagttgg cttaaaaaga 1920
 aaaaatccat tgatccatgg gaacgcaaga gttactggaa aaatatgtta gaggcagttc 1980
 40 acacaatcca tcaacatggc attgttcaca gtgatcttaa accagctaac tttctgatag 2040
 ttgatggaat gctaaagcta attgattttg ggattgcaa ccaaatgcaa ccagatacaa 2100
 caagtgtgt taaagattct caggttgga cagttaatta tatgccacca gaagcaatca 2160
 45 aagatatgtc ttctccaga gagaatggga aatctaagtc aaagataagc cccaaaagt 2220
 atgtttggtc cttaggatgt atttgtact atatgactta cgggaaaaca ccatttcagc 2280
 agataattaa tcagatttct aaattacatg ccataattga tcctaatcat gaaattgaat 2340
 50 ttcccgatat tccagagaaa gatcttcaag atgtgttaaa gtgtgttta aaaagggacc 2400
 caaacagag gatatccatt cctgagctcc tggctcatcc ctatgttcaa attcaaactc 2460
 atccagttaa ccaaatggcc aagggaaacca ctgaagaaat gaaatatggt ctggccaac 2520
 55 ttgttggctt gaattctct aactcattt tgaagctgc taaaacttta tatgaacact 2580

EP 2 395 103 A1

	atagtggg	tgaaagtc	aattcttc	cctccaag	acctttaa	aaagggg	2640
	aaaaatg	atgagtt	cgtaatgt	aataccac	ataaaata	ttggactgt	2700
5	atactctg	atccctgt	aaatctac	ttgaagac	catcactct	aagtgttat	2760
	agcaaaaa	attcagta	ttatcttta	aagaaaact	taaaaatag	aaccacttat	2820
	ggactgtat	atattgtag	cttgtttct	ctgttttat	ctcttggtg	atctacttga	2880
10	catcatttta	ctcttgaat	agtgggtg	tagcaagt	attctaaaa	actttgtaa	2940
	taaagtttg	tggctaaa	gacactaaa	aaaaaaaa	aaaa		2984
	<210>	108					
	<211>	2166					
15	<212>	DNA					
	<213>	human					
	<400>	108					
	gggggtcg	gtgcctgt	ccgtgtgat	cgaaaagt	tgcaaaatg	cggtgctgc	60
20	ttcgccggg	gggtaagg	ggtgccctg	tgaaatttc	tatcctggc	aactcaaatg	120
	aggatggca	gagagtgag	ccttgagag	agaggctgag	catcatgaag	agaagaccct	180
	gggagtccc	tggggacct	gagtctggag	ctggggcaag	gccccccagg	gcccgtcagt	240
25	ggcctgagga	gatggttga	tcattccaa	cattgtctca	gtgtggaaac	tgaggcagac	300
	agtggtcagg	caggaccata	tgagaactg	atgttggag	cagctctagc	cacaggagag	360
	gagctgccg	aactgacctt	gctgaccaca	ctgttggagg	gccctggaga	taagacgcag	420
30	ccacctgaag	aggagacttt	gtcccaagcc	cctgagagt	aggaggaaca	gaagaagaag	480
	gctctgaaa	ggagtatgta	tgtcctgagt	gaactggtag	aaacagagaa	aatgtacgtg	540
	gacgacttgg	ggcagattgt	ggagggttat	atggccacca	tggctgctca	gggggtcccc	600
35	gagagtcttc	gaggccgtga	caggatttg	tttgggaata	tccagcaaat	ctatgagtgg	660
	caccgagact	atctcttgca	agagctaca	cggtgtctga	aagatcctga	ttggctggct	720
	cagctattca	tcaaacacga	gcccggctg	catatgtatg	tgggtgactg	tcagaataag	780
	ccaagtccag	agcatgtggt	gtcagagttt	ggggacagct	actttgagga	gctccggcag	840
40	cagctggggc	accgcctgca	gctgaacgac	ctcctcatca	aacctgtgca	gcggatcatg	900
	aaataaccag	tgctgctcaa	ggattttctc	aagtattaca	atagagctgg	gatggatact	960
	gcagacctag	agcaagctgt	ggaggtcatg	tgctttgtgc	ccaagcgtg	caacgatatg	1020
45	atgacgctgg	ggagattgcg	gggatttgag	ggcaaaactga	ctgctcaggg	gaagctcttg	1080
	ggccaggaca	ctttctgggt	caccgagcct	gaggctggag	ggctgctatc	ttcccagggt	1140
	cgagagaggc	gcgtcttcct	ctttgagcaa	atcatcatct	tcagtgaagc	cctgggagga	1200
50	ggagtgagag	gtggaacaca	gcctggatat	gtatacaaga	acagcattaa	ggtgagctgc	1260
	ctgggactgg	aggggaacct	ccaaggtgac	ccttgccgct	ttgactgac	ctccagaggg	1320
	ccagaggggtg	ggatccagcg	ctatgtcctg	caggctgcag	accctgctat	cagtcaggcc	1380
55	tggatcaagc	atgtggctca	gatcttggag	agccaacggg	acttcctcaa	cgattgacg	1440

EP 2 395 103 A1

	tcaccattg agtaccagag acgggagagc cagaccaaca gcctggggcg gccaaagagg	1500
5	cctggagtgg ggagccctgg aagaattcgg cttggagatc aggccaggg cagcacacac	1560
	acacccatca atggctctct cccctctctg ctgctgtcac ccaaagggga ggtggccaga	1620
	gccctcttgc cactggataa acaggccctt ggtgacatcc cccaggctcc ccatgactct	1680
10	cctccagtct ctccaactcc aaaaaccctt ccctgccaaag ccagacttgc caagctggat	1740
	gaagatgagc tgtaactggt gaaaaccatg ggggtggtgc tgactcagcc gcctattccc	1800
	caaggagctt cagggcagtc cttctggcac tgctccagaa ttctccttc ttggtgtgtc	1860
15	tggaggggtgg gcaaggctgg gagggatatac aacttggagg agaacaccta gacccaagga	1920
	cttttttctg cccaaggaac acagtttctt tcagctccca tccctatgca tgcatcatgg	1980
	tcccccaaaa aggaggatat gtgggtgggt gggagggctg gggcaggggc cagatagaaa	2040
	ttattggttt tgttttttaa ttttgtttt cctgttttct gagaataaag gttttgttat	2100
20	atcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2160
	aaaaaa	2166
25	<210> 109 <211> 3486 <212> DNA <213> human	
30	<400> 109 gagccgactg cggctgcgcg gggatttcga atcggcggcg gcttctagtt tgcggttcag	60
	gtttggccgc tgccggccag cgtcctctgg ccatggacac cccggaaaat gtccttcaga	120
	tgcttgaagc ccacatgcag agctacaagg gcaatgacct tcttggtgaa tgggaaagat	180
35	acatacagtg ggtagaagag aattttctg agaataaaga atacttgata actttactag	240
	aacatttaat gaaggaattt ttagataaga agaaatacca caatgacca agattcatca	300
	gttattgttt aaaatttgct gagtacaaca gtgacctca tcaattttt gagtttctgt	360
	acaaccatgg gattggaacc ctgtcatccc ctctgtacat tgcttggcg gggcatctgg	420
40	aagcccaagg agagctgcag catgccagt ctgtcctca gagaggaatt caaaaccagg	480
	ctgaaccag agagttcctg caacaacaat acaggttatt tcagacacgc ctactgaaa	540
	cccatttgcc agctcaagct agaacctcag aacctctgca taatgttcag gttttaaact	600
45	aaatgataac atcaaatca aatccaggaa ataacatggc ctgcatttct aagaatcagg	660
	gttcagagct ttctggagt atattctcag cttgtgataa agagtcaaat atggaacgaa	720
	gagtgatcac gatttctaaa tcagaatatt ctgtgcactc atctttggca tccaaagttg	780
50	atgttgagca gtttgttatg tattgcaagg agaagcttat tcgtggggaa tcagaatttt	840
	cctttgaaga attgagagcc cagaatata atcaacggag aaagcatgag caatgggtaa	900
	atgaagacag acattatatg aaaaggaaag aagcaaatgc ttttgaagaa cagctattaa	960
55	aacagaaaat ggatgaactt cataagaagt tgcatcagg ggtggagaca tcccatgagg	1020

EP 2 395 103 A1

atctgcccgc ttcccaggaa aggtccgagg ttaatccagc acgtatgggg ccaagtgtag 1080
 gctcccagca ggaactgaga gcgccatgtc ttccagtaac ctatcagcag acaccagtga 1140
 5 .acatggaaaa gaaccaaga gaggcacctc ctgttgttcc tcctttggca aatgctattt 1200
 ctgcagcttt ggtgtcccca gccaccagcc agagcattgc tcctcctggt cctttgaaa 1260
 cccagacagt aacagactcc atgtttgcag tggccagcaa agatgctgga tgtgtgaata 1320
 10 agagtactca tgaattcaag ccacagagtg gagcagagat caaagaaggg tgtgaaacac 1380
 ataaggttgc caacacaagt tcttttcaca caactccaaa cacatcactg ggaatggttc 1440
 aggcaacgcc atccaaagtg cagccatcac ccaccgtgca cacaaaagaa gcattaggtt 1500
 15 tcatcatgaa tatgtttcag gtcctcacac ttctgatata ttctgatgac aaagatgaat 1560
 ggcaatctct agatcaaaat gaagatgcat ttgaagccca gtttcaaaaa aatgtaagg 1620
 catctggggc ttggggagtc aataagatca tctcttcttt gtcactgctt tttcatgtgt 1680
 20 ttgaagatgg aaacaaagaa aattatggat taccacagcc taaaaataaa cccacaggag 1740
 ccaggacctt tggagaacgc tctgtcagca gacttccttc aaaaccaag gaggaagtgc 1800
 ctcatgctga agagtttttg gatgactcaa ctgtatgggg tattcgtctgc aacaaaacc 1860
 25 tggcaccag tcctaagagc ccaggagact tcacatctgc tgcaactt gcgtctacac 1920
 cattccaaa gcttccagtg gagtcagtgc acattttaga agataaagaa aatgtggtag 1980
 caaacagtg taccaggcg actttggatt cttgtgagga aaacatggtg gtgccttcaa 2040
 30 gggatggaaa attcagtcca attcaagaga aaagccaaa acaggccttg tcgtctcaca 2100
 tgtattcagc atccttactt cgtctgagcc agcctgctgc aggtggggta cttacctgtg 2160
 aggcagagt gggcgttgag gcttgcagac tcacagacac tgacgctgcc attgcagaag 2220
 atccaccaga tgctattgct gggctccaag cagaatggat gcagatgagt tcaactggga 2280
 35 ctgttgatgc tccaaacttc attggtggga acccatggga tgataagctg attttcaaac 2340
 ttttatctgg gctttctaaa ccagtgagtt cctatccaaa tacttttgaa tggcaatgta 2400
 aacttccagc catcaagccc aagactgaat ttcaattggg ttctaagctg gtctatgtcc 2460
 40 atcaccttct tggagaagga gcctttgccc aggtgtacga agctaccag ggagatctga 2520
 atgatgctaa aaataaacag aaatttgttt taaaggcca aaagcctgcc aaccctggg 2580
 aattctacat tgggaccag ttgatggaa gactaaagcc atctatgcag cacatgttta 2640
 45 tgaagtctta ttctgcccac ttattccaga atggcagtgt attagtagga gagctctaca 2700
 gctatggaac attattaat gccattaacc tctataaaaa taccctgaa aaagtgtgc 2760
 ctcaaggctt tgtcatctt tttgctatga gaatgcttta catgattgag caagtgtgc 2820
 50 actgtgaaat cattcatgga gacattaaac cagacaattt catacttgga aacggatfff 2880
 tggaaacagga tgatgaagat gatttatctg ctggcttggc actgattgac ctgggtcaga 2940
 gtatagatat gaaacttttt ccaaaaggaa ctatattcac agcaaagtgt gaaacatctg 3000
 55 gttttcagtg tgttgagatg ctgagcaaca aaccatggaa ctaccagatc gattactttg 3060

EP 2 395 103 A1

	gggttgctgc aacagtatat tgcattgctct ttggcactta catgaaagtg aaaaatgaag	3120
	gaggagagtg taagcctgaa ggtcttttta gaaggcttcc tcatttggat atgtggaatg	3180
5	aatTTTTTca tgTtatgttg aatattccag attgtcatca tcttccatct ttggatttgt	3240
	taaggcaaaa gctgaagaaa gtatttcaac aacactatac taacaagatt agggccctac	3300
	gtaataggct aattgtactg ctcttagaat gtaagcgttc acgaaaataa aatttgata	3360
10	tagacagtcc ttaaaaatca cactgtaaat atgaatctgc tcactttaa cctgtttttt	3420
	tttcatttat tgTttatgta aatgtttgtt aaaaataaat cccatggaat atttccatgt	3480
	aaaaaa	3486
15	<210> 110 <211> 6641 <212> DNA <213> human	
20	<400> 110 ggttacattt tggatcctcg cggagtactg gtcaggcggg taagtcctgt acctaggaaa	60
	gagggcgagc tctggggcgc tctccgggtg catgaggagc ttcaaaagag tcaactttgg	120
	gactctgcta agcagccaga aggaggctga agagttgctg cccgccttga aggagtccct	180
25	gtccaaccct ccagctggtt ttcccagcag ccgatctgat gctgagagga gacaagcttg	240
	tgatgccatc ctgagggcct gcaaccagca gctgactgct aagctagctt gccctaggca	300
	tctggggagc ctgctggagc tggcagagct ggcctgtgat ggctacttag tgtctacccc	360
30	acagcgtcct cccctctacc tggaaacgaat tctctttgtc ttactgcgga atgctgctgc	420
	acaaggaagc ccagaggcca cactccgctt tgctcagccc ctccatgcct gcttggtgca	480
	gtgctctcgc gaggctgctc cccaggacta tgaggccgtg gctcggggca gcttttctct	540
35	gctttggaag ggggcagaag ccctgttggg acggcgagct gcatttgag ctcggctgaa	600
	ggccttgagc ttcctagtag tcttgaggga tgaaagtacc cctgtgagg ttcctcactt	660
	tgcttctcca acagcctgtc gagcggtagc tgcccatcag ctatttgatg ccagtggcca	720
40	tggtctaaat gaagcagatg ctgatttcct agatgacctg ctctccaggc acgtgatcag	780
	agccttggtg ggtgagagag ggagctcttc tgggcttctt tctcccaga gggccctctg	840
	cctcttgag ctcaccttg aacactgccg tcgcttttgc tggagccgcc accatgacaa	900
45	agccatcagc gcagtggaga aggctcacag ttacctaagg aacaccaatc tagcccctag	960
	ccttcagcta tgtcagctgg gggttaagct gctgcaggtt ggggaggaag gacctcaggc	1020
	agtggccaag cttctgatca aggcacagc tgtcctgagc aagagtatgg aggcaccatc	1080
	acccccactt cgggcattgt atgagagctg ccagtcttc ctttcaggcc tggaacgagg	1140
50	caccaagagg cgctatagac ttgatgccat tctgagcctc tttgcttttc ttggagggta	1200
	ctgctctctt ctgcagcagc tgcgggatga tgggtgtgat gggggctcct ccaagcaaca	1260
	gcagtctttt cttcagatgt actttcaggg acttcacctc tacactgtgg tggtttatga	1320
55	ctttgcccaa ggctgtcaga tagttgattt ggctgacctg acccaactag tggacagttg	1380

EP 2 395 103 A1

taaatctacc gttgtctgga tgctggagggc cttagagggc ctgtcgggcc aagagctgac 1440
 ggaccacatg gggatgaccg cttcttacac cagtaatttg gcctacagct tctatagtca 1500
 5 caagctctat gccgaggcct gtgccatctc tgagccgctc tgtcagcacc tgggtttggt 1560
 gaagccaggc acttatcccg aggtgcctcc tgagaagttg cacaggtgct tccggctaca 1620
 agtagagagt ttgaagaaac tgggtaaaca ggcccagggc tgcaagatgg tgattttgtg 1680
 10 gctggcagcc ctgcaaccct gtagccctga acacatggct gagccagtca ctttctgggt 1740
 tcgggtcaag atggatgctg ccagggctgg agacaaggag ctacagctaa agactctgctg 1800
 agacagcctc agtggctggg acccggagac cctggccctc ctgctgaggg aggagctgca 1860
 15 ggcctacaag gcggtgctgg ccgacactgg acaggaacgc ttcaacatca tctgtgacct 1920
 cctggagctg agccccgagg agacaccagc cggggcctgg gcacgagcca cccacctggt 1980
 agaactggct caggtgctct gctaccacga ctttacgctg cagaccaact gctctgctct 2040
 20 ggatgctatc cgggaagccc tgcagcttct ggactctgtg aggcctgagg cccaggccag 2100
 agatcagctt ctggacgata aagcacaggc cttgctgtgg ctttacatct gtactctgga 2160
 agccaaaatg caggaaggta tcgagcggga tcggagagcc caggcccctg gtaacttgga 2220
 25 ggaatttgaa gtcaatgacc tgaactatga agataaactc caggaagatc gtttcctata 2280
 cagtaacatt gccttcaacc tggctgcaga tgctgctcag tccaaatgcc tggaccaagc 2340
 cctggccctg tggaaggagc tgcttaca aa ggggcaggcc ccagctgtac ggtgtctcca 2400
 30 gcagacagca gcctcactgc agatcctagc agccctctac cagctggtgg caaagcccat 2460
 gcaggctctg gaggtcctcc tgctgctacg gattgtctct gagagactga aggaccactc 2520
 gaaggcagct ggctcctct gccacatcac ccagctcctc ctgaccctcg gctgtcccag 2580
 ctatgcccag ttacacctgg aagaggcagc atcgagcctg aagcatctcg atcagactac 2640
 35 tgacacatac ctgctccttt ccctgacctg tgatctgctt cgaagtcaac tctactggac 2700
 tcaccagaag gtgaccaagg gtgtctctct gctgctgtct gtgcttcggg atcctgccct 2760
 ccagaagtcc tccaaggctt ggtacttgct gcgtgtccag gtcctgcagc tgggtggcagc 2820
 40 ttaccttagc ctcccgtcaa acaacctctc acactccctg tgggagcagc tctgtgccc a 2880
 aggctggcag acacctgaga tagctctcat agactcccat aagctcctcc gaagcatcat 2940
 cctcctgctg atgggcagtg acattctctc aactcagaaa gcagctgtgg agacatcgtt 3000
 45 tttggactat ggtgaaaatc tgggtacaaa atggcagggt ctttcagagg tgctgagctg 3060
 ctgagagaag ctggtctgcc acctgggccg cctgggtagt gtgagtgaag ccaaggcctt 3120
 ttgcttgagg gccctaaaac ttacaacaaa gctgcagata ccacgccagt gtgccctggt 3180
 50 cctggtgctg aagggcgagc tggagctggc ccgcaatgac attgatctct gtcagtcgga 3240
 cctgcagcag gttctgttct tgcttgagtc ttgcacagag tttggtgggg tgactcagca 3300
 cctggactct gtgaagaagg tccacctgca gaaggggaag cagcaggccc aggtcccctg 3360
 55 tcctccacag ctcccagagg aggagctctt cctaagaggc cctgctctag agctggtggc 3420

EP 2 395 103 A1

cactgtggcc aaggagcctg gccccatagc accttctaca aactcctccc cagtcttgaa 3480
 aaccaagccc cagcccatac ccaacttcct gtcccattca cccacctgtg actgctcgct 3540
 5 ctgcgccagc cctgtcctca cagcagtctg tctgcgctgg gtattggtca cggcaggggt 3600
 gaggctggcc atggggccacc aagcccaggg tctggatctg ctgcaggtcg tgctgaaggg 3660
 ctgtcctgaa gccgctgagc gcctcaccca agctctccaa gcttccctga atcataaaac 3720
 10 acccccctcc ttggttccaa gcctcttggg tgagatcttg gctcaagcat acacactggt 3780
 ggactgagag ggcctgaacc agccatcaaa cgagagcctg cagaaggttc tacagtcagg 3840
 gctgaagttt gtagcagcac ggatacccca cctagagccc tggcgagcca gcctgctctt 3900
 15 gatttggggc ctcacaaaac taggtggcct cagctgctgt actaccaac tttttgcaag 3960
 ctctggggc tggcagccac cattaataaa aagtgtccct ggctcagagc cctctaagac 4020
 tcagggccaa aaacgttctg gacgagggcg ccaaaaagta gcctctgctc ccctgcgctt 4080
 20 caataatacc tctcagaaag gtctggaagg tagaggactg ccctgcacac ctaaaccctc 4140
 agaccggatc aggcaagctg gccctcatgt ccccttcacg gtgtttgagg aagtctgccc 4200
 tacagagagc aagcctgaag taccccaggc ccccagggta caacagagag tccagacgcg 4260
 cctcaaggtg aacttcagtg atgacagtga cttggaagac cctgtctcag ctgaggcctg 4320
 25 gctggcagag gagcctaaga gacggggcac tgcttcccgg ggccgggggc gagcaaggaa 4380
 gggcctgagc ctaaagacgg atgccgtggt tgccccaggt agtgcccctg ggaaccctgg 4440
 cctgaatggc aggagccgga gggccaagaa ggtggcatca agacattgtg aggagcggcg 4500
 30 tccccagagg gccagtgacc aggccaggcc tggccctgag atcatgagga ccatccctga 4560
 ggaagaactg actgacaact ggagaaaaat gagctttgag atcctcaggg gctctgacgg 4620
 ggaagactca gcctcaggtg ggaagactcc agctccgggc cctgaggcag cttctggaga 4680
 35 atgggagctg ctgaggctgg attccagcaa gaagaagctg cccagcccat gccagacaa 4740
 ggagagtgac aaggacctg gtccctcggc cgggctcccc tcagcccccg tagccactgg 4800
 tctttctacc ctggactcca tctgtgactc cctgagtgtt gctttccggg gcattagtca 4860
 40 ctgtcctcct agtgggctct atgcccact ctgccgcttc ctggccttgt gcctgggcca 4920
 ccgggatcct tatgccactg ctttcttgt caccgagtct gtctccatca cctgtcgcca 4980
 ccagctgctc acccacctcc acagacagct cagcaaggcc cagaagcacc gaggatcact 5040
 45 tgaaatagca gaccagctgc aggggctgag ccttcaggag atgcctggag atgtcccct 5100
 ggcccgcac cagcgcctct tttccttcag ggctttggaa tctggccact tccccagcc 5160
 tgaaaaggag agtttccagg agcgcctggc tctgatcccc agtggggtga ctgtgtgtgt 5220
 50 gttggccctg gccaccctcc agcccggaac cgtgggcaac accctcctgc tgaccggct 5280
 ggaaaaggac agtccccag tcagtgtgca gattccact ggccagaaca agcttcatct 5340
 gcgttcagtc ctgaatgagt ttgatgcat ccagaaggca cagaaagaga acagcagctg 5400
 55 tactgacaag cgagaatggt ggacagggcg gctggcactg gaccacagga tggaggttct 5460

EP 2 395 103 A1

catcgcttcc ctagagaagt ctgtgctggg ctgctggaag gggctgctgc tgccgtccag 5520
 tgaggagccc ggccctgccc aggaggcctc ccgcctacag gagctgctac aggactgtgg 5580
 5 ctggaatat cctgaccgca ctctgctgaa aatcatgctc agtggtgccg gtgccctcac 5640
 ccctcaggac attcaggccc tggcctacgg gctgtgccc aaccagccag agcgagccca 5700
 ggagctcctg aatgaggcag taggacgtct acagggcctg acagtaccaa gcaatagcca 5760
 10 ccttgtcttg gtcctagaca aggacttgca gaagctgccg tgggaaagca tgcccagcct 5820
 ccaagcactg cctgtcaccg ggctgccctc cttccgcttc ctactcagct actccatcat 5880
 caaagagtat ggggcctcgc cagtgtgag tcaaggggtg gatccacgaa gtaccttcta 5940
 15 tgtcctgaac cctcacata acctgtcaag cacagaggag caatttcgag ccaatttcag 6000
 cagtgaagct ggctggagag gagtggttgg ggaggtgcca agacctgaac aggtgcagga 6060
 agccctgaca aagcatgatt tgtatatcta tgcaggcat ggggctggtg cccgcttcct 6120
 20 tgatgggcag gctgtcctgc ggctgagctg tcgggcagtg gccctgctgt ttggctgtag 6180
 cagtgcggcc ctggctgtgc gtggaaacct ggagggggct ggcacgtgc tcaagtacat 6240
 catggctggt tgccccttgt ttctgggtaa tctctgggat gtgactgacc gcgacattga 6300
 ccgctacacg gaagctctgc tgcaaggctg gcttggagca ggcccagggg ccccccttct 6360
 25 ctactatgta aaccaggccc gccaaagctc ccgactcaag tatcttattg gggctgcacc 6420
 tatagcctat ggcttgctg tctctctgcg gtaaccccat ggagctgtct tattgatgct 6480
 agaagcctca taactgttct acctccaagg ttagatttaa tccttaggat aactcttcta 6540
 30 aagtgatttt ccccagtggt ttatatgaaa catttccttt tgatttaacc tcagtataat 6600
 aaagatacat catttaaacc ctgaaaaaaaa aaaaaaaaaa a 6641

35 <210> 111
 <211> 2080
 <212> DNA
 <213> human

40 <400> 111
 gcggccgctg ggctcaggct gtccgctctg ggctccgagg cctcggcccc gctgcactcc 60
 acctccgcc cctcggactc cctcccctct gcttctactc ctctgctcc agtgccgcatc 120
 gtttcgcaac tgcttgccac tcgtcccgtg cctggctggt tttccatttc ccggccccct 180
 45 cttcttgagt actttacccc ctgcatttgg ggacaggac tggaaaaggg gcgggtggag 240
 cgtccagtgg agaagaagga agcgaggccc gcaggaggag gaggatcggc ggactgtggg 300
 gaggagacc caccgccccc tttctggtca tctcccctcc cgccccgcc ctgcgcacac 360
 tccctcgcgg gcgagctact ttcggaccag gaaagtaaga gcggccctgg gtgacagcgc 420
 50 cgcggggcca gtcccggggt tagccgcgcg tctgctcgt tctggtccgt cgcgctccca 480
 gccagggcac agcccggacc gaggatggct tcgaccacaa cctgcaccag gttcacggac 540
 55 gagtatcagc ttttcgagga gcttgaaag ggggcattct cagtgggtgag aagatgtatg 600

EP 2 395 103 A1

5
 10
 15
 20
 25
 30
 35
 40

```

aaaattccta ctggacaaga atatgctgcc aaaattatca acaccaaaaa gctttctgct 660
agggatcatc agaaactaga aagagaagct agaatctgcc gtcttttgaa gcaccctaata 720
attgtgagac ttcattgatag catatcagaa gagggctttc actacttggg gtttgattta 780
gttactggag gtgaactggt tgaagacata gtggcaagag aatactacag tgaagctgat 840
gccagtcatt gtatacagca gattctagaa agtgtaatac attgtcacct aatggcata 900
gttcacaggg acctgaagcc tgagaatttg cttttagcta gcaaatccaa gggagcagct 960
gtgaaattgg cagactttgg cttagccata gaagttcaag gggaccagca ggcgtggttt 1020
ggttttgctg gcacacctgg atatctttct ccagaagttt tacgtaaaga tccttatgga 1080
aagccagtgg atatgtgggc atgtgggtgc atttcttata ttctacttgg ggggtatcca 1140
cccttctggg atgaagacca acacagactc tatcagcaga tcaaggctgg agcttatgat 1200
tttccatcac cagaatggga cacgggtgact cctgaagcca aagacctcat caataaaatg 1260
cttactatca accctgcca acgcatcaca gcctcagagg cactgaagca cccatggatc 1320
tgtcaacggt ctactgttgc ttccatgatg cacagacagg agactgtaga ctgcttgaag 1380
aaatttaatg ctagaagaaa actaaagggg gccatcttga caactatgct ggctacaagg 1440
aatttctcag cagccaagag tttgttgaag aaaccagatg gagtaaagga gtcaactgag 1500
agttcaata caacaattga ggatgaagat gtgaaagcac gaaagcaaga gattatcaaa 1560
gtcactgaac aactgatcga agctatcaac aatggggact ttgaagccta cacaaaaatc 1620
tgtgaccag gccttactgc ttttgaacct gaagctttgg gtaatttagt ggaagggatg 1680
gattttcacc gattctactt tgaaaatgct ttgtccaaaa gcaataaacc aatccacact 1740
attattctaa accctcatgt acatctggta ggggatgatg ccgcttgcac agcatatatt 1800
aggctcacac agtacatgga tggcagtgga atgccaagaa caatgcagtc agaagagact 1860
cgtgtgtggc accgcccggg tggaaagtgg cagaatgttc attttcatcg ctcggggatc 1920
ccaacagtac ccatcaagcc accctgtatt ccaaatggga aagaaaactt ctcaggaggc 1980
acctcttgt ggcaaaacat ctaaggcctg aaaaccattc acatatgggt cttctaaatt 2040
tcaacagtgc cacttctgca ttctctgttc tcaaggcacc 2080
  
```

45
 <210> 112
 <211> 11611
 <212> DNA
 <213> human

50
 55

```

<400> 112
ggcttcagcc ctgcagggaa agaaaagtgc aatgattctg gactgagacg cgcttgggca 60
gaggctatgt aatcgtgtct gtgttgagga cttcgtctcg aggagggag aggagggatc 120
ggctcgctcc tccggcggcg gcggcggcgg cgactctgca ggcggagttt cgcggcggcg 180
gcaccagggg tacgccagcc ccgcccggag gtctctccat ccagcttctg cagcggcgaa 240
agccccagcg cccgagcgcc tgagccggcg gggagcaagt aaagctagac cgatctccgg 300
ggagccccgg agtaggcgag cggcggccgc cagctagtgt agcgcacccc ccgcccggcc 360
  
```

EP 2 395 103 A1

cagcggcgcc gcggcggcg gcgtccaggc ggcattggaga aggacggcct gtgccgcgct 420
 gaccagcagt acgaatgcgt ggcggagatc ggggagggcg cctatgggaa ggtgttcaag 480
 5 gcccgcgact tgaagaacgg aggccgtttc gtggcgttga agcgcgtgcg ggtgcagacc 540
 ggcgaggagg gcatgccgct ctccaccatc cgcgaggtgg cgggtgctgag gcacctggag 600
 accttcgagc accccaacgt ggtcaggttg tttgatgtgt gcacagtgtc acgaacagac 660
 10 agagaaacca aactaacttt agtgtttgaa catgtcgcgc aagacttgac cacttacttg 720
 gataaagtcc cagagcctgg agtgcccact gaaaccataa aggatatgat gtttcagctt 780
 ctccgaggtc tggactttct tcattcacac cgagtagtgc atcgcgatct aaaaccacag 840
 15 aacattctgg tgaccagcag cggacaaata aaactcgcctg acttcggcct tgcccgcac 900
 tatagtttcc agatggctct aacctcagtg gtcgtcacgc tgtggtacag agcaccggaa 960
 gtcttgcctc agtccagcta cgccaccccc gtggatctct ggagtgttgg ctgcatatct 1020
 20 gcagaaatgt ttcgtagaaa gcctcttttt cgtggaagtt cagatgttga tcaactagga 1080
 aaaatcttgg acgtgattgg actcccagga gaagaagact ggcctagaga tgttgcctt 1140
 cccaggcagg cttttcattc aaaatctgcc caaccaattg agaagtttgt aacagatatc 1200
 25 gatgaactag gcaaagacct acttctgaag tgtttgacat ttaaccagc caaagaata 1260
 tctgcctaca gtgccctgtc tcaccatac ttccaggacc tggaaagggtg caaagaaaac 1320
 ctggattccc acctgccgcc cagccagaac acctcggagc tgaatacagc ctgaggcctc 1380
 agcagccgcc ttaagctgat cctgcggaga acacccttgg tggcttatgg gtccccctca 1440
 30 gcaagcccta cagagctgtg gaggattgct atctggaggc cttccagctg ctgtcttctg 1500
 gacaggctct gcttctcaa ggaaccgcc tagtttactg ttttgaaatc aatgcaagag 1560
 tgattgcagc tttatgttca tttgtttgtt tgtttgtctg tttgtttcaa gaacctggaa 1620
 35 aaattccaga agaagagaag ctgctgacca attgtgctgc catttgattt ttctaacctt 1680
 gaatgctgcc agtgtggagt gggtaatcca ggcacagctg agttatgatg taatctctct 1740
 gcagctgccg ggcctgattt ggtacttttg agtgtgtgtg tgcattgtgtg tgtgtgtgtg 1800
 40 tgtgtgtgtg tgtgtgtatg tgagagattc tgtgatcttt taaagtgtta ctttttgtaa 1860
 acgacaagaa taattcaatt ttaaagactc aagggtgtca gtaaataaca ggcatttggt 1920
 cactgaagggt gattcaccaa aatagtcttc tcaaattaga aagttaacc ccatgtcctca 1980
 45 gcatttcttt tctggccaaa agcagtaaat ttgctagcag taaaagatga agttttatac 2040
 acacagcaaa aaggagaaaa aattctagta tattttaaga gatgtgcatg cattctatct 2100
 agtcttcaga atgctgaatt tacttgttgt aagtctatct taaccttctg tatgacatca 2160
 50 tgctttatca tttcttttgg aaaatagcct gtaagctttt tattacttgc tataggttta 2220
 gggagtgtac ctgagataga ttttaaaaaa aagaatagaa agcctttatt tcctggtttg 2280
 aaattccttt cttccctttt tttgttgtt ttattgttgt ttgttgttgt tattttgttt 2340
 55 ttgttttttag gaattgttca gaaactcttt cctgttttgg tttggagagt agttctctct 2400

EP 2 395 103 A1

aactagagac aggagtggcc ttgaaat ttt cctcatctat tacactgtac tttctgccac 2460
aactgcctt gttggcaaag tatccatctt gtctatctcc cggcacttct gaaatatatt 2520
5 gctaccattg tataactaat aacagattgc ttaagctggt cccatgcacc acctgtttgc 2580
ttgctttcaa tgaacctttc ataaattcgc agtctcagct tatggtttat ggcctcgatt 2640
ctgcaaacct aacaggtca catatgttct ctaatgcagt ctttctacct ggtgtttact 2700
10 tttgctaccc aaataatgag taggatcttg ttttcgtata ccccaccac tccattgct 2760
accaactgtc accttgtgca ctctttttt atagaagata ttttcagtgt ctttacctga 2820
gggtatgtct ttagctatgt tttagggcca tacatttact ctatcaaag atcttttctc 2880
15 catccccag gctgtgctta tttctagtgc cttgtgctca ctctgctct ctacagagcc 2940
agcctggcct gggcattgta aacagctttt ctttttctc ttactgtttt ctctacagtc 3000
ctttatattt cataccatct ctgccttata agtggtttag tgctcagttg gctctagtaa 3060
20 ccagaggaca cagaaagtat cttttggaaa gtttagccac ctgtgctttc tgactcagag 3120
tgcatgcaac agttagatca tgcaacagtt agattatggt tagggtagg attttcaaag 3180
aatggagggt gctgactca gaaaataatt cagatcatgt ttatgcatta ttaagttgta 3240
25 ctgaattctt tgcaagctta tgtgatata gactatcttg aacaagagaa aaaactagga 3300
gatgtttctc ctgaagagct tttggggttg ggaactattc ttttttaatt gctgtactac 3360
ttaacattgt tctaattcag tagcttgagg aacaggaaca ttgttttcta gagcaagata 3420
ataaaggaga tgggccatac aaatgttttc tactttcgtt gtgacaacat tgattaggtg 3480
30 ttgtcagtac tataaatgct tgagatataa tgaatccaca gcattcaagg tcaggtctac 3540
tcaaagtctc acatggaaaa gtgagttctg cttttccttt gatcgagggt caaaatacaa 3600
agacattttt gctagggcct acaaattgaa tttaaaaact cactgactg attcatctga 3660
35 gctttttggt tagtattcat ggctagagtg aacatagctt tagtttttgc tgttgtaaaa 3720
gtgttttcat aagttcactc aagaaaaatg cagctgttct gaactggaat ttttcagcat 3780
tctttagaat tttaaatgag tagagagctc aacttttatt cctagcatct gcttttgact 3840
40 ctttctagg cagtgttat gaagaaaaat taaagcaca acattctggc attcaatcgt 3900
tggcagatta tcttctgatg acacagaatg aaagggcatc tcagcctctc tgaactttgt 3960
aaaaatctgt ccccagttct tccatcggtg tagttgttgc atttgagtga atactctctt 4020
45 gatttatgta ttttatgtcc agattcgcca tttctgaaat ccagatccaa cacaagcagt 4080
cttgccgta gggcattttg aagcagatag tagagtaaga acttagtgac tacagcttat 4140
tcttctgtaa catatggttt caacatctt tgccaaaagc taagcagtgg tgaactgaaa 4200
50 agggcatatt gcccgaagg tacactgaag cagctcatag caagttaaaa tattgtgaca 4260
gatttgaaat catgtttgaa tttcatagta ggaccagtac aagaatgtcc ctgctagttt 4320
ctgtttgatg tttggttctg gcggctcagg cattttggga actgttgcac aggggtcagt 4380
55 caaacaacc tacatataaa aattacataa aagaaccttg tccatttagc tttcataaga 4440

EP 2 395 103 A1

aatcccatgg caaagagtaa taaaaaggac ctaatcttaa aaatacaatt tctaagcact 4500
tgtaagaacc cagtgggttg gagcctccca ctttgcctt cctttgaagt ggatgggaac 4560
5 tcaaggtgca aagaacctgt tttggaagaa agcttggggc catttcagcc ccctgtattc 4620
tcatgatttt ctctcaggaa gcacacactg tgaatggcag acttttcatt tagccccagg 4680
tgacttacta aaaatagttg aaaattattc acctaagaat agaatctcag cattgtgtta 4740
10 aataaaaatg aaagctttag aaggcatgag atgttcctat cttaaataaa gcatgtttct 4800
tttctataga gaaatgtata gtttgactct ccagaatgta ctatccatct tgatgagaaa 4860
actcttaaat agtaccaaac attttgaact ttaaattatg tatttaaagt gagtgtttaa 4920
15 gaaactgtag ctgcttcttt tacaagtggg gcctatataa gtcagtaatg gccattattg 4980
ttccattgtg gaaattaat tatgtaagct tcctaataatc ataaacatat taaaattcct 5040
ctaaaatatt gcttttcttt taagtgacaa tttgactatt cttatgataa gcacatgaga 5100
20 gtgtcttaca ttttccaaa gcaggcttta attgcatagt tgagtctagg aaaaaataat 5160
gttaaaaagtg aatatgccac cataattact taattatggt agtatagaaa ctacagaata 5220
tttaccctgg aaagaaaata ttggaatggt attataaact cttagatatt tatataattc 5280
25 aaaagaatgc atgtttcaca ttgtgacaga taaagatgta tgatttctaa ggctttaaaa 5340
attattcata aaacagtggg caatagataa aggaaattct ggagaaaatg aaggatttta 5400
aagggtagtt tcaaagctat atatattttg aaggatatat tctttatgaa caaatatatt 5460
gtaaaaattt atactaaggt catctggtaa ctgtgggatt aatatggctg aaaacaaatg 5520
30 ttatggagaa gctgtcccaa gcaactaaa ttacctgtac ttttttcca tttcaagga 5580
agaggcaacc acatgaagca atacttctta cacatgccta agaacgttca ttgaaaaaat 5640
aaatttttaa aaggcatgtg tttcctatgc caccaatact tttgaaaaat tgtgaacctt 5700
35 acccaaaacc atttatcatg tccattaagt atatttgggt atataattag gaagatattt 5760
acatgttcca tctccacagt ggaaaaactt attgaggcta ccaaagtgtg ccaagaaatg 5820
taagtcctta gagtaattag aaatgctgtt tcctcaaaa gcatgagaaa ctagcatttt 5880
40 catttcttat ttactccctt tctatatcaa tgcaattcac aaccaattt taatacatcc 5940
ctatatctca agcatttcta tcttgtactt tttcagaaaa taaacaaaa ataatccttt 6000
ggctctctta tcttctgacc tttgtaagca acagaaatgt aaaaacagaa ggggtccaat 6060
45 ttttacacgt ttttttctca agtagccttt ctggggattt ttattttctt aatgaagtgc 6120
caatcagctt ttcaaatgt tttctatttc tcagcatttc caggaagtga taacgtttag 6180
ctaaatgagt agaagtggac ttccttcaac atattgttac cttgtctagc cttaggaaga 6240
50 aaacaagagc cacctgaaaa taatacagg ctcttttcga gcatctgctg aaatactggt 6300
acagcaattt gaagtgtatg tggtaggaaa ggaaggtgac ttttcttgca aaagtctttc 6360
taaacattca cactgtccta agagatgagc tttcttgttt tattccggta tattccacaa 6420
55 ggtggcactt ttagagaaaa acaaatctga tgaagactaa agaggtactt ctaaaagaga 6480

EP 2 395 103 A1

tttcattcta actttatfff tctgcgcata tttactcctt tcctagcact tgttttttgg 6540
 gatgattaat agtctctata atgttctgta acttcaatat tttacttggt acctaggttc 6600
 5 tgaacaattg tctgcaaata aattgttctt aaggatggat aatacaccca ttttgatcat 6660
 ttaagtaaag aaagcctagt cattcattca gtcaagaaaa aatffffttaa gtaccagtt 6720
 accttacttt tctagattaa aacaggctta gttactaaaa aggcagtcct catctgtgaa 6780
 10 caggatagtt tcgttagaag tataaaaactc ctttagtggc cccagttaaa acacacatac 6840
 cctctctgct gctttcaaat tccctagcat ggtggccttt caacattgat taaatfftaa 6900
 aatcctaatt taaagatcag gtgagcaaaa tgagtagcac atcagtaatt cagtagacaa 6960
 15 aactffttgct tgaaaaattg ctgtattgaa acagagccct aaaataccea aagaccaggt 7020
 aatfftaaca tttgtggaat cacaaatgta aattcataag aagctctaaf taaaaaaaaa 7080
 aagtctgaag tatatgagca taacaactta ggagtgtgtc tacatactta actffttgaa 7140
 20 tttffttggca actffatata cttfftttaa atffacaagt ctacttaaag actffctata 7200
 ccccaaatga ttaagffaat tfftagaggfc acctffctca cagcagtgfc actffgaaatt 7260
 tagtagggaa ggatattgca gtatffttca gfffccttag cacagcacca cagaaagcag 7320
 cttatfcctt ttgagtggca gacactcgac ggtgcctgcc caactffctt cctgagtggc 7380
 25 aagcagatga gtctcagtaa ttcatactga accaaaatgc cacatacact aggggcagtc 7440
 agaaactggc tgagaaatcc cccgcctcat tcgccccctt gctcccagga actagagfcc 7500
 agffaaagcc cctatgcgaa agggcgaatt ccaccccagg gffttgtata acagtgggcca 7560
 30 gtctgaacct catttgctcg tgctcaaaac ttgattcca cttgaaagcc ttccgggcgc 7620
 gctgcctcgt tgccccgcc ctttggcagg agagaggcag tgggcgaggc cgggctgggg 7680
 cccgcctcc cactcacctg ccggtgcctg aaattatgtg cggccccgcg ggctgctfftc 7740
 35 cgaggfcaga gtgcctgct gctgtctcag aggcattctgt tctgcaaatc ttaggaagaa 7800
 aaatgtccct agtagcaaac ggggtgtctt tgtgcataaa taagtacaac acaattctcc 7860
 gaaagffcg gtaaaaagag atgcggtagc agctgccctg tgtgaagctg tctacccgc 7920
 40 atctctcagg cgtaagctc agffffttgtt tffgtffttg tfffffttaa gaaaagatgt 7980
 ataattgcag gaatfftttt ttatfftttt atffttccatc attctatata tgtgatggtg 8040
 aaagatatgc ctggaaaagt tffgtffttg aaagffttatt tctgcttcg tcttcagffg 8100
 45 gcaaaagctc tcaattcttt agcttccagt tctffttctc tctffttctt tgttaggtaa 8160
 ttaaaggtat gtaaacaaat tatctcatgt agcaggggat tffcatgffg agaggaatct 8220
 tccgtgtgag tfftttggfc acacaaataa cctffttctca atffttaggag tffggattgt 8280
 50 caaatgtagg tffttctcaa agggggcata taactacata ttgactgcca agaactatga 8340
 ctgtagcact aatcagcaca catagagcca cacaaattatt taatffctaa ctctctgtgg 8400
 tccctagaaa aatccgffg atgtgcttag gfftaaagffc tgaagatacc cffttgtacc 8460
 55 ttactffgaa gffttctaafc ttaagffttta tgaaatgcaa taatatgtat cagctagcaa 8520

EP 2 395 103 A1

tatttctgtg atcaccaaca actctcagtt tgatcttaa gtctgaataa taaaacaaat 8580
 cccagcagta atacatttct taaacctcac agtgcagatg atactctttc attctgatcc 8640
 5 tgtgtttgca aaaatataca catgtatatac atagttcctc actttttatt catttgtttt 8700
 cctattacct gtagtaaata tattagttag tacatggaat ttatagcatc agctaccccc 8760
 agaacagca cctgacaggc gggggatttt tttcaagtt gttctacatt tgcataaatt 8820
 10 atttctatta ttattcatgt atgttattta tttctgaatc acactagtcc tgtgaaagta 8880
 caactgaagg cagaaagtgt taggattttg catctaagt tcatatcat ggtattgatg 8940
 gacctaagaa aataaaaatt agactaagcc ccaaataag ctgcatgcat ttgtaacatg 9000
 15 attagtagat ttgaatatat agatgtagta ttttgggtat ctagggtgtt tatcattatg 9060
 taaaggaatt aaagtaaagg actttgtagt tgtttttatt aaatatgcat atagtagagt 9120
 gcaaaaatat agcaaaaata aaaactaaag gtagaaaagc attttagata tgccttaatt 9180
 20 tagaaactgt gccaggtggc cctcggata gatgccaggc agagaccagt gcctgggtgg 9240
 tgcctcctct tgtctgccct catgaagaag cttccctcac gtgatgtagt gccctcgtag 9300
 gtgtcatgtg gagtagtggg aacaggcagt actgttgaga ggagagcagt gtgagagttt 9360
 25 ttctgtagaa gcagaactgt cagcttgtgc cttgaggctt ccagaacgtg tcagatggag 9420
 aagtccaagt ttcatgctt caggcaactt agctgtgtac agaagcaatc cagtgtggtta 9480
 ataaaaagca aggattgcct gtataattta ttataaata aaagggttt taacaaccaa 9540
 caattcccaa cacctcaaaa gcttgttgca ttttttggtta tttgaggttt ttatctgaag 9600
 30 gttaaagggc aagtgtttgg tatagaagag cagtatgtgt taagaaaaga aaaatattgg 9660
 ttcacgtaga gtgcaaatta gaactagaaa gttttatacg attatcattt tgagatgtgt 9720
 taaagtaggt tttactgta aaatgtatta gtgtttctgc attgccatag ggcctggtta 9780
 35 aaactttctc ttaggtttca ggaagactgt cacatacagt aagctttttt ccttctgact 9840
 tataatagaa aatgttttga aagtaaaaaa aaaaaatcta atttggaat ttgacttgtt 9900
 agtttctgtg tttgaaatca tggttctaga aatgtagaaa ttgtgtatat cagatactca 9960
 40 tctaggctgt gtgaaccagc ccaagatgac caacatcccc acacctctac atctctgtcc 10020
 cctgtatctc ttcttttcta cactaaagt gttccctgct accatcctgg cttgtccaca 10080
 tgggtgctct catcttctc cacatcatgg accacaggtg tgcctgtcta ggcctggcca 10140
 45 ccaactccaa cttgacctag ccacattcat ctagagatgg ttcctgatgc tgggcacaga 10200
 ctgtgctcat ggcaccatt agaaatgcct ctagcatctt tgtatgcatc ttgattttta 10260
 aaccaagtca ttgtacagag cattcagttt tggctgtggt accaagagaa aaactaatca 10320
 50 agaataaaa ccacattcca ggctgctgtt ttctctccat ctacaggcca cacttttact 10380
 gtatttcttc atacttgaaa ttcattctgc tattttcata tcagggtaca gacttataag 10440
 ggtgcatgtt ccttaaaggt gcataattat tcttattccg tttgcttata ttgctacaga 10500
 55 atgctctgtt ttgggtgctt gagttctgca gaccaagaa gcagtgtgga aattcactgc 10560

EP 2 395 103 A1

ctgggacaca gtcttataag aatggttgca ggtgactttg tatcagatgt tgcttctctt 10620
 ttctctgtac acagattgag agttaccaca gtggcctgtc ggggccaccc tgtgggtgca 10680
 5 gcacagctct ctgaaagcaa gaaccttctt acctattcta acgtttttgc cctctaagaa 10740
 aaatggcctc aggtatggtg tagacatagc aagaggggaa gggctgtctc actctagcaa 10800
 ccatccctcc attacacaca gaaagcctc ttgaagcaaa agaagaagaa agaaagaaag 10860
 10 cttatctcta aggctactgt cttcagaatg ctctgagctg aatgctcttg ctcttttccc 10920
 aagaggcaga tgaaaatata gccagtttat ctataccctt cctatctgag gaggagaata 10980
 gaaaagtagg gtaaatatgt aacgtaaaat atgtcattca aggaccacca aaactttaag 11040
 15 taccctatca ttaaaaatct ggttttaaaa gtagctcaag taagggatgc tttgtgacct 11100
 agggtttctg aagtcagata gccattctta cctgcccctt actctgactt attgggaaag 11160
 ggagaactgc agtgggtgtt ctgttgcaag ggcaaaggta acatgtcaga aaattcagag 11220
 20 ggttgcatc caataatcct ttggaaactg gatgtcttac tgggtgctag aatgaaaatg 11280
 taggtattta ttgtcagatg atgaagtta ttgtttttt caaaattggt gttgaaatat 11340
 cactgtccaa tgtgttctt tatgtgaaag ctaaattgaa tgaggcaaaa agagcaaata 11400
 gtttgtatat ttgtaatacc ttttgtatct cttacaataa aatatattgg agcaaataaa 11460
 25 aataataaaa acaataactt taaactgctt tctggagatg aattactctc ctggctatct 11520
 tcttttttac tttaatgtaa aatgagtata actgtagtga gtaaaattca ttaaattcca 11580
 agtttttagca gaaaaaaaa aaaaaaaaa a 11611
 30
 <210> 113
 <211> 3317
 <212> DNA
 <213> human
 35
 <400> 113
 agttctcgcg ggacaccgac ggggagcggg agccaggagg tattgctgct tcggcgaccg 60
 ggcggcggca ggcggcggcg cggctgtggc agagtctgtg cctgtggcgg tgacggcggc 120
 gggagcaagc gctgccctcg cagagcagcc ttggggctgc cggccgctcg cagcgttggt 180
 40 gaggggaggc cgggacgctg agcggagcag ctgcgccacg ggtggcattg tgtgtcccag 240
 agtgccggag cgagtcccag aagagaggcg aggctaagcc cagagcgtg ggttgcttca 300
 gcaggaaga ctcccttccc cctgcttcag gctgctgagc actgagcagc gctcagaatg 360
 45 gaagccatcg ccaaatatga cttcaaagct actgcagacg acgagctgag cttcaaaagg 420
 ggggacatcc tcaaggtttt gaacgaagaa tgtgatcaga actggtacaa ggcagagctt 480
 aatggaaaag acggcttcat tccaagaac tacatagaaa tgaaaccaca tccgtggttt 540
 50 tttggcaaaa tccccagagc caaggcagaa gaaatgctta gcaaacagcg gcacgatggg 600
 gcctttctta tccgagagag tgagagcgtc cctggggact tctccctctc tgtcaagttt 660
 ggaaacgatg tgcagcactt caaggtgctc cgagatggag ccgggaagta cttcctctgg 720
 55

EP 2 395 103 A1

gtggtgaagt tcaattcttt gaatgagctg gtggattatc acagatctac atctgtctcc 780
 agaaaccagc agatattcct gcgggacata gaacaggtgc cacagcagcc gacatacgtc 840
 5 caggccctct ttgactttga tccccaggag gatggagagc tgggcttccg ccggggagat 900
 tttatccatg tcatggataa ctacagacccc aactggtgga aaggagcttg ccacgggcag 960
 accggcatgt ttccccgcaa ttatgtcacc cccgtgaacc ggaacgtcta agagtcaaga 1020
 10 agcaattatt taaagaaagt gaaaaatgta aaacacatac aaaagaatta aaccacaag 1080
 ctgcctctga cagcagcctg tgagggagtg cagaacacct ggccgggtca ccctgtgacc 1140
 ctctcacttt ggttggaaact ttagggggtg ggagggggcg ttggatttaa aaatgcaaaa 1200
 15 acttacctat aaattaagaa gagtttttat tacaaaattt cactgctgct cctctttccc 1260
 ctctcttctg ttttttttca tctttttttc tcttctgtcc atcagtgcat gacgtttaag 1320
 gccacgtata gtcctagctg acgccaataa taaaaaaca gaaaccaagt gggctggtat 1380
 20 tctctctatg caaatgtct gttttagttg gaatgactga aagaagaaca gctgttctctg 1440
 tgttcttctg atatacacac aaaaggagc gggcagggcc gctcgatgcc tttgctgttt 1500
 agcttctctc agaggagggg actttagga atctgccttc cagcccagac ccccagtgtg 1560
 25 ttttgtccaa gttcacagta gagtagggtg gaaggaaagc atgtctctgc ttccatggct 1620
 tcctgagaaa gccacactgg gctgggcgcg gtggctcacg cctgtaatcc cagcactttg 1680
 ggaggccaag gtgggcggat cacaaggta ggagtctgag accaacctag ccaacatggt 1740
 gaaaccccgt ctctactaaa aataagaaat tagccgggtg tggcacgcac ctgtagtccc 1800
 30 agctacttgg gagcctgagg caggagaatc gcttgaacct ggaagtga ggttagtga 1860
 gccgggaccg tgccattgta ctccagcctg ggtgacagag cgagattccg tctcaaaaaa 1920
 aaaaaaaaaa agcccacctg aaagcctgtc tctttccact ttgttgccc ttccagtggg 1980
 35 attatcgagc atgttgtttt tcatagtgct ctttttctt atttcaaggg ttgcttctga 2040
 gtggtgtttt tttttttttt ttaatttgtt ttgttttaa ataagttaa ggcagtccag 2100
 agcttttcag ccaatttgtc tctactctg tgtaaatatt tttccctccg ggcaggggag 2160
 40 ccagggtaga gcaaaggaga caaagcagga gtggaagggtg aggcgttctc ctgcttgtag 2220
 taagccagga ggctttaagc tccagcttta agggttgtga gcccttggg ggttcagggg 2280
 actgcttgcc cagggtgcag tgtgagtgtg atgggccacc ggggcaagag ggaagggtgac 2340
 45 cgcccagctc tcccacatcc cactggatct ggcttacagg ggggtcggaa gcctgtcctc 2400
 accgtctcgg gggttgtggc ccccgcccc tccctatatg caccctgga accagcaagt 2460
 cccagacaag gagagcggag gaggaagtca tgggaacgca gcctccagtt gtagcaggtt 2520
 50 tcaactattcc tatgctgggg tacacagtga gactactcac ttttacttg tcttgctctt 2580
 agattgggcc atggctttca tctgtgtcc cctgacctgt ccaggtagt gtgagggcag 2640
 cactgggaag ctggagtgtc gcttgtgcct ccctcccag tgggctgtgt tgactgctgc 2700
 55 tccccacccc taccgatggt ccaggaagc agggagagt ggggaaggca agattggaag 2760

EP 2 395 103 A1

gacaggaaga ccaaggcctc ggcagaactc tctgtcttct ctccacttct ggtcccctgt 2820
 ggtgatgtgc ctgtaatctt tttctccacc caaacccctt cccacgacaa aaacaagact 2880
 5 gcctccctct cttccgggag ctggtgacag ccttgggcct ttcagtccca aagcggccga 2940
 tgggagtctc cctccgactc cagatatgaa cagggcccag gcctggagcg tttgctgtgc 3000
 caggaggcgg cagctcttct gggcagagcc tgtccccgcc ttcctcact cttcctcatc 3060
 10 ctgcttctct tttcctcgca gatgataaaa ggaatctggc attctacacc tggaccattt 3120
 gattgtttta ttttgaatt ggtgtatata atgaagcctt gctgaactaa gttttgtgtg 3180
 tatatattta aaaaaaaaaat cagtgtttaa ataaagacct atgtacttaa tcctttaact 3240
 15 ctgcggatag catttggtag gtagtgatta actgtgaata ataaatacac aatgaattct 3300
 tcaaaaaaaaa aaaaaaa 3317

 <210> 114
 <211> 4772
 20 <212> DNA
 <213> human

 <400> 114
 gctcagttgc cgggcggggg agggcgcgctc cggttttct caggggacgt tgaattatt 60
 25 tttgtaacgg gagtcgggag aggacggggc gtgccccgac gtgcgcgcgc gtcgtcctcc 120
 ccggcgctcc tccacagctc gctggctccc gccgcggaaa ggcgcatgc cgcccaaac 180
 cccccgaaaa acggccgcca ccgcccgcg tgcgcccgcg gaacccccgg caccgcccgc 240
 gccgccccct cctgaggagg acccagagca ggacagcggc ccggaggacc tgcctctcgt 300
 30 caggcttgag tttgaagaaa cagaagaacc tgattttact gcattatgtc agaaattaa 360
 gataccagat catgtcagag agagagcttg gttaacttgg gagaaagttt catctgtgga 420
 tggagtattg ggaggttata ttcaaaagaa aaaggaactg tggggaatct gtatctttat 480
 35 tgcagcagtt gacctagatg agatgtcggt cacttttact gagctacaga aaaacataga 540
 aatcagtgct cataaattct ttaacttact aaaagaaatt gataccagta ccaagttga 600
 taatgctatg tcaagactgt tgaagaagta tgatgtattg tttgactct tcagcaaatt 660
 40 ggaaaggaca tgtgaactta tatatttgac acaaccagc agttcgatat ctactgaaat 720
 aaattctgca ttggtgctaa aagtttcttg gatcacattt ttattagcta aaggggaagt 780
 attacaaatg gaagatgatc tggtgatttc atttcagtta atgctatgtg tccttgacta 840
 45 ttttattaa ctctcacctc ccatgttgct caaagaacca tataaacag ctgttatacc 900
 cattaatggt tcacctgaa caccagggc aggtcagaac aggagtgcac ggatagcaaa 960
 acaactagaa aatgatacaa gaattattga agttctctgt aaagaacatg aatgtaatat 1020
 50 agatgaggtg aaaaatgttt atttcaaaaa ttttatacct tttatgaatt ctcttgact 1080
 tgtaacatct aatggacttc cagaggttga aaatcttctt aaacgatagc aagaaattta 1140
 tcttaaaaaat aaagatctag atgcaagatt atttttggat catgataaaa ctcttcagac 1200
 55 tgattctata gacagttttg aaacacagag aacaccacga aaaagtaacc ttgatgaaga 1260

EP 2 395 103 A1

ggtgaatgta attcctccac acactccagt taggactggt atgaacacta tccaacaatt 1320
 aatgatgatt ttaaattcag caagtgatca accttcagaa aatctgattt cctattttaa 1380
 5 caactgcaca gtgaatccaa aagaaagtat actgaaaaga gtgaaggata taggatacat 1440
 ctttaaagag aaatttgcta aagctgtggg acagggttgt gtcgaaattg gatcacagcg 1500
 atacaaactt ggagttcgct tgtattaccg agtaatggaa tccatgctta aatcagaaga 1560
 10 agaacgatta tccattcaaa attttagcaa acttctgaat gacaacattt ttcatatgtc 1620
 tttattggcg tgcgctcttg aggttgtaat ggccacatat agcagaagta catctcagaa 1680
 tcttgattct ggaacagatt tgtctttccc atggattctg aatgtgctta atttaaaagc 1740
 15 ctttgatttt tacaaagtga tcgaaagttt tatcaaagca gaaggcaact tgacaagaga 1800
 aatgataaaa catttagaac gatgtgaaca tcgaatcatg gaatcccttg catggctctc 1860
 agattcacct ttatttgatc ttattaaaca atcaaaggac cgagaaggac caactgatca 1920
 20 ccttgaatct gcttgcctc ttaatcttcc tctccagaat aatcacactg cagcagatat 1980
 gtatctttct cctgtaagat ctccaaagaa aaaaggttca actacgcgtg taaattctac 2040
 tgcaaatgca gagacacaag caacctcagc cttccagacc cagaagccat tgaaatctac 2100
 25 ctctctttca ctgttttata aaaaagtgta tcggctagcc tatctccggc taaatacact 2160
 ttgtgaacgc cttctgtctg agcaccaga attagaacat atcatctgga cccttttcca 2220
 gcacaccctg cagaatgagt atgaactcat gagagacagc catttggacc aaattatgat 2280
 gtgttccatg tatggcatat gcaaagtga gaatatagac cttaaattca aaatcattgt 2340
 30 aacagcatac aaggatcttc ctcatgctgt tcaggagaca ttcaaactg ttttgatcaa 2400
 agaagaggag tatgattcta ttatagtatt ctataactcg gtcttcatgc agagactgaa 2460
 aacaaatatt ttgcagtatg cttccaccag gccccctacc ttgtcaccaa tacctcacat 2520
 35 tcctcgaagc cttacaagt ttcttagttc acccttacgg attcctggag ggaacatcta 2580
 tatttcaccc ctgaagagtc catataaaat ttcagaaggt ctgccaacac caacaaaaat 2640
 gactccaaga tcaagaatct tagtatcaat tggatgaatca ttcgggactt ctgagaagtt 2700
 40 ccagaaaata aatcagatgg tatgtaacag cgaccgtgtg ctcaaagaa gtgctgaagg 2760
 aagcaaccct cctaaaccac tgaaaaaact acgctttgat attgaaggat cagatgaagc 2820
 agatggaagt aaacatctcc caggagagtc caaatttcag cagaaactgg cagaaatgac 2880
 45 ttctactcga acacgaatgc aaaagcagaa aatgaatgat agcatggata cctcaaacia 2940
 ggaagagaaa tgaggatctc aggaccttgg tggacactgt gtacacctct ggattcattg 3000
 tctctcacag atgtgactgt ataactttcc caggttctgt ttatggccac atttaatatc 3060
 50 ttcagctctt tttgtggata taaaatgtgc agatgcaatt gtttgggtga ttcctaagcc 3120
 acttgaaatg ttagtcattg ttatttatac aagattgaaa atcttgtgta aatcctgcca 3180
 tttaaaaagt tgtagcagat tgtttcctct tcaaagtaa aattgctgtg ctttatggat 3240
 55 agtaagaatg gccctagagt gggagtcctg ataaccagg cctgtctgac tactttgcct 3300

EP 2 395 103 A1

tctttttag catataggtag atgtttgctc ttgtttttat taatttatat gtatatTTTT 3360
 ttaatttaac atgaacaccc ttagaaaatg tgcctatct atcttccaaa tgcaatttga 3420
 5 ttgactgccc attcaccaaa attatcctga actcttctgc aaaaatggat attattagaa 3480
 attagaaaaa aattactaat tttacacatt agattttatt ttactattgg aatctgatat 3540
 actgtgtgct tgttttataa aattttgctt ttaattaaat aaaagctgga agcaaagtat 3600
 10 aaccatatga tactatcata ctactgaaac agatttcata cctcagaatg taaaagaact 3660
 tactgattat tttcttcac caacttatgt ttttaaataa ggattattga tagtactctt 3720
 ggtttttata ccattcagat cactgaattt ataaagtacc catctagtac ttgaaaaagt 3780
 aaagtgttct gccagatctt aggtatagag gaccctaaca cagtatatcc caagtgcact 3840
 15 ttctaagtgt tctgggtcct gaagaattaa gatacaaatt aattttactc cataaacaga 3900
 ctgttaatta taggagcctt aatttttttt tcatagagat ttgtctaatt gcatctcaaa 3960
 attattctgc cctccttaat ttgggaaggt ttgtgtttc tctggaatgg tacatgtctt 4020
 20 ccatgtatct tttgaactgg caattgtcta tttatctttt atttttttaa gtcagtatgg 4080
 tctaactctg gcatgttcaa agccacatta tttctagtcc aaaattacaa gtaatcaagg 4140
 gtcattatgg gttaggcatt aatgtttcta tctgattttg tgcaaaagct tcaaatataa 4200
 25 acagctgcat tagaaaaaga ggcgcttctc cctccccta cacctaaagg tgtattttaa 4260
 ctatcttgtg tgattaactt atttagagat gctgtaactt aaaatagggg atatttaagg 4320
 tagcttcagc tagcttttag gaaaatcact ttgtctaact cagaattatt tttaaaaaga 4380
 30 aatctggtct tgttagaaaa caaaatttta tttgtgctc atttaagttt caaacttact 4440
 attttgacag ttattttgat aacaatgaca ctagaaaact tgactccatt tcatcattgt 4500
 tttctgatga atatcataca aatcagttag tttttaggtc aagggttac tatttctggg 4560
 35 tcttttgcta ctaagttcac attagaatta gtgccagaat tttaggaact tcagagatcg 4620
 tgtattgaga tttcttaaata aatgcttcag atattattgc tttattgctt ttttgtattg 4680
 gttaaaactg tacattttaa attgctatgt tactattttc tacaattaat agtttgtcta 4740
 40 tttttaaata aattagtgtg taagagtctt aa 4772

<210> 115
 <211> 1260
 <212> DNA
 <213> human

<400> 115
 aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca gtcagccgca 60
 tcttcttttg cgtcgccagc cgagccacat cgctcagaca ccatggggaa ggtgaaggtc 120
 50 ggagtcaacg gatttggtcg tattgggctc ctggctacca gggctgcttt taactctggt 180
 aaagtggata ttgttgccat caatgacccc ttcattgacc tcaactacat ggtttacatg 240
 ttccaatatg attccaccca tggcaaatc catggcaccg tcaaggctga gaacgggaag 300

55

EP 2 395 103 A1

	cttgatcatca atggaaatcc catcaccatc ttccaggagc gagatccctc caaaatcaag	360
	tggggcgatg ctggcgctga gtacgtcgtg gagtccactg gcgtcttcac caccatggag	420
5	aaggctgggg ctcatattgca ggggggagcc aaaagggtca tcatctctgc cccctctgct	480
	gatgccccca tgttcgcat ggggtgtgaac catgagaagt atgacaacag cctcaagatc	540
	atcagcaatg cctcctgcac caccaactgc ttagcacccc tggccaaggt catccatgac	600
10	aactttggta tcgtggaagg actcatgacc acagtccatg ccatcactgc caccagaag	660
	actgtggatg gcccctccgg gaaactgtgg cgtgatggcc gcggggctct ccagaacatc	720
	atccctgcct ctactggcgc tgccaaggct gtgggcaagg tcatccctga gctgaacggg	780
15	aagctcactg gcatggcctt ccgtgtcccc actgccaacg tgtcagtggg ggacctgacc	840
	tgccgtctag aaaaacctgc caaatatgat gacatcaaga aggtggtgaa gcaggcgctg	900
	gagggcccc tcaagggcat cctgggctac actgagcacc aggtggtctc ctctgacttc	960
20	aacagcgaca cccactctc cacctttgac gctggggctg gcattgccct caacgaccac	1020
	tttgtcaagc tcatttctctg gtatgacaac gaatttggct acagcaacag ggtggtggac	1080
	ctcatggccc acatggcctc caaggagtaa gaccctgga ccaccagccc cagcaagagc	1140
	acaagaggaa gagagagacc ctactgctg gggagtccct gccacactca gtccccacc	1200
25	acactgaatc tcccctctc acagttgcca tntagacccc ttgaagaggg gaggggccta	1260
	<210> 116	
	<211> 974	
	<212> DNA	
30	<213> human	
	<400> 116	
	gtttgcttag gtgaggcgca gacggggaag cggagccaac atgccagtgg cccggagctg	60
	ggtttgtcgc aaaacttatg tgaccccgcg gagacccttc gagaaatctc gtctcgacca	120
35	agagctgaag ctgatcggcg agtatgggct ccggaacaaa cgtgaggctt ggaggggtcaa	180
	atttacctg gccaaagatcc gcaaggccgc ccgggaactg ctgacgcttg atgagaagga	240
	cccacggcgt ctgttcgaag gcaacgccct gctgcggcgg ctggtccgca ttgggggtgct	300
40	ggatgagggc aagatgaagc tggattacat cctgggcctg aagatagagg atttcttaga	360
	gagacgcctg cagaccagg tcttcaagct gggcttggcc aagtcctacc accacgctcg	420
	cgtgctgatc cgccagcgc atatcaggta ccacctcgga tgggcacctg aatcttctc	480
45	cacctgcccc tctgatggtt gccctcacta agcctgctgt ccctatctcc tatgcagccc	540
	tcggaggtga tgggtgtgaa ctcacccaga gggtagagat tcacccttgc acacagctca	600
	ccagggagct ggggcagcct cttgccccaa tagccagcg caagggtcac tgcggctcta	660
50	gccgtacacc ttgtgaaggc ctctgccagg catgtgggca gctggacagg gtccgcaagc	720
	aggtggtgaa catcccgtcc ttcattgtcc gcctggattc ccagaagcac atcgacttct	780
	ctctgcgctc tccctacggg ggtggccgcc cgggccgct gaagaggaag aatgccaaga	840
55	agggccaggg tggggctggg gctggagacg acgaggagga ggattaagtc cacctgtccc	900

tcctgggctg ctggattgct tcgttttcct gccaaataaa caggatcagc gctttaaaaa 960
 aaaaaaaaaa aaaa 974

5

Claims

- 10 1. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:
- 15 a) obtaining a test sample from a cancerous area of said patient;
 b) obtaining a control sample;
 c) measuring the level of Mps1; and
 d) comparing the measured levels of Mps 1 in the test sample and the control sample;
 wherein a decrease in the level of Mps1 measured in the test sample as compared to the control sample indicates an increased resistance to a molecule of the taxoid family.
- 20 2. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of Claim 1 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to Mps 1.
- 25 3. A kit for predicting or monitoring a cancer patient's response to molecule of the taxoid family according to the method of Claim 1 wherein the kit comprises the means of:
- 30 a) obtaining total RNA from a bodily sample;
 b) reverse transcribing the total RNA to obtain cDNA; and
 c) subjecting the cDNA to a polymerase chain reaction using a set of primers;
 wherein one or both primers are detectably-labeled and both primers are derived from a nucleotide sequence of Mps1.
- 35 4. A method for predicting or monitoring a cancer patient's response to a molecule of the taxoid family, comprising the steps of:
- 40 a) obtaining a test sample from a cancerous area of said patient;
 b) measuring the level of Mps1;
 c) measuring the level of one or more reference genetic markers;
 d) comparing the measured levels of Mps1 and said one or more reference genetic markers in the test sample;
 wherein a decrease in the level of Mps1 as compared to the level of said one or more reference genetic markers indicates an increased resistance to a molecule of the taxoid family.
- 45 5. The method of Claim 1 or 4 wherein said molecule of the taxoid family is selected from the group consisting of paclitaxel, docetaxel XRP9881 and XRP6258.
6. The method of Claim 1 or 4 wherein said level of markers is measured by mRNA, DNA or protein.
- 50 7. The method of Claim 6 wherein said mRNA is measured by using a technique selected from the group consisting of in situ hybridization, reverse-transcriptase polymerase chain reaction, nucleic acid hybridization, electrophoresis, Northern blotting and mass spectrometry.
- 55 8. The method of Claim 6 wherein said DNA is measured by using a technique selected from the group consisting of quantitative polymerase chain reaction, genomic DNA-chips, in situ hybridization, electrophoresis, Southern blotting and mass spectrometry.
9. The method of Claim 6 wherein said protein is measured by using a technique selected from the group consisting of immunoassay, Western blots, ELISA, and mass spectrometry.

10. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the method of Claim 4 wherein the kit comprises detectable-labeled antibodies, detectable-labeled antibody fragments or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to Mps 1 and said one or more reference genetic markers.

5

11. A kit for predicting or monitoring a cancer patient's response to a molecule of the taxoid family according to the method of Claim 4 wherein the kit comprises the means of:

10

- a) obtaining total RNA from a bodily sample;
- b) reverse transcribing the total RNA to obtain cDNA; and
- c) subjecting the cDNA to a polymerase chain reaction using a set of primers wherein one or both primers are detectable-labeled and both primers are derived from a nucleotide sequence of Mps1.

15

12. The kit of any one of claims 2, 3, 10 and 11, wherein the detectable label comprises an enzyme, a radioactive isotope, or a chemical which fluoresces, a chemiluminescent molecule, radiopaque substances, liposomes, and haptic molecules.

20

13. The method of any one of claims 1 and 4 to 9, wherein the level of one or more additional genetic marker is measured, said additional genetic marker being selected from the group consisting of:

25

- BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);
- Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
- GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);
- Bubl, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336);
- hSeparase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);
- CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: NM_001221);
- CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259);
- and
- GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086) .

35

40

14. The kit of one of claims 2, 3, and 10 to 12, wherein the kit comprises in addition detectable-labeled antibodies, detectable-labeled antibody fragments or detectable-labeled oligonucleotides comprising nucleic acids capable of hybridizing under stringent conditions to one or more genetic markers selected from the group consisting of:

45

- BubR1, Homo sapiens similar to protein kinase (BUBR1) mRNA, complete cds (GenBank accession number: AF046079);
- Mad2, Homo sapiens mRNA for MAD2 protein (GenBank accession number: AJ000186);
- GEFT for Rac1/CDC42, Homo sapiens RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA (GenBank accession number: NM_133483);
- Bubl, Homo sapiens BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA (GenBank accession number: NM_004336);
- hSeparase, Homo sapiens extra spindle poles like 1 (*S. cerevisiae*) (ESPL1), mRNA (GenBank accession number: NM_012291);
- CamKIId, Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D), transcript variant 3, mRNA (GenBank accession number: M_001221);
- CDK6, Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA (GenBank accession number: NM_001259);
- and
- GRB2, Homo sapiens growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA (GenBank accession number: NM_002086).

55




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16



EUROPEAN SEARCH REPORT

Application Number
EP 11 00 3912

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	SUDO TAMOTSU ET AL: "Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint", CANCER RESEARCH, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2502-2508, XP002384388, ISSN: 0008-5472 * abstract *	1-14	INV. C12Q1/68 G01N33/574
Y	UENO NT ET AL: "Predicting paclitaxel sensitivity by functionality of the spindle assembly checkpoint", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, 27TH ANNUAL THE CHARLES A. COLTMAN, JR. SAN ANTONIO BREAST CANCER SYMPOSIUM, vol. 88, no. 1, 1100, 1 January 2004 (2004-01-01), page S75, XP002661609, ISSN: 1573-7217 * abstract *	1-14	
Y	VOLKERM. STUCKE ET AL: "Kinetochore localization and microtubule interaction of the human spindle checkpoint kinase Mps1", CHROMOSOMA, vol. 113, no. 1, 1 August 2004 (2004-08-01), pages 1-15, XP55010024, ISSN: 0009-5915, DOI: 10.1007/s00412-004-0288-2 * page 2, lines 9-12 *	1-14	TECHNICAL FIELDS SEARCHED (IPC) C12Q G01N
X	WO 02/068444 A1 (CHIRON CORP [US]; REINHARD CHRISTOPH [US]; JEFFERSON ANNE B [US]; CHAN) 6 September 2002 (2002-09-06) * page 19 *	2,3, 10-12,14	
----- -/--			
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 20 October 2011	Examiner Knudsen, Henrik
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 11 00 3912

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
A	STUCKE V M ET AL: "Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 21, no. 7, 2 April 2002 (2002-04-02), pages 1723-1732, XP002408934, ISSN: 0261-4189, DOI: 10.1093/EMBOJ/21.7.1723 * abstract *	1-14		
A	SASSE A ET AL: "Coxsackie-and-adenovirus receptor mRNA expression in human heart failure.", THE JOURNAL OF GENE MEDICINE. OCT 2003, vol. 5, no. 10, October 2003 (2003-10), pages 876-882, XP002384538, ISSN: 1099-498X * the whole document *	1-14		
A	SAVLI H ET AL: "Quantification of the FLI1 gene expression by real-time quantitative RT-PCR", TURKISH JOURNAL OF MEDICAL SCIENCES 2003 TURKEY, vol. 33, no. 1, 2003, pages 21-25, XP009067688, ISSN: 1300-0144 * the whole document *	1-14		TECHNICAL FIELDS SEARCHED (IPC)
E	WO 2006/059121 A2 (CANCER REC TECH LTD [GB]; MEDEMA RENE H [NL]; SCHMIDT MARC [DE]; BUDIR) 8 June 2006 (2006-06-08) * paragraphs [0018] - [0019], [0204] *	1		
The present search report has been drawn up for all claims				
Place of search Munich		Date of completion of the search 20 October 2011	Examiner Knudsen, Henrik	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		

2
EPO FORM 1503 03 82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 11 00 3912

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-10-2011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 02068444	A1	06-09-2002	CA 2438092 A1	06-09-2002
			CN 1492875 A	28-04-2004
			CN 101732717 A	16-06-2010
			EP 1377596 A1	07-01-2004
			JP 4429604 B2	10-03-2010
			JP 2004526716 A	02-09-2004
			JP 2009143890 A	02-07-2009
			NZ 527421 A	27-05-2005

WO 2006059121	A2	08-06-2006	NONE	

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4313734 A [0028]
- US 4373932 A [0028]
- WO 8808534 A [0028]
- EP 02805590281327 A [0028]
- US 4703017 A [0028]
- US 4857453 A [0029]
- US 4816567 A [0054]
- US 5225539 A [0054]
- US 5585089 A [0054]
- US 5693762 A [0054]
- US 5859205 A [0054]

Non-patent literature cited in the description

- HONG. *Oncology*, 2002, vol. 16, 9 [0002]
- RINGEL ; HORWITZ. *J Natl Cancer Inst*, 1991, vol. 83, 288 [0002]
- WANG et al. *Cancer*, 2000, vol. 88, 2619 [0002]
- KATSUMATA. *Br J Cancer*, 2003, vol. 89, S9 [0002]
- KOLFSCHOTEN et al. *Biochem Pharmacol*, 2002, vol. 63, 733 [0002]
- ANAND et al. *Cancer Cell*, 2003, vol. 3, 51 [0002] [0070]
- TANABE et al. *Int J Oncol*, 2003, vol. 22, 875 [0002]
- LI et al. *J Biol Chem*, 2002, vol. 277, 11352 [0002]
- LEE et al. *J Biol Chem*, 1998, vol. 273, 28253 [0002]
- OJIMA ; GENEY. *Curr Opin Investig Drugs*, 2004, vol. 4, 737 [0023]
- AUSUBEL et al. *Current Protocols in Molecular Biology*. Wiley Interscience, 1995 [0025]
- SAMBROOK et al. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Press, 1989 [0026]
- EVA ENGVALL. *Enzyme Immunoassay ELISA and EMIT in Methods in Enzymology*, 1980, vol. 70, 419-439 [0029]
- SAMBROOK ; FRITSCH ; MANIATIS. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0031]
- DNA Cloning: A Practical Approach. 1985, vol. I, II [0031]
- Oligonucleotide Synthesis. 1984 [0031]
- Nucleic Acid Hybridization. 1985 [0031]
- Transcription And Translation. 1984 [0031]
- Animal Cell Culture. 1986 [0031]
- Immobilized Cells And Enzymes. IRL Press, 1986 [0031]
- B. PERBAL. *A Practical Guide To Molecular Cloning*. 1984 [0031]
- *Current Protocols in Molecular Biology*. John Wiley & Sons, Inc, 1994 [0031]
- MCMANUS ; SHARP. *Nat Rev Genet*, 2002, vol. 3, 737 [0032]
- SIMMER et al. *PLoS Biol*, 2003, vol. 1, E12 [0032]
- LUM et al. *Science*, 2003, vol. 299, 2039 [0032]
- AZA-BLANC et al. *Mol Cell*, 2003, vol. 12, 627 [0032]
- ZHOU et al. *J Cell Sci*, 2002, vol. 115, 3547 [0037]
- TAYLOR ; MCKEON. *Cell*, 1997, vol. 89, 727 [0037] [0065]
- SHIN et al. *Cancer Cell*, 2003, vol. 4, 483 [0037] [0065] [0068]
- SUDO et al. *Cancer Res*, 2004, vol. 64, 2502 [0037] [0065]
- WANG et al. *Biochim Biophys Acta*, 2002, vol. 1593, 45 [0038] [0069]
- HAFNER et al. *Arch Pathol Lab Med*, 2003, vol. 127, 1221 [0040] [0048]
- RODRIGUEZ et al. *Clin Cancer Res*, 2004, vol. 10, 5785 [0040] [0047] [0048]
- CHANG et al. *Lancet*, 2003, vol. 362, 340 [0040]
- ESPINA et al. *J Immunol Methods*, 2004, vol. 290, 121 [0040]
- ULLMANN et al. *JBiomol Screen*, 2004, vol. 9, 95 [0041]
- BADIEE et al. *BMC Biotechnol*, 2003, vol. 3, 23 [0041]
- BONNER et al. *Science*, 1997, vol. 278, 1481 [0041]
- FEND et al. *Am J Pathol*, 1999, vol. 154, 61 [0041]
- CHIRGWIN et al. *Biochemistry*, 1979, vol. 18, 5294 [0041]
- DULAC. *Curr Top Dev Biol.*, 1998, vol. 36, 245 [0041]
- WANG et al. *Proc Natl Acad Sci USA*, 1989, vol. 86, 9717 [0041]
- WU ; WALLACE. *Genomics*, 1989, vol. 4, 560 [0042]
- GUATELLI et al. *Proc Natl Acad Sci USA*, 1990, vol. 87, 1874 [0042]
- KWOH et al. *Proc Natl Acad Sci USA*, 1989, vol. 86, 1173 [0042]
- PCR Technology: Principles and Applications for DNA Amplification. Freeman Press, 1992 [0042]
- PCR Protocols: A Guide to Methods and Applications. Academic Press, 1990 [0042]

- **CLARK, W. R.** The Experimental Foundations of Modern Immunology. Wiley & Sons, Inc, 1986 [0053]
- **ROITT, I.** Essential Immunology. Blackwell Scientific Publications, 1991 [0053]
- **CHANG et al.** *Lancet*, 2003, vol. 362, 362 [0058]
- **JACKSON et al.** *Nat Biotechnol*, 2003, vol. 21, 635 [0062]
- **KUNG et al.** *Proc Natl Acad Sci*, 1990, vol. 87, 9553 [0064]
- **LANNI ; JACKS.** *Mol Cell Biol*, 1998, vol. 18, 1055 [0064]
- **MASUDA et al.** *Am J Pathol*, 2003, vol. 163, 1109 [0065]
- **MICHEL et al.** *Proc Natl Acad Sci*, 2004, vol. 101, 4459 [0068]
- **ROH et al.** *Cancer Res*, 2003, vol. 63, 8079 [0069]
- **MERALDI et al.** *Curr Opin Genet Dev*, 2004, vol. 14, 29 [0070]
- **KIM et al.** *Int Mol Med*, 2003, vol. 11, 799 [0073]
- **ANAND S ; PENRHYN-LOWE S ; VENKITARAMAN AR.** AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. *Cancer Cell*, 2003, vol. 3, 51-62 [0078]
- **AZA-BLANC P ; COOPER CL ; WAGNER K ; BATALOV S ; DEVERAUX QL ; COOKE MP.** Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. *Mol Cell*, 2003, vol. 12, 627-37 [0078]
- **CHANG JC ; WOOTEN EC ; TSIMELZON A ; HILSENBECK SG ; GUTIERREZ MC ; ELLEDGER R ; MOHSIN S ; OSBORNE CK ; CHAMNESS GC ; ALLRED DC.** Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. *Lancet*, 2003, vol. 362, 362-9 [0078]
- **HONG, WK.** The current status of docetaxel in solid tumors. *Oncology*, 2002, vol. 16, 9-15 [0078]
- **JACKSON AL ; BARTZ SR ; SCHELTER J ; KOBAYASHI SV ; BURCHARD J ; MAO M ; LI B ; CAVET G ; LINSLEY PS.** Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol.*, 2003, vol. 21, 635-7 [0078]
- **KATSUMATA N.** Docetaxel: an alternative taxane in ovarian cancer. *Br J Cancer*, 2003, vol. 89 (3), S9-S15 [0078]
- **KIM R ; TANABE K ; UCHIDA Y ; EMI M ; TOGE T.** Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. *Int J Mol Med.*, 2003, vol. 11, 799-804 [0078]
- **KOLFSCHOTEN GM ; HULSCHER TM ; DUYN-DAM MC ; PINEDO HM ; BOVEN E.** Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. *Biochem Pharmacol.*, 2002, vol. 63, 733-43 [0078]
- **KUNG AL ; SHERWOOD SW ; SCHIMKE RT.** Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. *Proc Natl Acad Sci USA.*, 1990, vol. 87, 9553-7 [0078]
- **LANNI JS ; JACKS T.** Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. *Mol Cell Biol.*, 1998, vol. 18, 1055-64 [0078]
- **LEE LF ; LI G ; TEMPLETON DJ ; TING JP.** Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). *J Biol Chem.*, 1998, vol. 273, 28253-60 [0078]
- **LI Y ; DOWBENKO D ; LASKY LA.** AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. *J Biol Chem.*, 2002, vol. 277, 11352-61 [0078]
- **LUM L ; YAO S ; MOZER B ; ROVESCALLI A ; VON KESSLER D ; NIRENBERG M ; BEACHY PA.** Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. *Science*, 2003, vol. 299, 2039-45 [0078]
- **MASUDA A ; MAENO K ; NAKAGAWA T ; SAITO H ; TAKAHASHI T.** Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. *Am J Pathol.*, 2003, vol. 163, 1109-16 [0078]
- **MCMANUS MT ; SHARP PA.** Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet.*, 2002, vol. 3, 737-47 [0078]
- **MERALDI P ; HONDA R ; NIGG EA.** Aurora kinases link chromosome segregation and cell division to cancer susceptibility. *Curr Opin Genet Dev.*, 2004, vol. 14, 29-36 [0078]
- **MICHEL L ; DIAZ-RODRIGUEZ E ; NARAYAN G ; HERNANDO E ; MURTY VV ; BENEZRA R.** Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. *Proc Natl Acad Sci USA.*, 2004, vol. 101, 4459-64 [0078]
- **OJIMA, I. ; GENEY, R.** 109881 Aventis. *Curr Opin Investig Drugs*, 2004, vol. 4, 737-40 [0078]
- **RINGEL I ; HORWITZ SB.** Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. *J Natl Cancer Inst.*, 1991, vol. 83, 288-91 [0078]
- **ROH M ; GARY B ; SONG C ; SAID-AL-NAIEF N ; TOUSSON A ; KRAFT A ; ELTOUM IE ; ABDULKADIR SA.** Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. *Cancer Res.*, 2003, vol. 63, 8079-84 [0078]
- **SHIN HJ ; BAEK KH ; JEON AH ; PARK MT ; LEE SJ ; KANG CM ; LEE HS ; YOO SH ; CHUNG DH ; SUNG YC.** Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. *Cancer Cell*, 2003, vol. 4, 483-97 [0078]

- **SIMMER F ; MOORMAN C ; VAN DER LINDEN AM ; KUIJK E ; VAN DEN BERGHE PV ; KAMATH R ; FRASER AG ; AHRINGER J ; PLASTERK RH.** Genome-Wide RNAi of *C. elegans* Using the Hypersensitive *rrf-3* Strain Reveals Novel Gene Functions. *PLoS Biol.*, 2003, vol. 1, E12 [0078]
- **SUDO T ; NITTA M ; SAYA H ; UENO NT.** Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. *Cancer Res.*, 2004, vol. 64, 2502-8 [0078]
- **TANABE K ; KIM R ; INOUE H ; EMI M ; UCHIDA Y ; TOGE T.** Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. *Int J Oncol.*, 2003, vol. 22, 875-81 [0078]
- **TAYLOR SS ; MCKEON F.** Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. *Cell*, 1997, vol. 89, 727-35 [0078]
- **WANG TH ; WANG HS ; SOONG YK.** Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. *Cancer*, 2000, vol. 88, 2619-28 [0078]
- **WANG Z ; BHATTACHARYA N ; MIXTER PF ; WEI W ; SEDIVY J ; MAGNUSON NS.** Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. *Biochim Biophys Acta*, 2002, vol. 1593, 45-55 [0078]
- **ZHOU J ; YAO J ; JOSHI HC.** Attachment and tension in the spindle assembly checkpoint. *J Cell Sci.*, 2002, vol. 115, 3547-55 [0078]

15 If available, please enter the **Chinese abstract** text in the space below.

本發明涉及某些新穎、有效的方法，這些方法通過測量特定遺傳標記物尤其是TTK激酶較對照物的增加或減少，可預測或監測患者對紫杉醇類分子的反應。本發明還提供了某些試劑盒，這些試劑盒通過測量特定遺傳標記物的核酸或蛋白質水平並與對照物或參照標誌比較，可預測或監測患者對紫杉醇類分子的反應。